<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2026-01-26 09:27:36 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>97</td>
          <td>48</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/172abfa26a843e28557e6b2d1ff301ec813b0e13" target='_blank'>
              Selective Immune Silencing by Targeted TGF-β Agonists
              </a>
            </td>
          <td>
            Qinli Sun, Masato Ogishi, Hua Jiang, Alison K. Barrett, Hao Yan, Elsa Solà, Jie Zhang, Peng Xiao, Huiyun Lyu, Ahmad Salehi, Qizhi Tang, Tobias V. Lanz, , R. Negrin, K. C. Garcia
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/046a4759f61fd2ed00479ddd2426526fb3c7aa64" target='_blank'>
              Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade
              </a>
            </td>
          <td>
            Valeria Manriquez, Sofia Cavada-Silva, Kévin Beccaria, L. L. Niborski, Amaury Leruste, W. Richer, Mathias Vandenbogaert, Zhi-Yan Han, C. Sedlik, Jordan Denizeau, Jeremy Mesple, Zoé Fusilier, L. Laëtitia Lesage, Jérémie Goldstein, Yohan Gerber-Ferder, Stéphanie Fitte-Duval, Federico Marziali, R. Mena-Osuna, Jimena Tosello-Boari, Rachida Bouarich-Bourimi, Maria Florencia Pacini, Y. Missolo-Koussou, Mylène Bohec, Sylvain Baulande, Philippe Benaroch, J. Helft, Hélène D Moreau, J. Waterfall, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5984ff16cfe613f763f0430e61d72c3b4c0bbf01" target='_blank'>
              The breast tumor microenvironment exploits eosinophil plasticity to suppress their anti-tumor activity
              </a>
            </td>
          <td>
            Zofia Varyova, M. Pohin, Gracie J. Mead, Libby K. Jennings, Valeria da Costa, Sarah Spear, I. McNeish, A. Schwenzer, Adrian L. Harris, Audrey Gérard, Kim S. Midwood
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e10756da93e249564dafc2b41fce10c7b1ebac2e" target='_blank'>
              Dual PD-L1/TIGIT blockade induces PNAd⁺ HEV-like vessels and CD62L⁺ lymphocyte recruitment, driving rhabdoid tumor rejection
              </a>
            </td>
          <td>
            Stéphanie Fitte-Duval, Sofia Cavada Silva, R. Mena-Osuna, Owen Hoare, L. L. Niborski, Jordan Denizeau, Laëtitia Lesage, W. Richer, C. Sedlik, Kévin Beccaria, Maëva Veyssière, Rachida Bouarich-Bourimi, Jérémie Goldstein, Federico Marziali, Jimena Tosello Boari, J. Masliah-Planchon, Zhi-Yan Han, Dario Rocha, Mylène Bohec, Sylvain Baulande, J. Waterfall, Valeria Manriquez, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48deb9a97772c3939779b0a727ea3595d2e4a10f" target='_blank'>
              PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
              </a>
            </td>
          <td>
            Teresa Dinter, Sebastian Mackowiak, Zachary J. Rogers, Vidit Bhandarkar, Molly Carney, Yiming J. Zhang, D. Morgan, Lorelai Pop, Fiona Chatterjee, E. Lutz, Yajit Jain, Adityanarayanan Radhakrishnan, Eric Lander, K. Dane Wittrup, J. C. Love, Alexander Meissner, Stefani Spranger
          </td>
          <td>2025-11-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4⁺ T-cells, and CD8⁺ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS–ICOSL pathway, and are enriched for ICOS⁺ Th1-like CD4⁺ T cells and ICOSLhigh cDC1s. CD8⁺ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon-γ–responsive program that sustains CD8⁺ T-cell function and prevents dysfunction. Functionally, ICOSL⁺ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6a060eabfcbbb0a36b483e2912054f711b0272" target='_blank'>
              Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
              </a>
            </td>
          <td>
            Mehdi Chaib, M. Aminu, Shelley M Herbrich, Mahshid Arabi, Yue Xuan, Akshay V. Basi, Anna Casasent, Marc D. Macaluso, Kenneth H. Hu, Matthew M. Gubin, Xi Chen, James J. Mancuso, Sreyashi Basu, Sonali Jindal, Jared K. Burks, S. Watowich, Jia Wu, James P. Allison, Padmanee Sharma
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Tumor-specific CD8+ T lymphocytes play a critical role in anticancer immunity but frequently become dysfunctional and exhausted within the immunosuppressive tumor microenvironment. Although immune checkpoint inhibitors can restore T-cell activity, resistance to these treatments remains a significant challenge. Therefore, understanding the transcriptional and regulatory mechanisms underlying CD8+ T-cell exhaustion is crucial for the development of effective therapies. We developed two murine models of acquired immune checkpoint inhibitor resistance through prolonged anti-PD1 treatment. To gain insight into CD8+ T-cell exhaustion, we performed single-cell multiomics analysis, including both scRNA-seq and scATAC-seq, to capture gene expression profiles and chromatin accessibility. Moreover, we collected three external datasets to validate the results in silico. We further assessed the therapeutic potential of Runx2 through marker expression and cytotoxicity assays. Our single-cell analysis revealed distinct T-cell subsets, including early and terminally exhausted populations, along with their exhaustion trajectories. Runx2 was identified as a key transcription factor associated with CD8+ T-cell exhaustion in both models and correlated with immunotherapy response in clinical data. Additionally, functional marker expression and cytotoxicity assays demonstrated that inhibiting Runx2 improved CD8+ T-cell cytotoxicity. These findings highlight the role of Runx2 as a crucial regulator of CD8+ T-cell exhaustion in the context of prolonged immune checkpoint inhibitor treatment. Targeting Runx2 may provide a novel strategy to overcome immune checkpoint inhibitor resistance and enhance therapeutic efficacy, offering promising avenues for combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4efed637bde0b584b5806d223ee2a3f6b51d5e91" target='_blank'>
              Transcriptional dynamics of CD8+ T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution
              </a>
            </td>
          <td>
            Tzu-Yang Tseng, Ching-Hung Hsieh, Hsuan-Cheng Huang, Yu-Ching Wu, Chiun Hsu, Chia-Lang Hsu, D. Ou, Hsueh‐Fen Juan
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Glioblastoma (GBM), the most frequent and aggressive primary brain tumor, remains refractory to all current therapies including surgical resection, chemotherapy, radiotherapy and immunotherapy. Immunosuppressive mechanisms in the GBM tumor microenvironment contribute to the lack of anti-tumor adaptive immunity. We found that a subset of tumor associated macrophages (TAMs) can be repolarized into an anti-tumor phenotype via agonist stimulation of the retinoic acid-inducible gene I (RIGI), a cytosolic double-stranded RNA pattern recognition receptor (PRR). In silico analysis of adult GBM datasets available in the public domain revealed that RIGI expression by a subset of activated TAMs positively correlated with patient survival. Studies in syngeneic mouse models of GBM showed that intratumoral delivery of stem-loop RNA 14 (SLR14), a RIG-I agonist, improved the efficacy of chemotherapy, radiotherapy and immunotherapy treatments, beyond the effects of other nuclei acid sensor agonists. We found that RIGI+ macrophages are the main drivers of SLR14 effect, combining activation of TAMs and priming of functional cytotoxic CD8+ T lymphocytes and NK cells. The anti-GBM effect of SLR14 is opening a significant new avenue for adult GBM treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1342f808c2fd345588c30c0266370e6a04636995" target='_blank'>
              RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Han Xu, Sungwoon Lee, Felipe Leser, Olga Fedorova, Peiwen Lu, Eric Song, Mehdi Touat, Anne Eichmann, Akiko Iwasaki, A. Pyle, Jean-Leon Thomas
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8+ T cell responses. Constitutive Tmem33-/- mice exhibited delayed melanoma tumor growth and increased CD8+ T cell infiltration. Antigen-specific CD8+ compartments in tumors of Tmem33-/- mice showed TCF-1+PD-1+ progenitor-exhausted cell (Tpex) enrichment, elevated effector function and reduced exhaustion, alongside improved effector memory expansion and T-bet expression in draining lymph nodes. We highlight that TMEM33 functions intrinsically within the T cell compartment, as TMEM33 deletion (1) enhanced polyclonal activation of naive CD8+ T cells ex vivo, (2) promoted preferential Tpex accumulation among adoptively transferred naive OT-I cells in B16F10-OVA tumors and draining lymph nodes, and (3) improved the potency of ex vivo-expanded OT-I cells in controlling tumor growth during adoptive cell therapy. Finally, in a large, prospectively recruited metastatic melanoma cohort, lower TMEM33 expression in patient CD8+ T cells significantly correlated with improved survival and elevated TCF-7 (encoding TCF-1). Collectively, our findings define TMEM33 as a formerly unrecognized intrinsic determinant of tumor-directed CD8+ T cell fate that limits Tpex maintenance, and restrains cell therapy responses, suggesting that its modulation may strengthen immunotherapeutic efficacy. One sentence summary TMEM33 intrinsically limits progenitor exhausted CD8+ T cells, scales anti-tumor responses and predicts melanoma patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b5c85fa3ccdffaf374a3f09dd7d217b43c30d4c" target='_blank'>
              TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity
              </a>
            </td>
          <td>
            M. T. Jackson, Tianming Zhao, G. Milotay, I. Pedroza-Pacheco, Yanshu Cai, Claire Willis, S. Phyu, Bruno Beernaert, Jamie TW Kwon, Hala Estephan, Vinnycius Pereira Almeida, Maria Aggelakopoulou, Silvia Panetti, Christian Zierhut, Tim Elliott, Eleni Adamopoulou, J. Rehwinkel, Malcolm JW Sim, Amit Grover, Dmitry I. Gabrilovich, Benjamin P. Fairfax, E. Honoré, D. Withers, John C. Christianson, Eileen E. Parkes
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong C. Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5d6aac86da3cbb3bd85a8ebe57c0ff220d334a71" target='_blank'>
              Circulating immune profiling reveals impaired monocyte states and trajectories driving immunosuppression in glioblastoma
              </a>
            </td>
          <td>
            A. Scafidi, T. Kaoma, Claudia Cerella, Eleonora Campus, K. Grzyb, Bakhtiyor Nosirov, Frida Lind-Holm Mogensen, E. Klein, Raul da Costa, A. Skupin, Frank Hertel, G. Berchem, Michel Mittelbronn, A. Cosma, Beatrice Melin, Simone P. Niclou, Petr V Nazarov, A. Gołȩbiewska, Aurélie Poli, A. Michelucci
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Dogs play a major role in sustaining transmission of Leishmania infantum to people, thus prevention and treatment of canine leishmaniosis (CanL) to reduce transmission represents an unmet public health need. Although advances have been made in understanding how immunopathology correlates to infectiousness as CanL progresses, the immune mechanisms underlying transition between disease stages and terminal decline remain ill-defined. To address this knowledge gap, we generated a comprehensive atlas of peripheral immune cells from control dogs and naturally-infected dogs using single-cell RNA sequencing. The LeishDog Atlas captures the cellular and transcriptional complexity underlying CanL, tracing shifts in immune composition and gene expression across progressive, well-defined disease stages. Notably, we identified distinct myeloid, CD4+ and CD8+ T cell phenotypes and transcriptional states associated with disease progression. This resource provides a valuable framework for understanding systemic immune dysregulation in CanL, including determinants of T cell exhaustion and myeloid cell activation, and establishes a foundation for comparative, translational, and mechanistic studies of CanL immunopathology and transmissibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8412687f28e64e4d6b2558529c494e2ee4440eca" target='_blank'>
              A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis
              </a>
            </td>
          <td>
            Danielle P. Uhl, Daniel J. Holbrook, Max C Waugh, S. Dey, Najmeeyah Brown, Karen I. Cyndari, Jacob J. Oleson, Paul M. Kaye, Christine A. Petersen
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a82efc5b2c9cc4922bf6d2b205d9310648f4f84" target='_blank'>
              Single-cell multiomics reveals epigenetic rewiring of splenic memory B cells in murine malaria reinfection
              </a>
            </td>
          <td>
            Montserrat Coronado, Á. Vincelle-Nieto, Isabel G. Azcárate, S. Pérez-Benavente, A. Puyet, Amalia Díez, José M. Bautista, A. Reyes-Palomares
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0be57704ac8a67d3c2570360452cb391401b265a" target='_blank'>
              A Comprehensive Treatment-Induced Resistance Atlas of Glioblastoma Reveals a Fibrotic Niche Shielding the Tumor from Immunotherapy
              </a>
            </td>
          <td>
            Fei Wang, Run Huang, Hongyi Ling, Yuhan Bai, Chen Yang, Guozhen Zhao, Xin Wu, Wenqian Cao, Yue Lu, Yining Zhang, Deng-Feng Lu, Youjia Qiu, Juyi Zhang, Bixi Gao, Chao Ma, Hanhan Dang, Yulian Zhang, Yanbo Yang, Ting Sun, Zhouqing Chen, Zhong Wang
          </td>
          <td>2025-12-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/457d4de587553b09db9c04406c900e3b240f5c8f" target='_blank'>
              CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migration
              </a>
            </td>
          <td>
            Eleftheria Maranou, Gayoung Park, Pauline Weinzettl, Jonna Alanko, Otto I. Pulkkinen, Sarah E. Coupland, Marko Salmi, Carlos R. Figueiredo
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab0829fa668d3f68087f51374ae0be2ba943151" target='_blank'>
              Perturbational single-cell profiling of patient tumors defines lineage- and context-specific programs of innate immune resistance
              </a>
            </td>
          <td>
            C. Perry, A. Frey, Y. Fei, J. Wang, P. Costa, H. N. Amin, S. Ghadermarzi, D. Levine, W. Tong, A. Koda, M. Mackie, M. He, Y. Nie, K. Clulo, F. Ouerghi, J. Wei, T. Cordero Dumit, M. Yaskolko, M. Ding, A. Caldera, O. Kyrysyuk, L. Lum, J. W. Allen, W. Guo, A. Naqash, A. Elliot, A. Vanderwalde, M. Capelletti, T. Adeyelu, S. Barry, M. Hugaboom, A. Bacchiocchi, H. Kluger, M. Bosenberg, A. Iwasaki, D. Braun, J. Clune, D. van Dijk, K. Olino, J. Ishizuka
          </td>
          <td>2025-12-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="ABSTRACT The incorporation of the current immunotherapy, GD2-targeting monoclonal antibodies, into the standard of care has moderately improved clinical outcomes in children with high-risk neuroblastoma (HR-NB); however, overall survival remains low. More than 50% of patients with HR-NB are refractory to or eventually develop resistance to anti-GD2 treatment. HR-NBs are generally known to have a low tumor mutational burden, are immunologically cold and possess an immunosuppressive tumor microenvironment. Understanding the mechanisms of immune evasion may provide novel targets for improving the efficacy of immunotherapies for these immunologically cold HR-NBs. Here, utilizing immunocompetent mouse models of immunologically cold HR-NB, we revealed a novel function of IGF2BP1 in promoting the immune escape of neuroblastoma tumors. We demonstrate that neuroblastoma cell-specific knockdown of IGF2BP1 favorably alters the tumor microenvironment of HR-NBs, turning these “immunologically cold” tumors into an immunogenic type, thereby priming them for anti-GD2 therapy-induced immune responses. Downregulation of IGF2BP1 in NB cells decreased the number of immunosuppressive T-regulatory and dysfunctional/exhausted CD8+ T cells and promoted the accumulation of effector MHCII +  macrophages at the tumor site. Importantly, knockdown of IGF2BP1 along with anti-GD2 immunotherapy induced a synergistic immunogenic effect and achieved a potent antitumor response in an HR-NB mouse model, with increased accumulation of effector CD8+ T cells and CD86+  macrophages but decreased MDSC numbers in the tumor microenvironment. Thus, disrupting NB cancer cell IGF2BP1-mediated immunosuppression is a potential approach for improving the efficacy of anti-GD2 immunotherapy towards HR-NBs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f2673362b04d72c7ef9c09b32302276a86d8cfe" target='_blank'>
              IGF2BP1 fosters an immunosuppressive tumor microenvironment in high-risk neuroblastoma, contributing to their resistance to immunotherapy
              </a>
            </td>
          <td>
            Mayura R Dhamdhere, Chethana Gowda, Yuka Imamura, Hong-Gang Wang, Todd S Schell, V. Spiegelman
          </td>
          <td>2025-12-02</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Type 2 diabetes mellitus (T2DM) worsens stroke outcomes, but the underlying mechanisms linking T2DM to systemic immune dysfunction remain unclear. We investigated whether T2DM alters bone marrow (BM) hematopoiesis and dysregulate immune signaling following ischemic stroke in mice. Single-cell RNA sequencing, GeoMx digital spatial profiling (DSP), nCounter, and flow cytometry were used to analyze BM cells from control (db/+, Ctrl) and diabetic (db/db, T2DM) mice underwent experimental stroke or sham surgery. Diabetes caused marked structural remodeling of BM, with reduced cellularity and imbalance of hematopoietic lineages. Pseudotime trajectory analysis revealed impaired differentiation and maturation signatures of hematopoietic progenitor cells (HPC1) and granulocytes, and overactivation toward monocytes in diabetes after stroke. CellChat analysis demonstrated reorganization of intercellular communication, with hematopoietic progenitor cells (HPC1) and monocytes emerging as dominant signaling hubs through upregulated MIF, SIRP, and THBS pathways. AUCell enrichment indicated increased glycolysis and oxidative phosphorylation but reduced interferon-γ (IFN-γ) signaling, reflecting metabolic activation coupled with immune dysregulation. DSP and nCounter further confirmed upregulation of genes in the MIF, SIRP and THBS pathways in CD115⁺ monocytes and Ly6G⁺ neutrophils, indicating proinflammatory and migratory activation in diabetic bone marrow. Our data suggest that T2DM reprograms hematopoiesis and signaling networks, leading to maladaptive myeloid responses and impaired immune regulation after stroke. This maladaptive BM environment amplifies inflammation and limits repair, linking diabetic metabolic stress to worsened ischemic outcomes. Targeting bone marrow immune dysfunction may offer a therapeutic strategy to improve stroke recovery in diabetic patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ab79f630ee108b9ad79cdd23cb73d99a2673e4d" target='_blank'>
              Type 2 diabetes Reprograms Bone Marrow Hematopoiesis and Dysregulates Immune Signaling in Response to Stroke
              </a>
            </td>
          <td>
            Hongxia Zhang, Wanjun Gu, Kailin Yu, Chia-Ling Tu, Wenhan Chang, Jialing Liu
          </td>
          <td>2025-12-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9ae85bd79cada9f97140c874baf065a8524c49a" target='_blank'>
              NF1 Loss Remodels Tumor Niches for Immune Evasion
              </a>
            </td>
          <td>
            Milad Ibrahim, Irineu Illa-Bochaca, Tara Muijlwijk, Ines Delclaux, K. S. Ventre, G. Jour, Paola Angulo Salgado, Shi Qiu, Agrima Dutt, Amanda W. Lund, Iman Osman, Markus Schober
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Hematopoietic bone marrow progenitors are increasingly implicated as an origin of immunosuppression in cancer. We have previously shown that trained immunity induction using nanomedicine potentiates checkpoint blockade therapy. Here, we studied how this approach’s induction of trained immunity systemically overcomes the immunosuppressive tumor microenvironment. We found changes in the tumor microenvironment to mirror functional changes in the hematopoietic system in a melanoma mouse model. Single cell sequencing methods disclosed a shift in the tumor-associated macrophage population from immunosuppressive to antitumorigenic. Uniquely, a trained immunity and checkpoint blockade combination therapy mobilized natural killer cells which, in conjunction with the functional changes in the myeloid cell compartment, effectively activated T cells. Last, we established the effectiveness of our approach in mouse models of breast, lung, and pancreatic cancer. Collectively, our data show that the systemic induction of trained immunity rebalances the immune system for effective checkpoint blockade therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/779280ac3e11ac6a4d5d5956af8561bae6f79622" target='_blank'>
              Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment
              </a>
            </td>
          <td>
            Bram Priem, Lisa Willemsen, Tom Anbergen, Yuri van Elsas, Jeroen Deckers, David P. Schrijver, Stijn R. J. Hofstraat, Iris V. Messing, J. Munitz, Dionne Honing, Geoffrey Prévot, Yohana C. Toner, Judit Morla, William Wang, A. Ranzenigo, Isabella Sirchia, T. Post, Raphaël Duivenvoorden, E. Kluza, G. Cremers, J. Kreijtz, C. Pérez-Medina, M. V. van Leent, Abraham J. P. Teunissen, Roy van der Meel, Yi Zhou, C. Glass, J. Ochando, L. A. Joosten, Z. Fayad, R. Netea-Maier, M. Netea, M. D. de Winther, Thijs J. Beldman, A. Griffioen, Willem J. M. Mulder
          </td>
          <td>2026-01-01</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>125</td>
        </tr>

        <tr id="Immune rejection poses a major challenge in organ transplantation, with tissue-resident memory T (TRM) cells playing a critical role in graft rejection. This study investigated the impact of CCR8 on TRM cells using single-cell RNA sequencing (scRNA-seq), flow cytometry, and immunohistochemistry. The results show that CCR8 expression was upregulated on CD8⁺ TRM cells after transplantation, peaking on day 7. Blocking or knocking out CCR8, as well as neutralizing CCL1 and CCL8, significantly reduced CD8⁺ TRM cell accumulation in the graft and their cytokine production. These treatments prolonged graft survival, alleviated rejection severity, and impaired the ability of CD8⁺ TRM cells to produce GZMB, IFN-γ, and IL-2. Single-cell analysis of skin transplantation revealed that loss of CCR8 disrupted macrophage–T cell interactions, particularly CD8⁺ TRM–macrophage crosstalk, while enhancing CD40, PD-L1, and NRG signaling. These findings suggest that targeting CCR8 to limit the accumulation and function of CD8⁺ TRM cells may be an effective strategy to alleviate transplant rejection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90971d5b49b0f0a4e21364a3098badc63c73195f" target='_blank'>
              Single-cell analysis indicating CCR8 modulates CD8+ tissue-resident memory T cells to attenuates rejection in transplantation
              </a>
            </td>
          <td>
            Xueteng Wang, Xinqiang Li, Hailun Cai, Zhuoyu Jia, Xin Zhou, Ruidong Ding, Meiying Song, Huan Liu, Feng Wang, Bin Wu, Kai Zhao, Shipeng Li, Bei Zhang, Dahong Teng, Jinzhen Cai
          </td>
          <td>2025-12-16</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I⁻/MHC-II+), we can cure mice with a regimen that includes radiation therapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3⁺ T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4⁺ T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77253e2042c64402b4c27c711448fdd4c49c02c6" target='_blank'>
              Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
              </a>
            </td>
          <td>
            AK Erbe, Arika S. Feils, Anqi Gao, Sabrina N. VandenHeuvel, Simon Boyenga, Alina A. Hampton, M. Heck, Jen Zaborek, Dan Spiegelman, N. Tsarovsky, A. Hoefges, A. Pieper, Peter M. Carlson, Mildred A. Felder, Ravi B Patel, S. Gillies, Alexa R. Heaton, Zachary S. Morris, Huy Q. Dinh, A. Rakhmilevich, Paul M. Sondel
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>54</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8779b2bf6cba17b1530e13526c071bfe44406db3" target='_blank'>
              Regulatory T cells clonally expand and contribute to stromal cell function in fibrotic response to synthetic implants
              </a>
            </td>
          <td>
            Joscelyn C. Mejías, Kavita Krishnan, Anna Ruta, A. S. Ramanujam, Elise F. Gray-Gaillard, Locke Davenport Huyer, David R Maestas, Sushma Nagaraj, Frank Haoning Yu, Alexandra N. Rindone, Peter Abraham, Maria Browne, E. Fertig, Drew M. Pardoll, Jennifer H. Elisseeff
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Cancer immunotherapies, from checkpoint blockade to adoptive cell therapies like tumor-infiltrating lymphocytes (TILs), have revolutionized cancer treatment but are limited by variable efficacy and significant toxicities. A central challenge is identifying ideal T-cell populations that effectively eliminate tumors without causing off-target damage, a distinction not captured by existing biomarkers. We show that co-expression patterns of chemokine receptors (CRs) CXCR3, CCR5, and CXCR6 on CD8+ T cells provide a functional “code” defining subsets with divergent roles in on-target immunity versus off-target inflammation. In mouse and human melanoma, a triple-positive (CXCR3+CCR5+CXCR6+) T-cell subset is essential for tumor control, and its genetic signature correlates with positive clinical response, while a distinct CCR5+CXCR6+ subset drives liver immune-related adverse events (IRAEs). Crucially, this CR code reveals that immunotherapy actively reshapes T-cell trafficking patterns, uncovering profound heterogeneity within conventional populations and distinguishing potent anti-tumor progenitors from cells predisposed to exhaustion or off-target migration. This work establishes CR co-expression as a practical tool, providing a surface marker-based strategy to identify and enrich optimized T cells for adoptive therapies, thereby offering a framework to uncouple efficacy from toxicity. One Sentence Summary Co-expression of CCR5, CXCR6, and CXCR3 provides a functional ’code’ that separates T-cell-mediated anti-tumor efficacy from off-target toxicity, enabling the selection of superior cells for safer and more effective cancer immunotherapies. Graphical Abstract Highlights · CXCR6, CXCR3 and CCR5 co-expression signature stratifies patient survival in human melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 are critical effectors with high proliferative, cytotoxic, and activation profile in human and mice melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 drive anti-tumoral responses during checkpoint blockade in both human and mice">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ffb2ffb5ffbc1f04ce6b70ec760612828941d302" target='_blank'>
              A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma
              </a>
            </td>
          <td>
            Rodney Macedo, David W. Harle, Kevin Hoffer-Hawlik, X. Wang, Thomas McMahon-Skates, Alexandra Matschiner, Kirubel Belay, Y. M. Saenger, Benjamin Izar, Elham Azizi, Ran Reshef
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Current therapies for inflammatory bowel disease (IBD) often fail to achieve complete remission and are associated with systemic toxicity owing to their broad immunosuppressive effects. To overcome these limitations, we developed a bioengineered extracellular vesicle (EV) platform that modulates key immune signaling pathways to efficiently restore the T-cell balance in inflamed intestinal tissues. EVs derived from Wharton’s jelly mesenchymal stem cells were engineered to display PD-L1 on their surface and encapsulate miR-27a-3p. Surface PD-L1 engages the PD-1 checkpoint in activated T cells, attenuating T-cell receptor signaling via SHP2-mediated dephosphorylation of ZAP70 and AKT. In parallel, miR-27a-3p suppresses prohibitin 1 (PHB1), a mitochondrial regulator of Th17 cell bioenergetics and inflammatory function, thereby reducing Th17 polarization and increasing the number of FOXP3⁺ regulatory T cells. These dual-targeting EVs preferentially localized to inflamed intestinal tissues via chemokine (CCR2/CXCR4) and PD-1-dependent mechanisms. In humanized mouse models of colitis, these EVs attenuated mucosal inflammation, suppressed effector T-cell responses, and preserved epithelial integrity. In IBD patient-derived colonoid cultures, PD-L1/miR-27a-3p EVs maintained epithelial viability and barrier integrity without inducing cytotoxicity or structural disruption. Transcriptomic and single-cell analyses revealed the downregulation of inflammatory and exhaustion signatures, along with the enrichment of regulatory subsets. Collectively, this study presents a cell-free immunotherapeutic approach that reprograms T cells in inflamed tissues through the PD-1 and mitochondrial signaling pathways while maintaining intestinal epithelial integrity, offering a promising therapeutic strategy for IBD and other T cell-driven inflammatory disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21a759c51278c1cf53050a54d395a9872336d71e" target='_blank'>
              Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease
              </a>
            </td>
          <td>
            Mi-Kyung Oh, Hyun Sung Park, Dong-Hoon Chae, Aaron Yu, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Byeonghwi Lim, Jun-Mo Kim, Jordan Axelrad, Kyung Ku Jang, Jong Pil Im, S. Koh, Byung-Soo Kim, Kyung-Rok Yu
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d522a0c1e585eda2d8238200dfededee05868fa" target='_blank'>
              Leveraging TNFR2 for antitumour immunity: T reg depletion and myeloid reprogramming versus T cell costimulation
              </a>
            </td>
          <td>
            L. Mårtensson, P. Holmkvist, Kirstie Cleary, Carolin Svensson, M. Semmrich, Niyaz Yoosuf, Alexandra Gabriela Ferreira, M. Kovacek, Mimoza Boden, Therese Blidberg, Osman Dadas, J. Mattsson, David Ermert, Elin Birgersson, Vincentiu Pitic, Martin C Taylor, Mona Yazdani, Ulla-Carin Tornberg, Ingrid Karlsson, Sean H Lim, S. Beers, Mark Cragg, B. Frendéus, I. Teige
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Most patients with hepatocellular carcinoma (HCC) develop resistance to immune checkpoint blockade (ICB) or STING agonists despite their immune-stimulating activities. Here, we identify increased intratumoral B-cell infiltration as a mediator of acquired resistance. In HCC models with liver fibrosis in male mice, anti-PD-1 ICB or the STING agonist BMS-986301 increase intratumoral B-cell infiltration, circulating IL-10, and TIM-1+ B-cells, promoting tertiary lymphoid structure formation. B-cell depletion combined with ICB or STING agonism improves survival, and STING agonism inhibits distant metastasis. In addition, co-targeting STING and TIM-1 enhances B-cell differentiation and antigen presentation, reduces intratumoral TIM-1+ B-cells, and increases CD86 and MHC class II expression, thereby augmenting CD8+ T-cell-mediated anti-tumor immunity. These findings reveal that B-cells contribute to ICB and STING therapy resistance in HCC, and that B-cell depletion or TIM-1 blockade can overcome acquired resistance to these immunotherapies. B cell subsets expanding during tumor progression have been associated with impaired anti-tumor responses and resistance to immunotherapy. Here the authors report that STING agonism or anti-PD-1 induce intratumoral B cell infiltration, and that depleting B-cells improves response to immunotherapies in preclinical models of hepatocellular carcinoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aef0adfea1b3ee9cc082a0682a2dafd6789c8d9" target='_blank'>
              Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Xin Liu, Zelong Liu, Chengzhan Zhu, Tatsuya Kobayashi, Pin-Ji Lei, Yue Shi, Dandan Yuan, Jianguo Wang, Min Li, Aya Matsui, Kassiana Mafra, Tomofumi Ando, Ken Kojo, Rieke Schleinhege, Kento Miyazaki, Peigen Huang, Ming Kuang, Lloyd Bod, Dan G. Duda
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Glioblastoma (GBM) remains one of the most lethal brain tumors, characterized by extensive immune evasion and a macrophage-dominated tumor microenvironment (TME). However, the molecular determinants governing tumor-associated macrophage (TAM) states and their immunoregulatory functions remain poorly understood. We integrated bulk- and single-cell transcriptomic datasets (TCGA, CGGA, Ivy GAP, and Brain Immune Atlas) to systematically characterize the expression, prognostic relevance, and immune contexture of the myeloid biomarker membrane-spanning 4-domain A6A, MS4A6A, in GBM. Differential expression, survival, and pathway enrichment analyses were performed. Single-cell mapping and CellChat modeling delineated MS4A6A-associated TAM subpopulations, intercellular communication networks, and ligand–receptor signaling dynamics. Spatial transcriptomic validation and pharmacogenomic modeling were conducted to assess anatomic enrichment and therapeutic vulnerabilities. High MS4A6A expression predicted unfavorable survival and correlated with increased stromal and immune infiltration. Single-cell analyses localized MS4A6A predominantly to TAMs, especially Regulatory- and Ribo-TAM states enriched for antigen presentation, T-cell regulation, and ribosomal biogenesis pathways. CellChat analysis revealed that MS4A6A-high TAMs exhibited markedly enhanced communication with CD4+ T cells and Tregs through upregulated PGE2–PTGER2/PTGER4, PECAM1–CD38, and THBS1–CD36 signaling axes, implicating MS4A6A in prostaglandin-driven immune suppression. Spatial profiling confirmed preferential localization of MS4A6A within perivascular and angiogenic niches. Pharmacogenomic prediction indicated that MS4A6A-high tumors were more sensitive to ERK, mTOR, and CDK4/6 inhibition. MS4A6A defines a macrophage-centered, immunosuppressive ecosystem in GBM, mediated by the activation of the PGE2 signaling axis. These findings position MS4A6A both as a prognostic biomarker and as a potential therapeutic node linking myeloid reprogramming to actionable pathway vulnerabilities in glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2aace77685200c650b039b4e217d58ff78ecf5af" target='_blank'>
              The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis
              </a>
            </td>
          <td>
            Jianan Chen, Qiong Wu, Anders E. Berglund, Robert J. Macaulay, James J. Mulé, Arnold B. Etame
          </td>
          <td>2025-12-20</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Reducing calorie intake through dietary restriction (DR) slows tumour growth in mammals, yet the underlying mechanisms are poorly defined. Here, we show that DR enhances anti-tumour immunity by optimizing CD8+ T cell function within the tumour microenvironment (TME). Using syngeneic xenograft tumour models, we found that DR induces a profound reprogramming of CD8+ T cell fate in the TME, favouring the expansion of effector T cell subsets with enhanced metabolic capacity and cytotoxic potential, while limiting the accumulation of terminally exhausted T cells. This metabolic reprogramming is driven by enhanced ketone body oxidation, particularly β-hydroxybutyrate (βOHB), which is elevated in both the circulation and tumour tissues of DR-fed mice. βOHB fuels T cell oxidative metabolism under DR, increasing mitochondrial membrane potential and tricarboxylic acid cycle-dependent pathways critical for T cell effector function, including acetyl-CoA production. By contrast, T cells deficient for ketone body oxidation exhibit reduced mitochondrial function, increased exhaustion and fail to control tumour growth under DR conditions. Importantly, DR synergizes with anti-PD1 immunotherapy, further augmenting anti-tumour T cell responses and limiting tumour progression. Our findings reveal that T cell metabolic reprogramming is central to the anti-tumour effects of DR, highlighting nutritional control of CD8+ T cell fate as a key driver of anti-tumour immunity. Dietary restriction promotes the expansion of effector T cells via ketone bodies, which enhances anti-tumour immunity and synergizes with immunotherapy in mice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/319855c1ff8d38af76a937b591f2130f59f83394" target='_blank'>
              Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses
              </a>
            </td>
          <td>
            Brandon M Oswald, Lisa M. DeCamp, Joseph Longo, Michael S. Dahabieh, Nicholas Bunda, Benjamin K. Johnson, M. Watson, Shixin Ma, Samuel E. J. Preston, Ryan D. Sheldon, Michael P. Vincent, Abigail E. Ellis, Molly T. Soper-Hopper, Christine N. Isaguirre, Dahlya Kamarudin, Hui Shen, Kelsey S. Williams, Peter A. Crawford, S. Kaech, H. Jang, Evan C. Lien, Connie M. Krawczyk, Russell G. Jones
          </td>
          <td>2025-12-01</td>
          <td>Nature Metabolism</td>
          <td>1</td>
          <td>14</td>
        </tr>

        <tr id="Macrophages serve both as a first line of defense against invading pathogens and mediate tissue homeostasis. These cells are inherently responsive and heterogeneous and lie on a spectrum of activation states book-ended by M1-like (inflammatory) and M2-like (anti-inflammatory) extremes. The study of human macrophages is necessary to unravel the complex signals and environmental cues that these cells integrate to create their varied phenotypes. In vitro protocols to differentiate human monocytes into macrophages use many distinct activation stimuli at variable concentrations and for differing durations of treatment that can impact macrophage fate. These variations can make it challenging to reproduce findings and compare datasets across research environments. Additionally, few protocols to date have performed rigorous characterization with input material from frozen peripheral blood mononuclear cells (PBMCs). This is important since the availability of fresh blood can often be limiting and can lead to a loss of standardized procedures, particularly for cell therapy applications. Here, we have developed a comprehensive protocol to generate human macrophages from monocytes where we rigorously characterize the impact of differentiation conditions and polarization conditions on human macrophages. We compared 4 conditions for M1-like (50 ng/mL LPS, 50 ng/mL IFNγ, 20 ng/mL IFNγ + 10 ng/mL LPS and 20 ng/mL IFNγ + 100 ng/mL LPS) and for M2-like (10 ng/mL IL-4, 20 ng/mL IL-4, 20 ng/mL IL-13 and 20ng/mL IL-4 + 20 ng/mL IL-13). We provide a detailed protocol for their characterization using several ‘omics readouts, including their cytokine production and transcriptomes. We also perform depolarization experiments to determine durability of macrophage immunophenotype post-removal of polarizing stimuli for 0 to 72 hours. Finally, we demonstrate that nuclei can be isolated and profiled by snRNA-seq directly from macrophages in culture, alleviating the need to detach these adherent cells for downstream multi-ome analyses. Taken together, we provide a comprehensive, detailed and streamlined procedure for the differentiation and characterization of human macrophages from monocytes isolated from frozen PBMCs. This is important for enabling the study of macrophages in a more systematic way from biobanked material.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/26c17554acac58c3bbed110d75791474cfdb01fd" target='_blank'>
              A streamlined and comprehensive protocol for the generation and multi-omic analysis of human monocyte-derived macrophages
              </a>
            </td>
          <td>
            Olivia Palmer, Laurent Perreard, Fred W Kolling Iv, Patricia A. Pioli, Brittany A. Goods
          </td>
          <td>2025-12-01</td>
          <td>BMC Biotechnology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/34649c6562aa2175c877d0871438b8882a670ac3" target='_blank'>
              Integrated single-cell analysis reveals interferon-driven immune signatures in a DENV1 human infection model
              </a>
            </td>
          <td>
            A. Vermeersch, T. Verdonckt, C. Struyfs, E. De Meester, A. Waickman, S.J. Thomas, K. Ariën, O. Lagatie, F. van Nieuwerburgh
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we developed murine melanoma cell lines (R1 and R2) derived from MO4 tumors and that are resistant to anti-PD−1 therapy. These resistant cells exhibited increased tumor initiation capacity in vivo correlating with enhanced spheroid formation in vitro, and greater invasiveness and metastatic potential in a lung macrometastasis model. Mechanistically, both R1- and R2- derived tumors showed enrichment of a cancer stem cell (CSC)-like population overexpressing Wnt3a, which correlated with reduced infiltration and impaired function of CD8+ tissue-resident memory (TRMs) T cells. This suggested a functional link between Wnt-driven cancer stemness and TRMs dysfunction. Pharmacological inhibition of Wnt/β-catenin signaling in vitro enhanced CD8+ T cell proliferation and expression of functional markers. Notably, Wnt/β-catenin inhibition in vivo reversed anti-PD−1 resistance in resistant tumors, coinciding with reduced OCT4+Wnt3a+ CSC-like cells and restoration of TNFα+CD8+ TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f77e7d52138792d22d71c5dbfbe6f13abb61e07" target='_blank'>
              Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma
              </a>
            </td>
          <td>
            Julian A. Gajón, Ángel Juárez-Flores, Fatima Mendoza-Roldan, J. Hernández-Aceves, Samira Muñoz-Cruz, Armando Pérez-Torres, E. Fuentes-Pananá, L. C. Bonifaz
          </td>
          <td>2025-12-03</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Background Neoadjuvant immunotherapy has reshaped the treatment paradigm for esophageal squamous cell carcinoma (ESCC), yet mechanisms of resistance in non-responders remain poorly understood. Specifically, the spatial orchestration of the tumor microenvironment that limits effective antitumor immunity is not fully elucidated. Methods Integrating spatial transcriptomic analysis with large-scale tissue pathology, we mapped the spatial architecture of the immune landscape in immunotherapy-resistant ESCC to identify cellular and molecular determinants of treatment failure. Results We revealed a distinct immune exclusion phenotype in non-responders, characterized by peritumoral CD8+ T cell enrichment coupled with intratumoral depletion. At the invasive front, we identified COL11A1+ cancer-associated fibroblasts (CAFs) and SPP1+ tumor-associated macrophages as spatially correlated markers of immune exclusion, demarcating regions characterized by limited T cell infiltration. Mechanistically, a distinct subpopulation of LAMC2+ tumor cells localized at the tumor boundary acts as the master orchestrator of this barrier. These LAMC2+ cells exhibit aberrant lactate metabolism and elevated stemness, driving CAF activation via Semaphorin 3C secretion. Strikingly, this ‘LAMC2+ boundary tumor cell-immune-privileged niche’ axis exhibits pan-cancer correlations with immunotherapy resistance, positioning LAMC2 as a robust predictive biomarker. Conclusion In this study, we identify the tumor invasive margin as a critical determinant of immunotherapy resistance in ESCC. By defining the specific spatial markers and molecular architecture of an immune-privileged niche associated with the immune-exclusion barrier, our findings demonstrate the value of spatially resolved microenvironmental analysis. Moreover, we propose that therapeutic targeting of this boundary niche represents a promising strategy to overcome resistance in ESCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/858298d1227537940c73aee34b8d245e5b4c9498" target='_blank'>
              An Immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma
              </a>
            </td>
          <td>
            Li Wan, Boye Li, Tianyun Ma, Min Wang, Fei Xie, Haotian Ge, Zixuan Xiao, Xinyi Chen, Lingda Meng, Li Zhang, Kunxin Xie, Qilong Wang
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Despite advances in targeted therapies, treatment of chronic lymphocytic leukemia (CLL) remains challenging, highlighting the urgent need for effective new therapeutic strategies. Although chimeric antigen receptor (CAR) T‐cell therapy dramatically improved outcomes in acute lymphoblastic leukemia (ALL), its efficacy in CLL is limited. We hypothesize that this disparity results from pronounced CAR T‐cell exhaustion and the immunosuppressive tumor microenvironment (TME) in CLL. We utilized an autologous 3D TME co‐culture model to investigate the functionality of CAR T cells derived from CLL and ALL patients within physiologically relevant conditions. Our results revealed increased exhaustion levels and diminished cytotoxicity of CAR T cells from CLL patients compared to those from ALL patients. Importantly, combining CAR T‐cell treatment with interleukin‐10 (IL‐10) or CXCR4 blockade effectively improved cytotoxicity against CLL cells, even in stromal‐protected regions within the 3D model. These findings offer insights into CAR T‐cell dysfunction in CLL and support novel TME‐targeted combination strategies to improve clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1aec597c65d49a8cbf32e49d8a9716856ac9762a" target='_blank'>
              Functional differences between CLL‐ and ALL‐derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL‐10 as potential modulatory targets
              </a>
            </td>
          <td>
            J. Dingfelder, M. Aigner, Jana Lindacher, Pascal Lukas, C. Flamann, Gina Nusser, Katharina Zimmermann, Axel Schambach, F. Graw, Simon Völkl, Heiko Bruns, Manuela Krumbholz, Martina Haibach, Jochen Wilke, Andreas Mackensen, G. Lutzny-Geier
          </td>
          <td>2025-12-01</td>
          <td>HemaSphere</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Background Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of TH1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8+ T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8+ T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f10076dc13711bdee9c69a81615daf0299024df" target='_blank'>
              SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
              </a>
            </td>
          <td>
            Mei Huang, Run Shi, Cong Xu, Yihan Zhang, Xiaoyue Du, S. Wen, Chunbin Wang, F. Jiang, Guoren Zhou, Xin Wang, Bo Shen
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="This study systematically evaluated the immunomodulatory function of PD-L1-positive mesenchymal stem cells (PD-L1(+) MSCs) using single-cell RNA sequencing (scRNA-seq) and investigated their roles in suppressing inflammation and regulating pathological bone formation in curdlan-induced SKG ankylosing spondylitis (AS) mouse models. scRNA-seq identified MSC subpopulations with high immunomodulatory capacity and key biomarker PD-L1 for subpopulation classification. In vitro co-culture experiments were conducted to evaluate the effects of MSC subpopulations on T-cell proliferation and TNF-α levels. In vivo experiments were performed in forty-eight SKG mouse models to analyze the effects of MSC subpopulations on joint inflammation scores, T-cell subset proportions, inflammatory cytokines, histopathology, and pathological bone formation. scRNA-seq revealed significant heterogeneity in MSCs under inflammatory stimulation, with the immunomodulatory subpopulation exhibiting high expression of PD-L1 and IDO. In vitro experiments demonstrated that PD-L1(+) MSCs significantly suppressed T-cell proliferation and reduced TNF-α levels. Joint redness and swelling scores showed that the PD-L1(+) MSC group exhibited the most significant improvement in arthritis, while the IL-17Ai, PD-L1(-) MSC, and MSC groups also effectively reduced inflammation, with significantly lower scores than the model control(MC) group. Histological analysis revealed severe inflammatory cell infiltration in the MC group, while the IL-17Ai, PD-L1(+) MSC, and MSC groups exhibited reduced infiltration. Immunohistochemical analysis further confirmed these findings, with PD-L1(+) MSCs exhibiting a significant reduction in TNF-α and IL-17A-positive cells (P < 0.0001 and P < 0.01, respectively).PD-L1(+) MSCs regulated immune responses by reducing Th17 cell proportions, increasing Th2 and Treg cell proportions, and significantly lowering pro-inflammatory cytokines IFN-γ, IL-17A, and TNF-α. MicroCT analysis indicated that the PD-L1(+) MSC, MSC, and IL-17Ai group effectively suppressed pathological bone formation through immunomodulation, whereas the PD-L1(-) MSC group showed weaker effects, underscoring the importance of PD-L1 in regulating bone formation. hUC-MSCs demonstrated significant therapeutic effects in the AS mouse model, particularly the PD-L1(+) MSCs, which inhibited joint inflammation and pathological new bone formation through immunomodulatory mechanisms. These findings provide valuable insights into the therapeutic mechanisms of AS treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/454abfd41ac3fcba3b2ed2de727cc6ae38577ec2" target='_blank'>
              Single—cell RNA sequencing identifies PD—L1 + mesenchymal stem cells with enhanced immunomodulatory capacity and alleviated the degree of ectopic new bone formation in ankylosing spondylitis
              </a>
            </td>
          <td>
            Xiqing Luo, Liuzhong Zhou, Xianghui Wen, Jinwei Li, Dong Liu, Budian Liu, Shenghui Wen, Jie-Ruo Gu
          </td>
          <td>2025-12-01</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="The role of the tumor immune microenvironment (TIME) in modulating responses to antiestrogen therapy in hormone receptor-positive (HR+) breast cancers remains unclear. We analyzed pre- and on-treatment biopsies from patients with HR+ breast cancer treated with letrozole to induce estrogen deprivation (ED). Stromal tumor-infiltrating lymphocytes, assessed by H&E-staining, and immune-related gene sets, including IFNɣ signaling, measured by RNA sequencing, were increased in ED-resistant tumors. Cyclic immunofluorescence and spatial transcriptomics revealed an abundance of CD8+ T cells and enhanced antigen processing and immune gene signatures in ED-resistant tumors. In this group, the expression of CXCL9, CXCL10, and CXCL11 - chemokine genes involved in CD8+ T cell recruitment - and the CXCR3 receptor were upregulated both before and after letrozole. CXCL11 levels were higher in conditioned media from HR+ breast cancer cells co-cultured with CD8+ T cells. Both recombinant CXCL11 and co-culture with CD8+ T cells promoted MCF7 and T47D cell growth in estrogen-free conditions. Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to co-culture with CD8+ T cells in estrogen-free conditions. These findings suggest that CD8+ T cell-associated CXCL11 in the TIME modulates the response of HR+ breast cancer cells to estrogen suppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/415bbace3afb02abd0c993c7111f884259b3be03" target='_blank'>
              CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer.
              </a>
            </td>
          <td>
            Fabiana Napolitano, Yunguan Wang, D. Sudhan, Paula I. Gonzalez-Ericsson, Luigi Formisano, N. Unni, Shahbano Shakeel, James Z Zhu, Khushi Ahuja, Lei Guo, M. R. Chica-Parrado, Yuki Matsunaga, Pamela Luna, Chang-Ching A Lin, Yasuaki Uemoto, Kyung-min Lee, Hongli Ma, Nathaniel J. Evans, A. Servetto, Saurabh Mendiratta, Spencer Barnes, Roberto Bianco, Yi Fang, Lin Xu, Jeon Lee, Tao Wang, J. Balko, Gordon B. Mills, Marilyne Labrie, A. Hanker, Carlos L. Arteaga
          </td>
          <td>2025-12-09</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4aac0aaca436c5bc7203a87d69b89b490cdfd76a" target='_blank'>
              Mucosal-Associated Invariant T Cells Promote Atherosclerosis Through Monocyte-Driven Inflammation
              </a>
            </td>
          <td>
            Tobias Radecke, Thomas Nipoti, Louise Z. Wang, N. Mouttoulingam, Marc Diedisheim, M. Chajadine, E. Bacquer, Coraline Heron, P. Alayrac, Charles Caër, L. Laurans, Camille Knosp, Pierre Liénart, Kenza Damache, Rida Al-Rifai, Stéphane Camus, Mathilde Lemitre, Marie Piollet, Oliver Soehnlein, Pierre Julia, J. Alsac, S. E. Batti, F. Letourneur, C. Cochain, Alain Tedgui, H. Ait-Oufella, T. Mirault, Z. Mallat, Olivier Lantz, Jean-Sébastien Silvestre, Sophie Lotersztajn, S. Taleb
          </td>
          <td>2026-01-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>94</td>
        </tr>

        <tr id="Tumor-infiltrating regulatory T (Treg) cells contribute to immune evasion and are associated with poor prognosis in solid tumors. While CD47 blockade has demonstrated efficacy in hematologic malignancies, its application in solid tumors is hindered by the antigen sink effect and lack of tumor selectivity. Here, we report a rationally designed aptamer-siRNA chimera that selectively targets intratumoral Treg cells by exploiting their co-expression of PD-L1 and CD47 within the tumor microenvironment. The PD-L1 aptamer enables selective binding to PD-L1⁺ Treg cells and simultaneously inhibits PD-L1-mediated immune suppression. Conjugated CD47 siRNA silences CD47 expression, abrogating the “don’t eat me” signal and facilitating phagocytic clearance. Mechanistically, this chimera efficiently depletes tumor-infiltrating Treg cells with negligible impact on peripheral cells, and leads to a pronounced increase in intratumoral CD8⁺ T cell infiltration. Further investigation revealed that the chimera impairs Treg migration by disrupting glycolysis-related signaling pathways, including pERK1/2 and pRac1, and induces metabolic reprogramming characterized by reduced glycolysis, increased oxidative metabolism, and elevated fatty acid oxidation (FAO). In murine hepatocellular carcinoma models, treatment with the chimera significantly inhibited tumor growth, reduced angiogenesis, and prolonged survival. Our findings highlight a dual immune checkpoint-targeting strategy that integrates selective delivery with gene silencing, offering a tumor-specific, non-antibody approach for Treg depletion and a promising avenue for solid tumor immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e08750a58059534a9ab521c1290cb1dabc0d16" target='_blank'>
              Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera
              </a>
            </td>
          <td>
            Yu Zeng, Xiaoli Chen, Wenqiong Huang, Chi Ho Chan, Ziqi Chen, Minchuan Lyu, Yumeng Liu, Meijun Liu, Aiping Lyu, Claudio Mauro, Yuanyuan Yu, Kenneth C P Cheung
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation are not well defined. This study investigates the role of CD44, a marker of liver tumor-initiating cells (TIC), in age-associated liver pathophysiology. Aged livers showed accumulation of CD44-expressing hepatocytes exhibiting enrichment of immune modulatory genes and activation of the immunosuppressive IL6/JAK/STAT3 pathway. Indeed, in adoptive transfer assays, antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers, indicating an immunosuppressive aged milieu. Concordantly, spatial analyses showed that the proximal neighbourhoods of Cd44-expressing hepatocytes are enriched in T cells exhibiting reduced cytokine and chemokine gene expression. Finally, hepatocyte-specific knock out of Cd44 mitigated the IL6/JAK/STAT3 gene signature in aged livers. Overall, these findings suggest that CD44 expression in aged hepatocytes promotes activation of the immunosuppressive IL6/JAK/STAT3 pathway and this is associated with impaired T cell effector function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b8cfbe41c4f5eea58d4484e39d30b0c559a09da" target='_blank'>
              Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function
              </a>
            </td>
          <td>
            Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A. Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, M. Teneche, Rouven Arnold, Adarsh Rajesh, Jessica Proulx, Shanshan Yin, Aaron P. Havas, Charlene Miciano, Qian Yang, Elizabeth Smoot, S. Mamde, Andrew Davis, Kevin Y. Yip, Allen Wang, Bing Ren, April E. Williams, S. Kaech, Peter D. Adams
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3541227a821e9e9e6e75e4ddf9b12cd905133ab3" target='_blank'>
              A CD40-Targeted IL-21 Fusokine Enables Rapid Generation of Human IL-10⁺Granzyme B⁺ Regulatory B Cells
              </a>
            </td>
          <td>
            A. Pennati, S. Yuan, Rahul Das, Catigan Hedican, Amar Yeware, Jacques Galipeau
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Background Antiangiogenics promote immune activation by reducing myeloid-derived suppressor cells (MDSCs) and enhancing natural killer (NK) and T cell functions in metastatic RCC patients. However, these effects are transient, leading to compensatory immunosuppression. Platelets (PLT) and their extracellular vesicles (PLT-EVs) modulate immune and angiogenic pathways, suggesting a role in immune reprogramming during therapy. Methods Circulating EVs were longitudinally profiled in metastatic RCC patients (n=8) undergoing Pazopanib therapy. EVs, isolated by differential ultracentrifugation from baseline, 3- and 6-month plasma samples, were characterized by bead-based multiplex assay and nanoparticle tracking analysis. Results were correlated with blood counts, RNA-seq and flow cytometry immune profiles. Results Pazopanib induced temporally structured EV compartment alterations. After three months, EVs were enriched in immune markers (CD8, CD56, CD19, CD1c, HLA-DR), consistent with immune activation, whereas PLT-derived markers (CD41b, CD42a, CD29) were diminished. By six months, PLT-EV markers recovered, with CD62P+ and CD29+ EVs co-expressing immunoregulatory and angiogenic molecules (CD209, CD105). PLT-EV abundance correlated with the expansion of regulatory T cells (Tregs), PD-L1+ monocytes and MDSCs, together with suppression of NK cells. PLT activation and PDGF signaling pathways decreased in PBMC from patients with clinical benefit. Conclusions Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b6ad24127a68aa48867264bc8f9e8e0c3b3b86d" target='_blank'>
              Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC
              </a>
            </td>
          <td>
            Gianpiero Lupoli, Stefano Bergamini, J. Salsetta, A. Mereu, A. Cova, Elisa D’Angelo, Eriomina Shahaj, E. Vergani, Martina Stroscia, Emma Di Carlo, L. Rivoltini, Elena Verzoni, V. Huber
          </td>
          <td>2026-01-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>79</td>
        </tr>

        <tr id="CD19-directed chimeric antigen receptor T (CAR-T) cell therapy is promising for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), yet its long-term efficacy remains limited by CAR-T-cell exhaustion. Given the broad immunomodulatory activities of vitamin D, we investigate whether its active form, 1α,25(OH) 2D 3, enhances CAR-T-cell functionality and improves therapeutic outcomes. We demonstrate that 1α,25(OH) 2D 3 treatment significantly mitigates exhaustion and enhances the antitumor activity of CD19 CAR-T cells derived from both healthy donors and DLBCL patients, which is further validated in xenograft mouse models. Mechanistically, we show that 1α,25(OH) 2D 3 upregulates the expression of the vitamin D receptor (VDR), promoting transcriptional reprogramming associated with memory-like differentiation and downregulation of exhaustion-related genes, thereby reshaping the functional heterogeneity of CAR-T cells under tumor stimulation. Our study highlights 1α,25(OH) 2D 3 supplementation as a safe and accessible approach to mitigate terminal differentiation and exhaustion of CAR-T cells, offering a promising strategy to enhance the clinical efficacy of CAR-T therapy in patients with R/R DLBCL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d57a958be32992e03c454df63622a828b90d5ab" target='_blank'>
              1α,25(OH) 2D 3 prevents CD19 CAR-T cell exhaustion and differentiation via VDR-dependent transcriptional reprogramming.
              </a>
            </td>
          <td>
            Mengke He, Ningzhe Li, Yiwen Cao, Jie Jiang, Fan Zhang, Zeyi Li, Jie Shen, Dehao Zhu, Xiaxin Liu, Qiang Wang, Chenjing Ye, Junmin Li, Zhen Jin, Rufang Xiang
          </td>
          <td>2025-12-01</td>
          <td>Acta biochimica et biophysica Sinica</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2ee83b5054f5bde67b928648f9ddcab5bf45bc4" target='_blank'>
              FAK inhibitor treatment systemically regulates the glioblastoma immune environment via blocking monocyte trafficking
              </a>
            </td>
          <td>
            E. Webb, Annabel Black, Giovana Carrasco, M. Furqan, R. L. Hollis, A. Loftus, Julián Corzo Ochoa, Romain Enjalbert, Tara Best, Bo Peng, Morwenna Muir, Fraser Laing, Martin Lee, Sofian Al Shboul, Tongjie Wang, Colin Smith, Ted R Hupp, Ajitha Rajan, Javier A Alfaro, Paul M Brennan, Zhaoyuan Liu, Florent Ginhoux, M. O. Bernabeu, A. Serrels, Rebecca Gentek, M. Frame, V. Brunton
          </td>
          <td>2025-12-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy, with HPV driving approximately 50% of cases and correlating with improved outcomes. In this study, we perform single-cell RNA sequencing on tumor microenvironment (TME) cells from 23 treatment-naive PSCC patients, including 11 cases reported previously, and validate our findings in a larger cohort of 85 patients. Our analysis reveals significant immune cell infiltration in PSCC, with HPV+ tumors exhibiting elevated levels of tumor-infiltrating B cells, plasma cells, tertiary lymphoid structures, and IgA secretion. A subset of malignant epithelial cells in HPV+ PSCC express the polymeric IgA receptor (PIGR), facilitating IgA transcytosis and inducing anti-tumor responses. Functional studies show that PIGR overexpression promotes tumor apoptosis and enhances immune responses, with these effects diminish in IgA-deficient mice. Elevated IgA and PIGR expression correlate with improved survival. These findings provide a single-cell atlas of the PSCC TME, highlighting the B cell–IgA–PIGR axis as a pivotal driver of antitumor immunity and clinical outcomes in HPV+ PSCC. The mechanisms underlying the improved survival in HPV-positive penile squamous cell carcinoma (PSCC) compared to HPV-negative counterparts remain to be explored. Here, single-cell sequencing highlights the role of the B cell-IgA-PIGR axis in enhancing antitumor immunity and improving clinical outcomes in HPV-positive PSCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/410f1998b2c04adc9c0c462f3d613fa02e71a11e" target='_blank'>
              A B cell-IgA-epithelial axis enhances antitumor immunity and improves outcome in HPV-associated penile squamous cell carcinoma
              </a>
            </td>
          <td>
            Tao Tao, Lianbang Zhu, Deyun Shen, Jiayang Zhang, Panrui Zhang, Zhixi Gu, Dan Cao, Jun Xiao, Wen Pan
          </td>
          <td>2025-12-11</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Objectives This study aimed to investigate the role of natural killer (NK) cell and interferon (IFN) signaling in the peripheral circulation of anti-MDA5+ dermatomyositis (DM) patients, particularly in the context of interstitial lung disease (ILD) development. Methods Peripheral blood mononuclear cells (PBMCs) from six newly diagnosed, active anti-MDA5+ DM patients (3 with ILD, 3 without ILD) were analyzed using single-cell RNA sequencing (scRNA-seq), focusing on NK cell features. The correlation between serum cytokine levels and ILD severity assessed by HRCT scores was further analyzed. Flow cytometry in an independent cohort validated NK cell apoptosis, and in vitro experiments evaluated IFN-induced apoptosis in NK-92 cells. Results ScRNA-seq revealed widespread activation of IFN responses in PBMCs from anti-MDA5+ DM-ILD patients, with pronounced upregulation in innate immune cells (e.g., NK cells and monocytes). A reduction in circulating NK cell proportions was observed in ILD patients. Serum levels of cytokines (IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12P70, TNF-α, and IFN-α) positively correlated with the radiologic severity of ILD as quantified by HRCT scores. Flow cytometry confirmed significantly decreased NK cell counts and increased apoptosis in the ILD group. PBMCs from healthy donors exposed to an ILD-like cytokine milieu exhibited upregulated IFN pathway genes (ISG15, MX2, IFIT3), EIF2AK2 (encoding protein kinase R), and apoptosis-related genes (BCL2, BAX2). In vitro, IFN stimulation directly induced apoptosis in NK-92 cells. Conclusion Excessive IFN activation drives NK cell apoptosis in anti-MDA5+ DM-ILD, contributing to NK cell depletion and ILD development. IFN-related biomarkers may serve as valuable indicators for assessing ILD severity in these patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f561d51a5fa1e3b04b78d86a4673eadd69564ec1" target='_blank'>
              Exhaustion of NK cells and interferon activation in anti-MDA5+ dermatomyositis are associated and determine the development of ILD
              </a>
            </td>
          <td>
            Chenyi Shao, Yan Zhen, Nana Xia, Xueliang Zhang, Ninghui Yan, Mengmeng Zhou, Yiyuan Guo, Limin Tan, Qiang Guo
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC. Methods Functional studies were conducted in azoxymethane/dextran sodium sulfate and MC38 murine CRC models using CD300e systemic and myeloid-specific CD300e knockout mice, and adoptive transfer experiments assessed macrophage-intrinsic effects. Human studies included analysis of CD300e expression in matched tumor and normal tissue from patients with CRC and in vitro co-culture of patient-derived colon tumor organoids with monocytes to study CD300e induction and TAM polarization. Results In vivo, CD300e deficiency led to reduced tumor burden, enhanced major histocompatibility complex expression on TAMs, and improved T-cell responses. CD300e-deficient macrophages exhibited increased phagocytic activity, antigen presentation, and support for T-cell proliferation and cytotoxicity. Adoptive transfer confirmed that macrophage-intrinsic CD300e expression is sufficient to suppress T-cell function and promote tumor growth. In patients with CRC, CD300e is selectively upregulated in tumor-infiltrating monocytes and macrophages, driving a suppressive phenotype marked by impaired antigen presentation. Tumor-derived signals in vitro induce CD300e expression and promote a protumorigenic macrophage profile. Conclusions Our findings identify CD300e as a critical regulator of macrophage-mediated immune suppression in CRC and a potential target for reprogramming TAMs to enhance immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/16c56c500ab6751223d28c46c0f7327dc521a283" target='_blank'>
              CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming
              </a>
            </td>
          <td>
            Annica Barizza, Stefania Vassallo, L. Masatti, Mattia Laffranchi, Sofia Giacometti, S. Lonardi, Mattia Bugatti, Sara Coletta, C. Della Bella, M. D’Elios, Simone Pizzini, A. Rosato, W. Vermi, Matteo Fassan, G. Spolverato, Silvano Sozzani, E. Calura, R. Sommaggio, Gaia Codolo
          </td>
          <td>2025-07-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Reprogramming the immunosuppressive milieu in pancreatic cancer (PaCa) remains an important yet unmet therapeutic goal. Although tumor-associated macrophages (TAMs) are known to promote tumor growth and metastasis, little is known about the underlying mechanisms driving macrophage plasticity in PaCa. Herein, we show that extracellular vesicles (EVs) released by PaCa cells as well as circulating EVs in patient plasma, facilitate cellular crosstalk thereby promoting preferential skewing of recipient macrophages towards an M2-like TAM phenotype. PaCa-EV educated macrophages predominantly secrete anti-inflammatory cytokines, adapt an M2-like metabolic phenotype, have a higher expression of PD-L1, and suppress the proliferation of CD8+ T cells. An increased payload of miR-182-5p in PaCa-EV cargo causes a decrease in TLR4 expression in recipient macrophages and a concomitant upregulation of JAK/STAT3 pathway and elevated secretion of IL-10 and TGF-β, leading to increased PD-L1 expression. Most notably, targeted therapeutic delivery of antagomiR-182-5p in pancreatic tumor-bearing mice with varying immunogenic potential results in a significant decrease in tumor volume, increased survival, restoration of M1/M2 ratio, and an overall increase in CD8+ T cell activation in the TME. Taken together, we demonstrate a direct role of EVs in subverting the immune microenvironment and altering macrophage plasticity in a manner conducive to both tumor growth and proliferation. As such, a targeted delivery of microRNA inhibitors as drugs for altering macrophage plasticity may likely achieve better therapeutic response in pancreatic tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/934885801642cb8c2056560a4186551b7da4ccea" target='_blank'>
              Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer
              </a>
            </td>
          <td>
            Baldev Singh, Pankaj Gaur, Pritha Bose, Yanjun R. Zhang, Yaoxiang Li, Zihao Zhang, Jeyalakshmi Kandhavelu, William Klotzbier, Meth B. Jayatilake, Shivani Bansal, Mohd Farhan, Sunain Deol, P. Banerjee, Keith Unger, Seema Gupta, Vivek Verma, Amrita K. Cheema
          </td>
          <td>2026-01-16</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fda0edb364952e5067fda86230619632242ae72" target='_blank'>
              Cancer-Associated Mesothelial Cells Drive Immune Escape and Therapy Resistance in Ovarian Cancer
              </a>
            </td>
          <td>
            M. Chauvin, Julien Roche-Prellezo, Virginie Lafont, Henri-Alexandre Michaud, Estelle Tromelin, Robin Michel, Clara Freixinos, Marie-Charlotte Meinsohn, Pierre-Emmanuel Colombo, Nathalie Bonnefoy, Laurent Gros, David Pépin
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Tumour-associated macrophages (TAMs) are key components of the tumour microenvironment with a demonstrated ability to modulate anti-tumour T-cell responses and immunotherapy outcomes. With increasing realisation that the M1/M2 paradigm does not reflect the complexity of macrophage phenotypes in cancer patients, an urgent need has arisen to develop improved, translatable in vitro models for human TAMs. To address this gap, we have screened conditioned media from a panel of tumour cell lines for their ability to induce suppressive marker upregulation on human monocyte-derived macrophages, as well as active T-cell immunosuppression. We performed secretome characterization of these tumour-conditioned media (TCM) to shed light on cancer cell-derived soluble factors that may contribute to TAM polarisation. Furthermore, we characterized the proteomic and transcriptomic signatures of macrophages exposed to either TCM or primary ascites fluid from ovarian cancer patients and performed bioinformatics analysis to determine the most translationally relevant models of TAMs. In summary, our work provides mechanistic insights on tumour-macrophage crosstalk in the context of establishing suppressive TAM phenotypes and addresses the long-standing gap of defining translationally relevant human in vitro TAM models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/30facde6ef46ddd2505962e83549fbeaa8fcb60c" target='_blank'>
              Characterisation of human in vitro tumour-associated macrophage models to define translational relevance
              </a>
            </td>
          <td>
            Arthur Dyer, Rebecca Dudley, Shreya Ahuja, Clara Alsinet, Pawan Poudel, Georgina Bowyer, Kalvin Sahota, Saly Songvilay, Des C Jones, Matthew Glover, Sonja Hess, Elina Timosenko, S. Dovedi
          </td>
          <td>2025-11-28</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="The contribution of chemotherapy-induced tissue injury to individual susceptibility to metastasis remains largely unexplored. We report that chemotherapy indirectly prevents colorectal cancer (CRC) liver metastases by inducing a lasting systemic “chemomemory”. Chemotherapy-induced intestinal mucositis alters nutrient availability, promoting the expansion of tryptophan-metabolizing bacteria and production of the microbial metabolite indole-3-propionic acid (IPA). IPA reprograms bone marrow myelopoiesis by redirecting common myeloid progenitor fate toward the macrophage lineage, limiting generation of immunosuppressive Ly6ChighCCR2+ monocytes. This shift enhances CD4+ T cell antitumor function by promoting Th1 differentiation and spatially reorganizing CD8+ and CD4+ T cell interactions within the metastatic microenvironment. In a subset of CRC patients, circulating IPA levels increase after chemotherapy and inversely correlate with monocyte abundance, while high monocyte levels were associated with reduced survival. Our findings reveal that chemotherapy-induced intestinal injury normalizes pathological myelopoiesis through a microbiota-derived metabolite and identify IPA as a potential adjuvant to counteract monocyte-driven immunosuppression and metastasis. The microbiota influences the cytotoxicity of chemotherapy in patients with colorectal cancer but the impact on metastatic relapse is less clear. Here, the authors report that chemotherapy-induced intestinal mucositis induces systemic immune changes via production the microbial metabolite, indole-3-propionic acid (IPA), preventing metastases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/15a21dacb8c45e65545bd42db1f0f3a748edfc8e" target='_blank'>
              Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state
              </a>
            </td>
          <td>
            Ludivine Bersier, L. F. Lorenzo-Martín, Yi-Hsuan Chiang, Stephan Durot, Aleksander Czauderna, T. Yarahmadov, Tania Wyss Lozano, I. Roci, Jaeryung Kim, N. Zamboni, N. Vannini, C. Pot, T. Collet, D. Stroka, J. Bernier-Latmani, Matthias P. Lutolf, Simone Becattini, Thibaud Koessler, Tatiana V. Petrova
          </td>
          <td>2025-12-15</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ce380aea2613d07a2569ea17ef622bcc9b49b6c" target='_blank'>
              Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening
              </a>
            </td>
          <td>
            Ting Pan, Tingting Wang, Jiaqi Wu, Heping Wang, Bo Zeng, Yangyang Li, Ming Yi, Ruirui He, Lingyun Feng, Zhihui Cui, Guoling Huang, Panyin Shu, Yuan Wang, Xi Li, Yanyun Du, Zhen Li, Xue Xiao, Chenhui Wang
          </td>
          <td>2026-01-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background Human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (Mtb) co-infection remains a major cause of mortality in AIDS patients, yet the mechanisms of pathogen interplay and host immune remodeling remain poorly understood. Methods To capture early untreated states, we applied single-cell RNA sequencing (scRNA-seq) to peripheral blood mononuclear cells from healthy controls, and from participants newly diagnosed with HIV mono-infection or HIV-Mtb co-infection, before therapy initiation. Integration guided by a Directed Acyclic Graph (DAG) inferred a pseudo-temporal trajectory from health to HIV infection to co-infection. Results Along this continuum, TNF-α and TGF-β signaling progressively declined in CD8+ T cells and monocytes. Th1 cells emerged as the dominant anti-tuberculosis effectors, whereas Th17 cells exhibited transcriptional exhaustion and ribosomal stress signatures consistent with a non-responsive state. Cell communication analysis revealed fewer overall interactions but increased signaling strength within pathways during co-infection. Notably, we observed a transition in T cell from MHC class II to class I, a shift that was most pronounced in the CD4+ effector memory subset. These rewired interactions featured selective upregulation of inhibitory checkpoint molecules (PGE2–PTGES3–PTGER2/4, PPIA-BSG, PECAM1) and loss of stimulatory signals (CD6-ALCAM, CLEC2B/C/D-KLRB1). Discussion Our study provides a single-cell roadmap of HIV-Mtb co-infection and identifies Th1/Th17 imbalance and MHC-I-biased T-cell signaling reconfiguration as candidate targets for restoring immune homeostasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3079e80670107d8df959c9a9373c58fb84ac742d" target='_blank'>
              Single‐cell transcriptomics reveals pathogen interactions and T cell reprogramming in HIV and Mycobacterium tuberculosis co‐infection
              </a>
            </td>
          <td>
            Zihui Zhao, Suyue Huang, Wei Huang, Wei Song, Li Liu, Jun Chen, Ren-fang Zhang, Yinzhong Shen
          </td>
          <td>2025-11-28</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Melanoma remains a major challenge in oncology because of its aggressive behavior and intricate immune interactions. Advances in immunophenotyping and single-cell atlas technologies have revealed heterogeneous regulatory T cell (Treg) subsets, among which peripheral blood CD39+PD-1+ Tregs have emerged as key mediators of systemic immunosuppression. This review summarizes current evidence on their immunoregulatory functions, emphasizing their role in suppressing anti-tumor immunity and contributing to poor clinical outcomes. By integrating immune atlas data with clinical observations, we outline the mechanisms by which this subset shapes both the tumor microenvironment and systemic immune responses. We further discuss their potential as prognostic biomarkers and therapeutic targets to optimize immunotherapy strategies. In addition, we highlight how this subset interacts with other immunosuppressive pathways, reinforcing resistance to immune checkpoint inhibitors. Despite these advances, challenges remain in fully characterizing this population and translating findings into clinical application. This review provides a comprehensive overview of the significance of CD39+PD-1+ Tregs in melanoma immunopathology and highlights future directions to advance precision immunotherapy and improve patient prognosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc33012596eab785fba7e6d8eba704e87044622b" target='_blank'>
              CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers
              </a>
            </td>
          <td>
            Guanlin Qiao, Hongxia He, Xiaobing Wang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="CD8+ T cells are an important weapon in the therapeutic armamentarium against cancer. While CD8+CD103+ T cells with a tissue-resident memory T (TRM) cell phenotype are associated with favorable prognoses, the tumor microenvironment also contains dysfunctional exhausted T (TEX) cells that exhibit a variety of TRM-like features. Here we deconvolute TRM and TEX cells across human cancers, ascribing markers and gene signatures that distinguish these populations and enable their functional distinction. Although TRM cells have superior functionality and are associated with long-term survival post-tumor resection, they are not associated with responsiveness to immune checkpoint blockade. Tumor-associated TEX and TRM cells are clonally distinct, with the latter comprising tumor-independent bystanders and tumor-specific cells segregated from cognate antigen. Intratumoral TRM cells can be forced toward an exhausted fate when chronic antigen stimulation occurs, indicating that the presence or absence of continuous antigen exposure within the microenvironment is the key distinction between tumor-associated TEX and TRM populations. These results highlight unique functions for TRM and TEX cells in tumor control, underscoring the need for distinct strategies to harness these populations for cancer therapies. Here the authors show that tissue-resident memory and exhausted T cells in tumors are distinct populations that are shaped by relative presence or absence of TCR signals, suggesting that a tailored therapeutic strategy is needed to target each subset.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/23a712967a1f06be04c88812bdec6b8089c56c0b" target='_blank'>
              Antigen reactivity defines tissue-resident memory and exhausted T cells in tumors
              </a>
            </td>
          <td>
            Thomas N. Burn, Jan Schröder, Luke C. Gandolfo, M. Osman, Elanor N. Wainwright, E. Lam, Keely M. McDonald, Rachel B. Evans, Shihan Li, Daniel Rawlinson, Lachlan Dryburgh, Ali Zaid, Z. Maliga, Dominick Schienstock, Philippa Meiser, H. J. Lee, Hongjin Lai, Marcela L. Moreira, Pirooz Zareie, Louis H-Y. Lee, Lutfi Huq, Susan N. Christo, Justine Seow, Keith A. Ching, Stéphane M. Guillaume, Kathy Knezevic, Simone L. Park, Maximilien Evrard, Jason Waithman, T. Gebhardt, Scott N. Mueller, G. Riddiough, M. V. Perini, S. C. Tsao, Terence P. Speed, P. Sorger, S. Loi, Francis R. Carbone, Stephanie Gras, Timothy S Fisher, Bas J Baaten, M. Dawson, Laura K. Mackay
          </td>
          <td>2025-12-29</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="Resistance to immune checkpoint blockade (ICB) remains a major challenge in lung adenocarcinoma (LUAD), with stromal mechanisms underlying CD8⁺ T cell exhaustion still poorly understood. By integrating single-cell, bulk, and spatial transcriptomic datasets using EcoTyper, we identified a distinct immunosuppressive ecotype, EC10, enriched for TGF-β signaling and epithelial–mesenchymal transition. EC10 exhibited spatial co-localization of fibroblasts, malignant epithelial cells, and exhausted CD8+ T cells, and was consistently associated with immune exclusion, poor progression-free survival, and elevated TIDE scores across four ICB-treated LUAD cohorts. Cell–cell communication analyses revealed a dominant TGFB1–SERPINE1 signaling axis originating from fibroblasts, linking stromal remodeling to T cell dysfunction. In contrast, EC12 represented an inflamed, ICB-responsive state enriched in interferon signaling. These findings define EC10 as a spatially organized, fibroblast-driven immunosuppressive ecosystem predictive of ICB resistance, and highlight the therapeutic potential of targeting the TGF-β axis in LUAD. This research identifies a fibroblast-driven immunosuppressive ecosystem in lung adenocarcinoma, linking TGF-β signaling to immune resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130525b051ffbdab87e5edbec0e75b95564de9c8" target='_blank'>
              Fibroblast TGF-β signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance
              </a>
            </td>
          <td>
            Seo-Young Lee, Youngjoo Lee
          </td>
          <td>2025-12-01</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4eb287f4be34ac61e66b972c8521500710a820fd" target='_blank'>
              Dual inhibition of the nonsense mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and potentiates checkpoint blockade
              </a>
            </td>
          <td>
            Ivan Zadra, Davor Orsolic, Dimitri Kounis, Mario Acera, Guillermo Palou Márquez, Etna Abad, Laura Ortet, Anna Benito, Y. Kharraz, Carlos M. Martínez, Elisabetta Mereu, Fran Supek, Ana Janic
          </td>
          <td>2025-12-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Abstract Mucosal-associated invariant T (MAIT) cells are unique unconventional T cells with diverse roles in immunity, yet how their context informs their function is not well known. This contextual regulation is particularly relevant in cancer, where MAIT cells have an enigmatic role. We performed a systematic review and meta-analysis to identify MAIT cell transcriptomic signatures under different environmental conditions. We identified 4 bulk-RNA-sequencing studies that compared multiple activation stimuli. We found a stimulus-specific transcriptional signature for immune checkpoint genes, that we confirmed in a single-cell RNA-sequencing dataset. We used flow cytometry to examine in vitro human MAIT cells across 4 activation stimuli and confirmed that stimulus drives unique checkpoint signatures upon MAIT activation for Lag3, PD-L1, PD-1, NKG2A, and Tigit. Strikingly, PD-L1 was more highly induced in vitro than PD-1 in MAIT cells up to 72 h. Our data suggest that human MAIT cell regulation is context-dependent. These findings have the potential to critically inform efforts targeting MAIT cells for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ecf762a805ede9d94ba29010a5a748ff3406109" target='_blank'>
              Immune checkpoint expression in mucosal-associated invariant T cells is stimulus-dependent
              </a>
            </td>
          <td>
            C. Clutter, Audrey Re, Kenadee Jacobson, Kendell Clement, Jeffrey Aubé, Ryan M O'Connell, D. Leung
          </td>
          <td>2025-12-06</td>
          <td>Journal of Leukocyte Biology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Bispecific T cell engagers (TCEs) often exhibit limited efficacy in solid tumors, in part due to immunosuppressive cues in the tumor microenvironment and low expression of targetable tumor antigens. Therapeutic strategies to improve TCE target sensitivity and enhance T cell effector functions therefore have significant translational potential. Here, we engineered TCEs that induce T cell activation in vitro against the low-abundance target antigens, TRP2/Kb and DLL3. Despite in vitro activity in these models, TCE monotherapy showed limited control of tumor growth in immunocompetent mice. Leveraging this in vivo model of TCE treatment failure, we discovered that co-treatment with TCE and a CD25-biased Interleukin-2 (IL2) rescues anti-tumor activity. Further, multimodal single-cell transcriptomic and immune repertoire analyses revealed that TCE-IL2 combination therapy controlled tumors by recruiting and activating new CD8+ T cells into the tumor microenvironment. These findings demonstrate that TCE-mediated anti-tumor responses function through a CD8+ T cell clonal replacement mechanism that can be augmented by cytokine therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b88f987398014e44f618252c969f839bb8ea3a65" target='_blank'>
              Bispecific T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells
              </a>
            </td>
          <td>
            Matthias Obenaus, Clara L. Poupault, Chris McGinnis, Céline Prange, Hua Jiang, Leon L. Su, Xiaojing Chen, Zhuang Miao, Joseph J. Muldoon, Winnie Yao, Deepa Waghray, Qinli Sun, Justin Eyquem, Rogelio A. Hernandez-Lopez, Ansu Satpathy, Julien Sage, K. C. Garcia, Christopher Garcia
          </td>
          <td>2025-12-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Background Intratumoral vaccines offer a promising avenue in cancer immunotherapy by harnessing the tumor microenvironment to stimulate immune responses. However, challenges persist in maximizing their effectiveness and addressing immune suppression within tumors. Methods Conventional in situ vaccine (CisVac) and α-CD137 antibody were administered in implanted mouse models of lung and colon cancer to evaluate therapeutic efficacy. The initiation mechanism of CD8+ T cells was determined using antibody blockade and transgenic mouse models. Single-cell RNA sequencing was used to further characterize the activation mechanism of T cells. Results Our findings indicate that this synergistic approach markedly inhibits tumor growth while eliciting a robust antitumor immune response, characterized by heightened activation and cytotoxic differentiation of CD8+ T cells, as well as the polarization of conventional dendritic cells (cDC1). Mechanistically, it promotes the cDC1-dependent proportion and cytokine production of tumor antigen-specific CD8+ T cells, mobilizes and establishes enduring systemic immune memory. Our single-cell transcriptome analyses revealed that the therapy facilitates a functional remodeling of regulatory T cells (Tregs) with upregulated inflammatory genes, potentially attenuating immune suppression. Cell–cell communication analyses highlighted interactions between CD4+ Th1-like/Th17 cells and monocytes/DCs through the CD40L-CD40 pathway, indicating potential intercellular regulatory mechanisms. Conclusions Our results highlight the transformative potential of the CisVac/α-CD137 combination in cancer immunotherapy, paving the way for further exploration of its clinical utility and long-term efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9a1786508ee836cc9d2222e3b459dc374fa507ff" target='_blank'>
              In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses
              </a>
            </td>
          <td>
            Mengjiao Wang, Li Qiu, Cheng Tang, Danqing Huang, Qiaocong Zheng, Zunyi Li, Zhenhui Zhang, Shupei Wei, Lanfang Chen, Hongxin Huang, Jun Liu, Junfeng Zhou, Tao Lu, Guanxin Liu, Yingjie Nie, Qibin Leng, Tao Chen
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="The gut microbiota plays an essential role in mucosal immunity, with secretory immunoglobulin A (IgA) acting as a key effector in neutralizing pathogens and maintaining host-microbiota homeostasis. IgA production occurs via T cell-dependent (TD) and -independent pathways, with T follicular helper (Tfh) cells driving high-affinity, antigen-specific IgA responses. However, the specific microbial taxa and metabolites that regulate Tfh-mediated IgA responses under steady-state conditions remain poorly understood. This study investigated how gut microbiota-derived signals shape Tfh responses and IgA production, with implications for enhancing mucosal vaccine efficacy. We demonstrate that Peyer’s patches (PP)-derived Tfh cells exhibit superior IgA-inducing capacity compared to splenic Tfh cells. RNA sequencing revealed distinct transcriptional profiles in PP-Tfh cells, including upregulation of the genes associated with Tfh differentiation and activation (Bcl6, Cd40lg, Maf), T-B cell interactions (Il21, Sh2d1a, Fyn), and migration (Ccr6, Cxcr5). Functionally, PP-Tfh cells formed larger T-B cell contact areas and induced significantly higher IgA secretion in co-culture than their splenic counterparts. Microbiota depletion experiments revealed that eliminating neomycin-depleted bacteria reduced fecal IgA levels and diminished PP-Tfh cell frequencies. Fecal microbiota transplantation from neomycin-treated mice restored both IgA production and Tfh responses in germ-free (GF) mice. Bioinformatic analysis (PICRUSt2 and LEfSe) identified butyrate-producing Lachnospiraceae and Ruminococcaceae as key drivers of the Tfh-IgA axis. Butyrate supplementation enhanced Tfh differentiation and IgA⁺ germinal center B cell development in vitro and increased fecal IgA levels in vivo. Mechanistically, butyrate promoted IgA production via GPR43 signaling, as its effect was lost in co-cultures with Gpr43⁻/⁻ Tfh cells. Moreover, treatment with tributyrin, a butyrate prodrug, enhanced vaccine-induced IgA and protected mice against Salmonella Typhimurium infection, reducing bacterial burden and tissue damage. These findings define a functional microbiota-Tfh-IgA axis sustained by neomycin-depleted, butyrate-producing bacteria. Our study underscores the crucial role of the gut microbiota, particularly neomycin-depleted butyrate producing taxa, in regulating PP-Tfh cell function and IgA production. Butyrate emerges as a metabolite linking microbial metabolism to Tfh differentiation and IgA class switching. Together, these findings establish a microbiota-metabolite-Tfh cell axis essential for mucosal immune homeostasis and suggest novel strategies for enhancing vaccine efficacy and protection against enteric infections. 65SkT5T5U4s1JHPzYWZphR Video Abstract Video Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/258f08bfcfc4875278debbc54438c4cb8dd78ba9" target='_blank'>
              Commensal microbe-derived butyrate enhances T follicular helper cell function to boost mucosal vaccine efficacy
              </a>
            </td>
          <td>
            Haeun Ko, Chan Johng Kim, Seungyeon Choi, Jaegyun Noh, Seung Won Kim, Juhun Lee, Seohyun Byun, Haena Lee, J. Park, H. Park, Amit Sharma, Minhyuk Park, Junghwan Park, Choong-Gu Lee, Kwang Hyun Cha, Sin-Hyeog Im
          </td>
          <td>2026-01-21</td>
          <td>Microbiome</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Background Programmed cell death protein-1 (PD-1) blockade has shown promising clinical efficacy in hepatocellular carcinoma (HCC), yet the underlying immunological mechanisms governing response and resistance remain unclear. This study aimed to delineate the temporal and spatial dynamics of T-cell clonotypes and their relationship with pathological response in neoadjuvant PD-1 blockade therapy in HCC. By integrating T-cell receptor (TCR) repertoire analysis with transcriptomic profiling, we sought to elucidate the immune landscape alterations associated with treatment outcomes. Methods We analyzed longitudinal, matched tumor and blood samples from our previous clinical trial (NCT05471674), encompassing 114 specimens, including pre-nivolumab tumor biopsies, post-treatment resected tumors, adjacent non-tumorous livers, and peripheral blood collected before, after, and during follow-up from 19 treatment-naïve HCC. TCR clonality, diversity, and transcriptomic signatures were assessed to characterize immune responses. Results Elevated clonality of intratumoral TCR clonotypes (ITCs) post-treatment correlated with increased pathological tumor necrosis, predominantly driven by the most abundant top 1% ITCs. These dominant clonotypes occupied a significantly larger clonal space and demonstrated increased spatial sharing across tumor, non-tumorous liver, and peripheral blood compartments in nivolumab responders (nivo-Rs). Shared clonotypes were positively associated with tumor necrosis extent and cytolytic activity, suggesting active immune engagement. Post-treatment, shared clonotypes exhibited peripheral expansion and greater intratumoral dominance in nivo-Rs, whereas tumor unique intratumoral TCR clonotypes (ITCs) remained prevalent in non-responders (nivo-NRs). These divergent patterns were linked to higher chemokine expression within the tumor microenvironment of nivo-Rs and impaired human leukocyte antigen (HLA) class II antigen presentation in nivo-NRs, indicating distinct immune landscape configurations influencing therapeutic response. Conclusions Our findings demonstrate that the peripheral infiltration and expansion of high-frequency intratumoral T-cell clonotypes are critical drivers of pathological response to neoadjuvant PD-1 blockade in HCC, highlighting potential immune biomarkers and therapeutic targets to enhance immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/901935af9edd3945285033fa6917d3b60bbe154f" target='_blank'>
              Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Yajing Zhang, Y. Tsui, J. Lee, T. Cheung, DanielWai-Hung Ho, I. Ng
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="ABSTRACT Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8+ T cells and CD16A+ NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A+ NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b68faec76c8019914aaaeb0bb112e3f2ed84b4a" target='_blank'>
              NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells
              </a>
            </td>
          <td>
            L. Heger, Tomasz Kaszubowski, L. Amon, C. H. Lehmann, Susanne Wingert, J. Medina-Echeverz, Joachim Koch, Holger Hackstein, A. Purbojo, Arndt Hartmann, Christoph Alexiou, R. Cesnjevar, J. Pahl, Diana Dudziak
          </td>
          <td>2026-01-18</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="The CD40 pathway has become one of the most promising immunologic axes in oncology. As a central intermediary between innate and adaptive immunity, CD40 activation engages dendritic cells (DCs), amplifies antigen presentation, and stimulates potent cytotoxic T‐cell (CTL) activity. Therapeutic CD40 agonists have been studied in a broad range of cancers over the past decade to reconfigure the tumor's immune microenvironment (TIME) and overcome immune refractoriness to standard immunotherapies. Clinical development has been most significant in pancreatic cancer, an exemplar cold tumor resistant to immune checkpoint blockade. Here, CD40 agonists have demonstrated efficacy to repolarize immune‐desert phenotypes to a more inflamed and treatable phenotype, particularly in combination with chemotherapy or programmed cell death protein 1 (PD‐1) inhibitors. Clinical evidence has also been gained in melanoma and non‐small cell lung cancer, where CD40‐targeted strategies are examined in combination with current checkpoint inhibitors to accelerate T‐cell priming. In hematologic malignancies and B‐cell lymphomas, in particular, CD40 agonists exploit the natural activity of the B‐cell activating receptor, providing a strong biological rationale for their clinical efficacy. Exploratory studies have gone on to extend into bladder, prostate, mesothelioma, and head and neck cancers, demonstrating the broad translational relevance of this pathway. Hopes fostered by preliminary signs of activity remain to be qualified in light of the difficulties. Systemic immune activation‐associated toxicities, such as cytokine release syndrome, have justified cautious dosing schedules and exploration of local routes of drug administration. Additionally, heterogeneity between tumors in response underscores an urgent need for predictive biomarkers to enable the selection of patients and to tailor optimal clinical effects. In the future, drug development will be reliant on prudent combinations and novel delivery methods. Conjugation to vaccines, bispecific antibodies, radiotherapy, and oncolytic viruses is an attractive route to achieve their fullest immunostimulatory capabilities. Through a flexible approach to reeducate the immune microenvironment within tumors, CD40 agonist therapy can extend the use of immunotherapy to traditionally immune‐refractory malignancies. This review intends to present a cross‐cancer approach to CD40 agonist therapy, compiling existing clinical evidence while highlighting common issues and prospects for harnessing this pathway across various tumor settings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be05bece04ba4f9ae6c853fd6509daabc054db80" target='_blank'>
              Cross‐Cancer Perspectives on CD40 Agonist Therapy: Modulating the Tumor Immune Microenvironment
              </a>
            </td>
          <td>
            Xudong Hua, Junyan Hua, Yanzhong Wang
          </td>
          <td>2026-01-01</td>
          <td>Journal of Biochemical and Molecular Toxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Background Colorectal cancer (CRC) continues to represent a major cause of cancer-related mortality worldwide, with its progression and therapeutic outcomes strongly shaped by the complexity and heterogeneity of the tumor immune microenvironment (TME). This review critically examines the cellular and molecular mechanisms driving immune evasion in CRC, emphasizing the dual roles of immune cell populations—including tumor-associated macrophages, neutrophils, dendritic cells, T cells, B cells, and natural killer cells—as well as non-cellular elements such as the extracellular matrix and extracellular vesicles. Objective A key objective is to evaluate recent developments in immunotherapeutic approaches, including immune checkpoint inhibitors, tumor vaccines, adoptive cell transfer, and novel combinatorial regimens, while addressing their therapeutic promise and inherent limitations, especially in microsatellite-stable (MSS) tumors that exhibit primary resistance to standard immunotherapies. Further analysis integrates perspectives on metabolic reprogramming within the TME, epigenetic alterations, and advances in engineered cellular therapies, thereby providing a comprehensive framework for overcoming immunosuppressive mechanisms. Discussion and conclusion Special consideration is directed toward the translational value of targeting immune-metabolic interactions and spatial dynamics within the TME. Ultimately, this work synthesizes current knowledge and outlines forward-looking strategies to advance personalized, multi-target immunotherapy, with the potential to reshape clinical paradigms in CRC management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/03fb3a1b140db8c8ae9afa2ff97c1f40f6b8cd5d" target='_blank'>
              Cellular characteristics of the immune microenvironment of colorectal cancer and progress in immunotherapy research
              </a>
            </td>
          <td>
            Chunbaixue Yang, Jianchun Fan, Yixuan Zhang, Yixiao Zhang, Lei Xia, Xinran Cao, Xueliang Wu
          </td>
          <td>2025-11-30</td>
          <td>Annals of Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="T cells are central components of the adaptive immune system and play key roles in antitumor and antiviral responses. The diverse cell fates of T cells enable them to respond to different durations and strengths of antigen stimulation and various cytokine milieus in a context-dependent manner. During acute infection or vaccination, T cells differentiate into effector cells and later develop into memory cells after antigen clearance, which mediate immune protection against the same antigen. In contrast, during cancer and chronic infection, T cells fail to enter the canonical effector or memory cell differentiation path. Instead, antigen-specific T cells enter a dysfunctional, partially responsive state called exhaustion. Exhausted T cells are heterogeneous. A subset of exhausted T cells exhibits stem cell-like properties. These stem-like T cells sustain immunity through self-renewal and repopulation of terminally differentiated progenies. Stem-like properties are critical for T cell immunity induced by immunotherapy. This review summarizes recent advances in understanding the molecular mechanisms controlling the exhaustion and stemness of T cells and explores the potential of rewiring these circuits to increase the efficiency of T-cell-based immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01145f359013ec590de5209ce820dcb252b3001d" target='_blank'>
              Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy
              </a>
            </td>
          <td>
            Zeyu Chen, Ziang Zhu, Taidou Hu, Chen Yao, Tuoqi Wu
          </td>
          <td>2025-12-19</td>
          <td>Cellular and Molecular Immunology</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Background Challenges to developing immunotherapies for acute myeloid leukemia (AML) include the identification of suitable target antigens due to on-target-off-leukemia toxicity. CD70, expressed on AML bulk and leukemic stem cells with limited expression on healthy cells, has emerged as a promising target. Methods This study evaluated CD70 as a target for NK-cell-based immunotherapy using a sugar-engineered antibody (PF-08046040, SEA-CD70). CD70 surface expression was assessed in primary AML samples by multiparameter flow cytometry. The cytotoxic capacity of SEA-CD70 was analyzed through antibody-dependent cellular cytotoxicity (ADCC) assays using AML cell lines, primary AML samples, and a severe combined immunodeficiency (SCID) mouse xenograft model. The effects of cytokines on CD70 expression and ADCC were investigated by exposing AML cells to conditioned medium (CM) derived from activated T cells or recombinant cytokines. Results Flow cytometry revealed CD70 expression ranging from 0.2% to 89.6% (median=7.0%, n=86) in primary AML cells across genetic subgroups; this expression remained unchanged at relapse (median=3.9%, n=14). SEA-CD70 showed potent, dose-dependent cytotoxicity against AML cell lines, primary cells, and in an SCID mouse model, which correlated with CD70 expression levels. Notably, AML cells exposed to CM from activated T cells upregulated CD70. TNF-α was identified as the driver of CD70 upregulation, translating into enhanced ADCC against AML cells (cytotoxicity w/o TNF-α = 17.9% vs with TNF-α = 34.3%, n=13–15). Conversely, IFN-γ exposure led to reduced ADCC (cytotoxicity w/o IFN-γ = 17.9% vs with IFN-γ = 9.2%, n=15), which is attributed to increased expression of NK inhibitory receptor ligands (HLA-ABC, HLA-E). Blocking of the corresponding inhibitory NK receptors (KIR/CD158b and NKG2A) partially reversed this effect. Similar findings were observed with a CD33-directed antibody, indicating a universal resistance mechanism against ADCC-based immunotherapy in AML. Conclusions CD70 is a promising target for NK cell-based immunotherapy in AML. However, IFN-γ-dependent upregulation of HLA molecules on AML cells contributes to resistance to ADCC. These findings underscore the need for rationale combination strategies in clinical trials to overcome this inducible immune escape mechanism.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/321683ea9d2468a9eb12f049ac98e9491571ec0e" target='_blank'>
              TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity
              </a>
            </td>
          <td>
            M. Sponheimer, Kieron White, Michelle Ulrich, Maryam Kazerani, Andreas Maiser, Emil Thore Tyborski, G. Rappa, Daniel Richter, Eva Briem, G. Hänel, N. Philipp, D. Nixdorf, L. Rohrbacher, Anetta Marcinek, A. Linder, Niklas Kuhl, Ignazio Piseddu, Tobias Straub, H. Harz, Christian Wichmann, Denis Maenner, Martina Rudelius, Veit Hornung, Heinrich Leonhardt, C. V. Van Elssen, Sherif Abdelhamed, Daniel Diolaiti, Veit L Bücklein, M. Subklewe
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Background Stem-like progenitor exhausted CD8+ T cells (TPEX), located within the tumor-draining lymph nodes (TDLNs), are responsible for maintaining tumor-specific responses in cancer. Although cytokines such as interleukin (IL)-15 are known to expand CD8+ T-cell subsets, transforming growth factor (TGF)-β in the TDLN is known to arrest the egress of these TPEX to the tumor microenvironment. We hypothesized that combining IL-15 stimulatory and TGF-β blocking activity would boost antitumor responses mediated by TPEX in the TDLN. Methods We developed a bifunctional TGF-βRII/IL-15 protein complex (HCW9218) and evaluated its antitumor activity in two murine models of melanoma and breast cancer. Peripheral blood, TDLN and tumor-infiltrating CD8+ T cells were characterized by flow cytometry following a single subcutaneous dose (s.c.) of HCW9218. Transcription profiling of CD8+ T cells in both murine models was performed. Synergistic activity of HCW9218 with immune-checkpoint inhibitors (ICIs) was evaluated. Finally, safety and immune profiling in patients with chemo-refractory/relapsed solid tumors was performed in a Phase 1 dose-escalating trial. Results HCW9218 was capable of localizing to the TDLNs and tumors after s.c. administration, neutralized TGF-β, expanded TPEX in TDLNs, increased chemokine-expressing effectors in peripheral circulation and promoted their infiltration into murine tumors. These data were corroborated in RNA sequencing analysis of TDLNs. ICIs significantly enhanced the effects of HCW9218 on TPEX and synergistically improved HCW9218 antitumor efficacy in melanoma and reduced spontaneous lung metastasis in breast cancer models. In a Phase 1 clinical trial, HCW9218 monotherapy was well-tolerated, reduced serum TGF-β levels, promoted and sustained CD8+ T-cell expansion in peripheral blood and CD8+ T-cell infiltration in tumor biopsies. Stable disease was reported for four of six subjects (67%) with advanced ovarian cancer treated with HCW9218. Conclusions Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f82b5cbb01e571f68c6670c836a87ce958c90377" target='_blank'>
              TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors
              </a>
            </td>
          <td>
            Varghese George, Hing C. Wong, M. Felices, M. Rubinstein, Niraj Shrestha, Natalia Valderrama, Hamidreza Farzaneh, Lin Kong, Crystal Gilkes, Alyssa Thompson, Megan Larson, Bai Liu, Xiaoyun Zhu, Gilles M Leclerc, Dongjun Chung, Juan Xie, Jordan E. Krull, Lucas Gomez, Leah Kanakaraj, Ann Bialik, J. Egan, Lijing You, Xianglan Liu, Rachael N. Teodorescu, Ana K Karen Gutierrez, Christian A Echeverri, Reynier Rodriguez, Zheng Wang, J. Xing, Neicy Gonzalez, P. Chaturvedi, Manish R Patel, R. Wangen, Qing Cao, P. Rhode, Jeffrey S Miller, Melissa A Geller
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="Tumor-infiltrating CD8+ T cells are a key determinant of anti-tumor efficacy in immunotherapy. IL-7 has been explored as a cytokine therapy to expand CD8+ T cells, showing promising anti-tumor effects in preclinical models. However, clinical outcomes remain limited, likely due to the immunosuppressive tumor microenvironment. To enhance the efficacy of IL-7 therapy, we reanalyzed publicly available single-cell RNA-sequencing (scRNA-seq) data of tumors treated with IL-7, identifying elevated TGF-β signaling in CD8+ T cells following treatment. As TGF-β impairs CD8+ T cell function and antagonizes IL-7 signaling, we developed a bifunctional fusion protein, recombinant human IL-7 (rhIL-7)-hyFc-sTBRII (IL7-TBRII), by fusing a TGF-β trap (Fc-TBRII) to rhIL-7-hyFc (IL7-Fc). We evaluated the binding affinities and functionalities of each domain in vitro and in vivo, and assessed anti-tumor effects in the MC38 colon cancer model. IL7-TBRII demonstrated superior anti-tumor efficacy compared to IL7-Fc or Fc-TBRII alone, primarily through increased infiltration of cytotoxic CD8+ T cells into tumors. Also, IL7-TBRII expanded the number of activated CD44+ CD8+ T cells. Furthermore, IL7-TBRII reduced metastasis in the 4T1 breast cancer model by reshaping the immune cell composition, and demonstrated synergistic efficacy when combined with radiotherapy or anti-CTLA-4 therapy in the EMT6 breast tumor model. These findings suggest that dual modulation of the IL-7 and TGF-β pathways by IL7-TBRII effectively reprograms the immune microenvironment in both primary and metastatic tumors, particularly by promoting CD8+ T cell activation and infiltration, thus offering a promising strategy to improve clinical responses to immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/668a2fcd9bd4e6e6aba2749532273a5507bd3f87" target='_blank'>
              IL7-TBRII, a Dual Cytokine Modulator Targeting IL-7 and TGF-β Pathways, Inhibits Tumor Progression and Metastasis
              </a>
            </td>
          <td>
            Youngsik Oh, Sora Kim, Ji-Hae Kim, Kun-Joo Lee, D. Moon, Chaerim Jeong, Hyun Gyung Kim, Seung-min Chun, Mi-Sun Byun, Seung-Woo Lee
          </td>
          <td>2025-12-01</td>
          <td>Immune Network</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Tissue-resident memory T (TRM) cells persist long-term in non-lymphoid tissues and provide rapid local immune protection, yet emerging evidence shows they also act as key drivers of chronic inflammation and relapse in rheumatoid immune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and primary Sjögren’s syndrome (pSS). A systematic search of PubMed, Web of Science, and Google Scholar (through October 2025) identified studies on TRM cell biology, pathogenic roles, and therapeutic modulation in autoimmune diseases. This review summarizes the fundamental features of TRM cells, including their TGF-β and IL-15 dependent development, tissue-specific heterogeneity, and unique metabolic programs. It highlights disease-specific pathogenic mechanisms: promotion of osteoclastogenesis and chronic synovial inflammation via Granulocyte-macrophage colony stimulating factor (GM-CSF) and the IL-23/IL-17 axis in RA; amplification of type I interferon responses and autoantibody production in SLE; potential contribution to fibrosis through TGF-β secretion in SSc; and mediation of glandular injury through cytotoxicity in pSS. Therapeutic strategies targeting TRM cells—such as JAK inhibitors, IL-17/IL-23 blockade, disruption of residency signals, metabolic interventions, and microenvironmental remodeling via nanotechnology—are critically evaluated. Challenges remain in achieving tissue-specific targeting without compromising systemic immune memory. Future directions include spatial transcriptomics, organoid models, and artificial intelligence to support precision medicine. Targeting TRM cells presents a promising novel avenue for achieving long-term remission and potentially even a cure for rheumatoid immune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1201e244b31ebcc016319c4d8203919cb836f463" target='_blank'>
              Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies
              </a>
            </td>
          <td>
            Yu Tian, Jie Zhang, Lianying Wu, Chi Zhang, Fan Zheng, Yang Yang, Guanting Lu, Daoyuan Xie
          </td>
          <td>2025-11-30</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Interferon gamma (IFNγ) priming is a prominent approach to enhance the immune-regulatory capacity of mesenchymal stromal cells (MSCs). Despite its potential, the concentration of IFNγ vary between studies, and how MSCs response to different concentrations of IFNγ is unclear. MSCs were treated with various concentrations of IFNγ (0, 1, 5, 10, 50, and 100 ng/mL) for 48 h. Followed by RNA sequencing (RNA-seq) and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) to profile gene expression and chromatin accessibility, respectively. Integrative analysis was conducted to elucidate the epigenetic regulation of MSCs response to different doses of IFNγ. We found that low dose IFNγ (1 ng/mL) treatment was sufficient to induced significant changes in gene expression and chromatin accessibility. RNA-seq revealed that IFNγ activated genes involved in immune response and inactivated genes related to cell-cycle regulation. ATAC-seq showed that IFNγ reduced global enhancer accessibility of MSCs, possibly by downregulation of the SWI/SNF complex. Moreover, IFNγ selectively opened enhancer regions associated with immune response genes while closing regions linked to proliferation-related genes. Motif enrichment analysis identified binding sites for transcription factors such as IRF and AP-1 family members in open and closed regions, respectively, highlighting selective regulatory mechanisms. This study demonstrates that low dose IFNγ is sufficient to modulate the transcriptional and epigenetic landscape of MSCs by selectively altering enhancer landscape. Our results provide insights into the regulatory mechanisms underlying IFNγ priming and offer a resource for the rational design of strategies to optimize MSC licensing for therapeutic applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af01cd1af8cf4bfaab7e2f30456504cdc937852d" target='_blank'>
              Low dose IFNγ remodels enhancer landscape to potentiate mesenchymal stromal cell activation
              </a>
            </td>
          <td>
            Junxin Lin, Dengfeng Ruan, Qiongying Hu, Xuan Cao, Wenyan Zhou, Siwang Hu
          </td>
          <td>2025-12-01</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Secreted phosphoprotein 1 (SPP1+) macrophages are a recurrent and functionally critical immune cell subset across multiple cancer types. They drive adverse clinical outcomes by promoting immunosuppression, tumor invasion, metastasis, and therapy resistance. Given their prevalence and pivotal role, SPP1+ macrophages have become a major focus in cancer immunology and a promising target for therapeutic development. SPP1+ macrophages have been identified in a wide range of human malignancies through single-cell RNA sequencing and spatial transcriptomics studies. Their differentiation and maintenance are strongly influenced by reciprocal cellular interactions and hypoxic conditions within the tumor microenvironment (TME). Within the tumor microenvironment (TME), SPP1+ macrophages promote tumor progression by interacting with cancer-associated fibroblasts (CAFs) and helping to form a physical barrier that restricts immune cell infiltration into the tumor core. Specifically, they impair the recruitment of CD8+ T cells and promote T cell exhaustion (TEX). In this review, we focus on recent advances in understanding the differentiation of SPP1 macrophages in hypoxic tumor microenvironment and the role of SPP1+ macrophages in immunosuppression and their therapeutic implications in cancer. Targeting this subset of macrophages has emerged as a highly promising therapeutic strategy, with several approaches demonstrating encouraging results in preclinical models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7c7489149a391c5b3e442dad42f10334718f488" target='_blank'>
              SPP1+ macrophages in tumor immunosuppression: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Juanjuan Wang, Ya Wang, Yuqing Liu, Rongcun Yang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with distant metastasis, prognosis remains poor. PD-1 is not only expressed by αβ T cells but also by γδ T cells, making this numerically minor population of unconventional T cells, whose role in melanoma is still elusive, a target of ICB. Methods Here, we present a detailed γδ T-cell profiling study in late-stage melanoma at single-cell level using mass and polychromatic flow cytometry, T-cell receptor repertoire analyses and immunohistochemistry. Results Our analyses link high frequencies of peripheral Vδ1 T cells before the start of anti-PD-1 therapy to a significantly reduced overall survival. In these patients, the Vδ1 compartment is dominated by a late-differentiated senescent-like phenotype that is presumably unresponsive to therapy. This phenotype is less prevalent at the tumor site and analysis of RNA sequencing data revealed that the abundance of Vδ1 T cells within the tumor was positively associated with survival. Conclusions Our study suggests that Vδ1 T cells are associated with clinical outcomes, with a responsive subset expanding under ICB in patients where such a response remains possible. The observed clinical effects may be supported by the infiltration of these cells into the tumor, where they contribute to cancer immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad77c14a3cfc3aa02688cb2c4360370f794926a0" target='_blank'>
              Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma
              </a>
            </td>
          <td>
            Nicola Herold, Jonas Bochem, Johanna Leyens, Svenja Wingerter, Stephan Forchhammer, Janine Spreuer, M. Deseke, Can Yurttas, Paola Nocerino, Rita Antunes Dos Reis, T. Amaral, N. Wagner, K. Thiel, Daniel Soffel, Kristin Bieber, P. Terheyden, D. Wesch, H. Oberg, Susanne Sebens, Manfred Claassen, Alfred Königsrainer, Claus Garbe, Graham Pawelec, F. Meier, Markus W. Löffler, B. Weide, I. Prinz, S. Ravens, Shahram Kordasti, T. Eigentler, K. Wistuba-Hamprecht
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>61</td>
        </tr>

        <tr id="Immunotherapy has transformed cancer treatments, but the majority of cancer patients would inevitably develop resistance to immunotherapy. Th17 cells play complex but crucial roles in anti-cancer immune response, although their therapeutic potential remains underutilized. Segmented filamentous bacteria (SFB) function as prototypical commensal bacteria that can induce intestinal Th17 cells and impact host immune response. In this study, we investigated how SFB antigen-mediated immune responses modify the tumor microenvironment and enhance anti-tumor efficacy through a coordinated gut–lung immunological axis. We engineered B16F1 melanoma cells to express either the SFB3340 epitope (B16-3340, an I-Ab-restricted epitope derived from SFBNYU_003340 and recognized by 7B8 TCR) or a control vector (B16-MEM) to evaluate SFB antigen effects on tumor immunogenicity. We found that expression of the SFB epitope in cancer cells decreased the number of lung tumor nodules, and SFB colonization further reduced tumor growth in a lung metastasis model. In addition, Th1, Th17, and CD8+ Tc1 cells were all increased in the lungs of the B16-3340 tumor-bearing mice compared with B16-MEM control tumor-bearing mice without triggering a compensatory expansion of immunosuppressive Tregs. Interestingly, SFB triggers systemic metabolic changes and an increase metabolites from aromatic amino acid degradation pathways, providing biochemical evidence for a functional gut–lung conduit, which integrates innate microbial detection with adaptive tumor-specific immunity. Our research provides evidence to further investigate and develop novel cancer immunotherapies that utilize microbial antigens and microbiome modifications to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5429a38be4e5ce2d81f913e703a35d6e85fa2f2" target='_blank'>
              Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity
              </a>
            </td>
          <td>
            Jessica Tzu-Chieh Lee, Soo Ngoi, Brian Deng, Megan Hill, Kai He, Yi Yang, Bei Liu
          </td>
          <td>2025-12-24</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed50cf99fb67ea8136c8c566f1253db09fe9441" target='_blank'>
              Modeling anti-tumor immune responses using patient-derived melanoma organoids
              </a>
            </td>
          <td>
            Kamila Kaminska, B. Phung, Jacob Karlström, M. Lauss, K. Harbst, Teresa Svensson, Kristian Pietras, Kari Nielsen, Ana Carneiro, Henrik Ekedahl, K. Isaksson, G. Jönsson
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Abstract Despite durable viral suppression, cellular sources of human immunodeficiency virus type 1 (HIV-1) persistence in human lymphoid tissues remain uncharacterized, with germinal center (GC) macrophages representing an understudied, potentially noteworthy reservoir population. Using integrated spatial, phenotypic, and molecular profiling of 42 excisional lymph nodes (LNs) from 39 individuals living with HIV-1 Clade C, including 25 under suppressive antiretroviral therapy (ART), we reveal that GC macrophages harbor HIV-1 DNA, RNA, and proteins, defining them as a functional HIV reservoir. Super-plex imaging confirms HIV co-localization with GC macrophages, which were predominantly IBA-1+CD68+and CD206-CD163-. Among individuals with sustained viral suppression, the presence of proviral DNA (3/6) and inducible multiply spliced HIV-1 RNA (3/3) confirms that LN-resident myeloid cells serve as inducible HIV-1 reservoirs. These reservoirs were markedly enriched in the LNs, with both CD4⁺ and myeloid compartments showing higher inducible activity than their peripheral blood counterparts. While CD4⁺ T cells remain the predominant source of inducible, replication-competent HIV, our detection of a LN myeloid reservoir underscores the imperative to redesign cure approaches to eliminate reservoirs across both CD4⁺ T cell and myeloid lineages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b25f4bc7e5b9342be9b9516fab322d9e829ccf36" target='_blank'>
              IBA-1+CD68+ Germinal Center Macrophages Harbor Proviral and Inducible Clade C HIV Reservoirs in ART-Suppressed Human Lymph Nodes
              </a>
            </td>
          <td>
            Z. Ndhlovu, Merantha Moodley, Tanvir Hossain, Caroline Chasara, T. Khaba, B. Mahlobo, Nicole Reddy, K. Reddy, T. Ngubane, Johan Pansegrouw, Crystal A Mendoza, P. Madlala, T. Ndung’u, T. Mahmoudi
          </td>
          <td>2026-01-07</td>
          <td>Research Square</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="Background The CpG/α-OX40 in situ vaccine strategy has shown efficacy in immune-hot tumors but remains ineffective in immune-cold tumors possibly due to immunosuppressive microenvironments characterized by myeloid-derived suppressor cells (MDSCs) infiltration and T cell exclusion. This study aims to investigate the antitumor effect of non-α-biased IL-2 combined with CpG/α-OX40 in mice. Methods Using 4T1 breast cancer and CT26 colon cancer models, we evaluated the antitumor effects of combining CpG/α-OX40 with a non-α-biased IL-2 variant via both intratumoral and subcutaneous routes. Tumor growth, lung metastasis, immune profile, and in vitro function analysis were assessed through flow cytometry, transcriptomic analysis, and T cell suppression assays. Results The combination therapy significantly inhibited primary and distant tumor growth and reduced lung metastasis in 4T1 models. Subcutaneous administration induced complete tumor regression in 55% (5/9) of CT26-tumor-bearing mice and conferred durable tumor-specific memory. Mechanistically, the treatment enhanced CD8+ T cell activation, metabolic reprogramming, and IFN-γ production, while suppressing MDSC expansion and immunosuppressive function. Conclusions These findings demonstrate that non-α-biased IL-2 synergizes with CpG/α-OX40 to overcome microenvironmental immunosuppression and achieve systemic antitumor immunity via a subcutaneous route, offering a translatable combinatorial strategy for immune-cold tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d42396ce9a3d36225ebbc84de8f92b7df49fd80" target='_blank'>
              Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice
              </a>
            </td>
          <td>
            Kejie Huang, Xiaobo Ding, Xuehuan Wen, Chaoming Huang, Yan Chen, Xujie Zhou, Leying Zhou, Yi He, Zhixiang Bai, Chunhong Zhang, Yi-Li Jin, Jianmin Li, Zhenghua Fei, Wenfeng Li, Chen Chen
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Simple Summary Understanding how colorectal tumours interact with immune cells is critical for improving immunotherapy responses. In this study, we used air–liquid interface organoids derived from patient tumours and adjacent healthy colon tissues to reproduce the original tumour microenvironment in the laboratory. These organoids preserved the three-dimensional tissue structure, the native immune infiltrates, and the genetic mutations of the original samples more faithfully than conventional Matrigel-based cultures. When compared with Matrigel organoids co-cultured with blood immune cells, the air–liquid interface model more accurately reflected the immune and molecular features of each patient’s tissue. Notably, treatment with the immune checkpoint inhibitor nivolumab (anti–PD-1) led to a consistent expansion of regulatory T cells, recapitulating a mechanism of adaptive resistance. This approach offers a physiologically relevant platform to study colorectal cancer–immune interactions and to predict patient-specific responses to immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1a3eadb0b685bd8cfaac8a74e4695da291cec8c8" target='_blank'>
              Colorectal Air–Liquid Interface Organoids Preserve Tumour-Immune Architecture and Reveal Local Treg Expansion After PD-1 Blockade
              </a>
            </td>
          <td>
            Laura Córdoba, Francisco J Cueto, Ramón Cantero-Cid, Rebeca Abad-Moret, Esteban Díaz, Jaime Álvarez-Benayas, Jesús Fernández-Felipe, Jesús Jiménez-Rodríguez, Daniel Arvelo-Rosario, Pablo Mata-Martínez, Marina Arranz-Álvarez, Yaiza Pedroche-Just, Sandra Nieto-Torrero, J. Valentín-Quiroga, Verónica Terrón-Arcos, Jaime Fernández-Pascual, Paloma Gómez-Campelo, Nieves Cubo-Mateo, Olivia Fernández-Medina, Laura Hurtado-Navarro, Gonzalo Sáenz de Santa María, Julia del Prado-Montero, Agustín L. Santos, R. Lozano-Rodríguez, C. del Fresno, E. López-Collazo
          </td>
          <td>2025-12-30</td>
          <td>Cancers</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Background Acute myeloid leukemia (AML) is characterized by a complex interplay between genomic alterations, aberrant hematopoiesis, and immune evasion. The aryl hydrocarbon receptor (AHR) pathway is a critical player in this phenomenon determining the fate of stem cell differentiation as well as dictating immune cell development and function. Despite this critical connection, little is known about how AHR regulates the immune microenvironment in AML. Methods We performed a retrospective study examining the pre-treatment effect of immune cell numbers (T and NK cells) in the bone marrow and their impact on overall survival in AML patients undergoing 7+3 induction chemotherapy. Utilizing flow cytometry and both bulk and single-cell RNA sequencing of AML patient samples, we characterized the immune signature of blast cells and the influence of AHR on the immune microenvironment. Lastly, we performed functional studies to determine impact of pharmacological and genomic AHR inhibition on NK cell function. Results Higher bone marrow NK cell percentage in ND-AML correlated with poorer OS and expression of HLA-E on leukemic blasts. AHR upregulation was associated with HLA-E expression on blasts and an innate immune resistant signature defined by upregulation of key cytokine pathways, interferon gamma (IFN-g) pathway, and MHC class I/II as well as impaired NK cell profiles. High AHR expression in AML was associated with monocytic maturation and discrepant MHC class I/II profiles. Pre-treatment of blasts with an AHR inhibitor (AHRi) prior to NK cell killing assay downregulated key checkpoint molecules, including HLA-E, and key IFN-g signaling transcription factors (STAT1, IRF1) and led to enhanced NK cell killing among multiple FAB subsets in AML. Conclusion The data support targeting the AHR pathway as a dual tumor intrinsic and immune targeting therapeutic strategy for AML, particularly in combination with NK cellular therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7893eab44f440eeeac15c67dc9e41e9217e3fc7f" target='_blank'>
              The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor
              </a>
            </td>
          <td>
            Jennifer N Saultz, D. Bottomly, Faith Burns, K. Byrd, Yoko Kosaka, Bernhard Alber, Daniel J Chandra, Stephen Kurtz, Guang Fan, A. Kaempf, Nicola Long, Marta Sanchez-Martin, Lei Wang, Karen McGovern, D. S. Kaufman, Shannon K. McWeeney, B. Druker, Jeffrey W. Tyner, Evan F. Lind
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>127</td>
        </tr>

        <tr id="Small cell lung cancer (SCLC) is characterized by its highly aggressive phenotype and dismal outcome. Despite the benefit of adding immune checkpoint blockade to standard chemotherapy, tumors acquire the ability to evade immunosurveillance and develop resistance. To investigate these underlying mechanisms, we perform high-dimensional profiling of human and murine SCLC specimens. In matched primary and metastatic human samples, we observe MHC-I loss in metastases, highlighting its role in immune evasion. Correspondingly, silencing MHC-I in SCLC cells drastically reduces immune infiltration and promotes metastasis in mice. Using mass spectrometry and phospho-tyrosine kinase analyses, we identify ERBB2 signaling as a suppressor of MHC-I and driver of immune-modulatory transcripts. Mechanistically, genetic and pharmacologic blockade of ERBB2 induces MHC-I in a STING-dependent manner and prevents immune evasion in autochthonous murine SCLC. Strikingly, combining ERBB2 inhibition with anti-PD-1 elicits profound synergistic responses in preclinical models, suggesting this combination for future clinical trials in SCLC patients. While the emergence of immune checkpoint inhibitors has improved outcomes in patients with small cell lung cancer (SCLC), tumour that develop means of immune evasion become resistant. Here, the authors report that ERBB2 signalling induces loss of MHC Class I expression and subsequently immune evasion in preclinical models of SCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f612388efd2f0a9c1ebc8d3e60e6b396ae989beb" target='_blank'>
              ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
              </a>
            </td>
          <td>
            L. Meder, C. Orschel, C. Bouchez, R. Gholamipoorfard, C. V. Orschel, David Stahl, Christoph Kreer, Mirjam Koker, Marieke Nill, Ilayda G Kocak, Ka-Won Noh, Xinlei Zhao, Leon Ullrich, B. Häupl, Josefine Jakob, Marie-Lisa Eich, Alexandra Florin, Holger Grüll, J. Wolf, Filippo Beleggia, R. Buettner, T. Oellerich, Florian Klein, J. Brägelmann, H. C. Reinhardt, Nima Abedpour, R. Ullrich
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9487b7d55d4857b031bd0974fcc9aeac38c92126" target='_blank'>
              Neonatal liver niches program T cell tolerance
              </a>
            </td>
          <td>
            Eva-Lena Stange, T. Nguyen, Dustyn Mendoza, Aiara Lobo Gomes, Marlene Sophia Kohlhepp, Jonas Pes, Shahed Al Bounny, Julian Brueck, Yunus Cetiner, Urs Moerbe, Milas Ugur, Cristina Kalbermatter, Jarrett Lopez-Scarim, Aline Dupont, Susan A. V. Jennings, Julia Heckmann, A. Silva-Sánchez, Solveig Runge, C. Kuppe, Oliver Pabst, Thomas Clavel, Dorothee Viemann, S. Rosshart, V. Cerovic, S. C. Ganal-Vonarburg, Adrien Guillot, E. Billerbeck, Mathias W. Hornef, N. Torow
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Extracellular vesicles (EVs) are central mediators of intercellular communication in both healthy and malignant states. In normal B lymphocyte (cell) biology, EVs derived from B cells, mast cells, T cells, and mesenchymal stromal cells regulate maturation, antigen presentation, and activation. B cell-derived EVs can either suppress excessive activation to maintain immune homeostasis or amplify responses during an active immune response. Modulation of these responses often occurs via phosphoinositide 3-kinase signaling pathways in recipient cells. In B cell malignancies, such as leukemias, lymphomas, and multiple myeloma, EVs play pivotal roles in disease progression and therapy resistance. Tumor- and stromal-derived EVs can transfer pro-survival proteins, regulatory RNAs, and drug-resistance factors to directly promote tumor progression. In addition, EVs can shape the tumor microenvironment to indirectly promote tumor progression through macrophage polarization, stromal cell reprogramming, and suppression of anti-tumor immunity. Conversely, under certain conditions, B cell EVs can enhance immune surveillance by stimulating T cells and presenting antigen, highlighting their dual potential in cancer biology. Clinically, B cell-derived EVs represent promising liquid biopsy biomarkers: increases in EV abundance, expression of surface antigens, altered protein cargo, and distinct RNA signatures have been associated with disease stage, treatment response, and patient outcomes. Despite this potential, variability in EV isolation and analysis methods remains a barrier to clinical translation. Moving forward, identifying robust biomarker signatures across platforms and clarifying mechanisms of cargo selection and EV uptake will be critical for advancing diagnostic and therapeutic applications. Overall, B cell-derived EVs act as contextual regulators of immune function and malignancy, positioning them as both modulators of disease progression and promising clinical tools.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62930a7e9c707674957a1f9402a815a0e545b47b" target='_blank'>
              Extracellular vesicles in malignant and normal B lymphocyte growth and development
              </a>
            </td>
          <td>
            Kaitlyn E. Mayne, Rashid Jafardoust, Hong-Dien Phan, S. L. Christian
          </td>
          <td>2025-12-10</td>
          <td>Extracellular Vesicles and Circulating Nucleic Acids</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dc6a28b4224c2b2503480a6b2e0edc6bbd8d9c3" target='_blank'>
              Innate antiviral readiness drives the expansion of protective T stem cell memory against influenza
              </a>
            </td>
          <td>
            Ivan Tomic, David J Ahern, J. Tomalka, Alba Escalera, T. Aydillo, Matthew D. Pauly, Nadine G Rouphael, S. Lakdawala, Naseem Sadek, E. Clutterbuck, Nisha Singh, P. Aley, H. Robinson, S. Marinou, Stephanie Hao, Matthew Fish, Helder Nakaya, Claudia Monaco, Adolfo García-Sastre, Andrew J Pollard, Adriana Tomic
          </td>
          <td>2025-12-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Rationale : Peritoneal carcinomatosis (PC) remains a major clinical challenge with limited therapeutic options across tumor types. Adoptive cell therapy (ACT) with tumor-specific T cells offers promise, but its efficacy is often impaired by the immunosuppressive tumor microenvironment (TME). Intraperitoneal ACT is under investigation to improve its effectiveness against metastases within the peritoneal cavity. IL-33, a cytokine of the IL-1 family, plays dual roles in immunity and inflammation and may enhance antitumor responses. We evaluated whether IL-33 mRNA-engineered T cells improve ACT efficacy in murine PC models and assessed potential synergy with IL-12 mRNA. Methods : OT.I, PMEL-1, and CEA-specific CAR T cells were electroporated with mRNA encoding IL-33, IL-12, or an IL-33 mutein. In vitro assays measured cytokine production and cytotoxicity. RNA-seq was performed to analyze transcriptomic changes following IL-33 mRNA electroporation. ST2 -/- T cells were used to evaluate the role of IL-33 receptor expression on transferred T cells versus host cells. In vivo studies in murine PC models assessed survival and immune responses using ELISA, ELISpot, and flow cytometry. Results : IL-33 mRNA-electroporated OT.I T cells exhibited enhanced IFN-γ expression in a ST2-dependent, T cell-intrinsic manner. In vivo , IL-33-engineered T cells significantly improved survival in PC models. IL-33 reshaped the TME by increasing infiltration of innate lymphoid cells and eosinophils while reducing neutrophils. Engineering T cells with a stabilized IL-33 mutein further enhanced antitumor activity. Co-electroporation of IL-33 mutein and IL-12 mRNA in PMEL-1 T cells led to synergistic increases in IFN-γ production, cytotoxicity, and long-term memory, resulting in superior tumor control and protection upon rechallenge. These findings were confirmed using IL-33 mutein/IL-12 mRNA-electroporated CEA CAR T cells in peritoneal tumor models. Conclusions : IL-33 enhances ACT efficacy by promoting IFN-γ expression via autocrine ST2 signaling and by modulating the TME. The IL-33 mutein improves cytokine stability and antitumor activity, while combination with IL-12 yields synergistic effects. This strategy holds promise for enhancing ACT in peritoneal carcinomatosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05603afeaaa666282542151cda77d982f29e43a9" target='_blank'>
              Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA
              </a>
            </td>
          <td>
            Leire Arrizabalaga, C. D. Di Trani, C. Gomar, Daniel Moreno-Luqui, N. Ardaiz, Virginia Belsue, José González-Gomariz, David Ruiz-Guillamón, Aline Risson, Yufei Zheng, Eduardo Huarte, Ignacio Matos, Ignacio Melero, P. Berraondo, Fernando Aranda
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Background Bone metastasis (BM) drives therapeutic resistance and mortality in nasopharyngeal carcinoma (NPC). Tumor metabolites are crucial for NPC metastasis; however, the mechanisms by which these metabolites synergistically alter the immune microenvironment to promote BM remain unclear. Methods In this study, limited immune infiltration was observed in the NPC BM tumor microenvironment. Multiomics analysis has identified sphingosine kinase 1 (SPHK1) as a pivotal mediator driving BM and immune evasion in NPC, orchestrating the production of 1-phosphorylated sphingosine (S1P), which is critical for NPC pathogenesis. Results The aberrant buildup of lipid metabolites, along with immune microenvironment shifts, serves as a critical driver of NPC BM. Mechanistically, S1P enhanced osteoclast recruitment via S1PR3 binding and activated the Hippo pathway, worsening bone colonization and facilitating immune evasion by expanding the exhausted CD8+ T cell population. Conclusions The synergy between the SPHK1 inhibitor PF543 and anti-programmed cell death protein 1 therapy amplified treatment effectiveness beyond standalone approaches. Overall, the SPHK1/S1P pathway advances NPC growth and aids in suppressing immune defense. Regulation of lipid metabolism may be a therapeutic target against BM in NPC and may improve the effectiveness of immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7f5767ecd0ec511f2027d46eb857b0d775229ca9" target='_blank'>
              Aberrant lipid metabolism reshapes the immune landscape in bone metastasis of nasopharyngeal carcinoma
              </a>
            </td>
          <td>
            Yuanyuan Feng, Hongmei Wang, Ziyan Zhu, Wenxiang Deng, Xiaoyue He, Yingying Yao, Miao Song, Xiaohong Peng, Yanling Lin, Longmei Cai
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>14</td>
        </tr>

        <tr id="Staphylococcal enterotoxins (SE) crosslink the MHC‐II on antigen‐presenting cells (APC) with the T‐cell receptor, inducing a polyclonal T‐cell response. Although APCs are the initial targets of SE and are critical in shaping subsequent T‐cell activation, the effects of SE on APC function remain poorly understood. This study investigates the immunomodulatory effects of staphylococcal enterotoxin A (SEA) on monocytes and their differentiation into monocyte‐derived dendritic cells (moDC) or macrophages (MDM). Transcriptomic analyses of human monocytes via RNA sequencing revealed SEA‐induced enrichment of gene pathways associated with inflammation, infection, and dermatitis, effects that were amplified in the presence of T cells. Phenotypic and functional characterization showed that SEA‐primed monocytes differentiated into MDM with an altered polarization, deviating from classical M1/M2 pathways. SEA‐primed MDM exhibited downregulation of key markers, including HLA‐DR, CD80, CD86, and PD‐L1. Functional assays demonstrated that SEA‐primed MDM pushed hyperinflammatory T‐cell responses, with significantly enhanced proliferation and IFN‐γ secretion. In contrast, following SEA‐priming, moDC retained robust antigen‐presenting capabilities and displayed enhanced expression of molecules involved in T‐cell interactions. These findings provide mechanistic insights into SEA‐mediated immune modulation, illustrating how SEA reprograms MDM functions and amplifies proinflammatory T‐cell responses. This advances our understanding of superantigen‐driven immune interactions, offering a foundation for developing therapeutic strategies to mitigate superantigen‐mediated immune conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31b8b3bf0438451c3b982c5f615c660d9c3ce361" target='_blank'>
              Staphylococcal Enterotoxin A Shapes Monocyte Transcription and Macrophage Polarization: Implications for Immune Responses in Infection and Inflammation
              </a>
            </td>
          <td>
            C. Arasa, Khaleda Rahman Qazi, David Brodin, Manuel Mata Forsberg, E. Sverremark-Ekström
          </td>
          <td>2025-12-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Immunotherapy has significantly improved cancer treatment. However, it is not effective in all cancer patients, rendering the need to further delineate the differences among responders and non-responders at the molecular and cellular level. Unresponsiveness to immunotherapy has been attributed to dysfunctional immune cell states such as T-cell exhaustion and anergy, whereas the contribution of cellular senescence remains elusive. Herein, we have investigated the role of immune cell senescence in the response to checkpoint inhibitors in melanomas where these immunotherapies are applied as a first line treatment. Two senescence detecting complementary approaches were utilized in a case control study we conducted. First, we implemented a senescence molecular signature we developed, termed "SeneVick", retrospectively in a single cell RNA-seq dataset from melanoma patients who received immunotherapy. Prior to this analysis, the signature was extensively validated in a variety of cell/tissue contexts, senescence types and species. Second, cellular senescence was assessed via an established experimental algorithmic approach in circulating immune cells of an analogous melanoma clinical cohort. Melanoma patients who did not respond to immunotherapy exhibited increased cellular senescence in the CD8 + T-cell, CD4 + T-cell, B-cell (CD19 + /CD20 +) and NK cell compartments compared to responders. This phenomenon was independent of patients’ clinical features (age, sex, melanoma type, stage) and not an outcome of immunotherapy, in contrast to conventional anti-cancer treatments. Interestingly, alterations of cell-to-cell interactions among the immune sub-populations in non-responders compared to responders were identified, supporting, along with cytotoxicity assays, that senescent immune cells display immunosuppressive properties driving defective immune responses and treatment failure. Overall, our findings provide evidence that cellular senescence within the immune cell compartment of the tumor micro-environment is a potent determinant of the response to immunotherapy and pave the way for strategies targeting it as promising approaches to improve the outcome of such interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0fd775fd66f6d7a2f86c80eb9a0def25877dc288" target='_blank'>
              Immune cell senescence drives responsiveness to immunotherapy in melanoma
              </a>
            </td>
          <td>
            Pavlos Pantelis, Dimitrios Christos Tremoulis, K. Evangelou, Panagiotis Bakouros, Sophia Magkouta, Orestis A. Ntintas, D. Veroutis, Giorgos Theocharous, Ioannis V. Kostopoulos, Dimitris-Foivos Thanos, E. Chatziioannou, Ioanna A. Anastasiou, N. Lagopati, Dimitrios Valakos, Dimitrios Skaltsas, O. Pop, Marie-Therese Abdou, S. Gagos, Dimitris Kletsas, Dimitris-Foivos Thanos, Alexandros J Stratigos, M. Röcken, Lukas Flatz, G. Chrousos, Dimitrios Vlachakis, O. Tsitsilonis, R. Petty, T. Karamitros, V. Gorgoulis
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>1</td>
          <td>80</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c884624194df8c0680f4019f2ac1093daf979a9b" target='_blank'>
              Macrophage immunosenescence prolongs intraocular inflammation in aged mice via impaired induction of regulatory T cells
              </a>
            </td>
          <td>
            Taku Yamamoto, Keitaro Hase, Joseph B. Lin, Shinobu Yamaguchi, Norihiko Misawa, Jiayi Li, Kenta Kato, Ryo Terao, Brian S. Sohn, Daniel Du, Mitsukuni Yoshida, Charles W Pfeifer, Tae Jun Lee, Jason J. Colasanti, A. Santeford, James T. Walsh, R. Apte
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Autoimmune regulator (Aire) orchestrates the presentation of self-antigens to developing thymocytes, playing a key role in central tolerance. However, it remains unclear how Aire deficiency influences immune cell development and function. Recent studies show that Aire-expressing thymic epithelial cells produce type I and III interferons, but how impaired IFN signalling from Aire deficiency contributes to immune dysregulation remains unclear. Single-cell RNA sequencing was used to profile immune cells from Aire-deficient and wild-type mice across thymus, bone marrow, and lymph nodes. In the thymus, thymocytes at late maturation stages, non-conventional T cells, myeloid cells, immature Ccl21+ mTECs and cTECs had reduced expression of type I interferon-stimulated genes in the absence of Aire. In contrast, interferon-stimulated gene expression in bone marrow immune cells appeared independent of Aire. These findings support a role for Aire in thymic interferon production and highlight type I IFNs’ influence on transcriptomes of developing immune cells. Single cell RNA sequencing reveals reduced expression of type I interferon-stimulated genes in late stage thymocytes and thymic epithelial cells when Aire is deficient, suggesting a role for Aire in thymic interferon production.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f56bfeb46496a9aad0771517571da08f962e5b04" target='_blank'>
              Aire-dependent interferon signalling shapes thymocyte maturation and central tolerance in mice
              </a>
            </td>
          <td>
            Adrianna Jebrzycka, L. Breivik, David Dolan, Yael Goldfarb, Jakub Abramson, Anette S. B. Wolff, Eystein S Husebye, Anagha Joshi, B. Oftedal
          </td>
          <td>2025-12-09</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45c2ca81a481fda74a9aa7e8819b9cca2d44ec26" target='_blank'>
              Targeting thymidylate synthase enhances CD8 + T-cell infiltration and inhibits tumor growth in cervical cancer
              </a>
            </td>
          <td>
            Yongyan Pei, Zheng Zhong, Hongliang Li, Yuanchang Tan, Hua Cao
          </td>
          <td>2026-01-19</td>
          <td>Medical Oncology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Bacillus Calmette-Guérin (BCG) remains the standard treatment for non-muscle invasive bladder cancer (NMIBC), yet approximately 30% of patients fail to respond. To enhance therapeutic efficacy, we developed rBCG-LTAK63, a recombinant BCG strain, as a novel immunotherapeutic candidate. In vitro, rBCG outperformed BCG in MB49 cell/splenocyte co-cultures by enhancing T cell activation and improving spheroid growth control. In vivo, rBCG demonstrated superior antitumor efficacy, significantly reducing the growth of subcutaneously implanted MB49 tumor cells. Immune profiling revealed that rBCG uniquely promoted systemic activation of both CD4⁺ and CD8⁺ T cells, alongside stronger activation of NK and dendritic cells in the spleen. Within the tumor microenvironment, rBCG increased immune cell infiltration, enhanced activation of CD8⁺ T cells and dendritic cells, and decreased the frequency of regulatory T cells, fostering a less immunosuppressive environment. Unlike parental BCG, rBCG-LTAK63 sustained a potent immunostimulatory profile, marked by robust activation of dendritic cells and effector T cells. Similar results were also observed in the orthotopic model, suggesting a translational potential of rBCG-LTAK63. Collectively, our findings demonstrate that rBCG outperforms conventional BCG and represents a promising strategy for improving NMIBC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e4e9e8703be24629b575d1f1ca3d777b67f2abfa" target='_blank'>
              rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model
              </a>
            </td>
          <td>
            Matheus Ferreira de Almeida, Bruna Gennari Rosa, Daniela Delechiave, Lucas Francisco Annequin, Lázaro M Marques-Neto, M. Trentini, Johanna Christine van Vliet, Isabelle Carolina Cotrim Gozzi, Ana Carolina de Oliveira Carvalho, Dunia Rodriguez, L. R. Pereira, G. Gaboardi, Luís Carlos de Souza Ferreira, Luciana Cezar de Cerqueira Leite, Ana Carolina Ramos Moreno
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to chimeric antigen receptor (CAR)-T cell therapy. Insufficient T cell infiltration, a highly immunosuppressive microenvironment, and antigen loss pose major challenges for CAR-T cell therapy. Methods We investigated therapeutic synergies of synthetic 5′-triphosphate RNA (3p-RNA), an agonist of the cytoplasmic double-stranded RNA sensor Retinoic Acid Inducible Gene I (RIG-I), and CAR-T cell therapy using syngeneic and human xenograft PDAC models. Tumor growth, chemokine secretion, immune-cell composition, CAR-T persistence, and endogenous T cell responses were assessed by flow cytometry, multiplex cytokine arrays, Enzyme-linked Immunospot (ELISpot), and vaccination-challenge. Results 3p-RNA provoked rapid type I interferon accompanied with chemokine ligand CCL5 and CXCL9/10/11 secretion, creating chemokine gradients that recruited chemokine receptor CCR5+/CXCR3+ CAR-T cells into tumors. RIG-I activation enhanced CAR-T cell proliferation, activity, and CAR-T persistence. Combination therapy eradicated established tumors in 60%–70% of mice, whereas either monotherapy was largely ineffective. Cured animals rejected CAR antigen-negative tumor cell rechallenge, demonstrating antigen-spreading and endogenous T cell responses. Conclusions Intratumoral RIG-I priming reprograms the PDAC microenvironment, transforming a non-responsive cancer into a CAR-T-permissive one, supporting durable, poly-antigenic immunity. These findings position 3p-RNA as a rapid, clinically tractable co-therapy to extend CAR-T efficacy to solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0740cdf905664a78725635003b567ad13fe803cb" target='_blank'>
              RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma
              </a>
            </td>
          <td>
            Anne Marie Senz, B. Cadilha, Julia Teppert, Simone Formisano, Charlotte Marx, T. Lorenzini, D. F. Boehmer, Christine Hoerth, Simon Delahais, S. Endres, P. Duewell, M. Schnurr, S. Kobold, Lars M Koenig
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, characterized by an immunosuppressive microenvironment. To address the immune desert in GBM, immunocytokine, an innovative recombinant fusion protein that combines antibodies and cytokines, has been proposed. This molecule, targeting tumor cells while stimulating immune cells, effectively enhances the anti-tumor response. Developing a novel immunocytokine presents a promising strategy for GBM. In this study, we developed a novel immunocytokine, αBC-IL15, composed of a bispecific T cell engager (BsTCE) fused to the interleukin-15 receptor alpha-sushi domain/interleukin-15 complex (IL-15/IL-15Rα). To analyze its affection on immune cells, we co-cultured it with peripheral blood mononuclear cells in vitro. To investigate whether it enhances the cytotoxicity of T cells compared to B7-H3 BsTCE, we performed cytotoxicity assays on cell lines and spheroids in vitro. Moreover, we assessed its efficacy in vivo and analyzed the tumor microenvironment using flow cytometry and bulk sequencing. Our study assessed the bioactivity and efficiency of αBC-IL15. In vitro, αBC-IL15 effectively bound to tumor cells and T cells, inducing immune cell activation, cytokine release, and cytotoxicity toward tumor cells. In vivo, αBC-IL15 connects cytotoxic immune cells with tumor cells, leading to effective immune cell infiltration and potent redirected lysis. Overall, we developed a novel bispecific immunocytokine, αBC-IL15, which targets tumor cells while enriching and activating effector immune cells. This agent significantly enhanced anti-tumor effects both in vitro and in vivo, highlighting its potential to overcome the immunosuppressive microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04303ca0c55b928916530495ef259008c917a0c2" target='_blank'>
              A novel immunocytokine promotes T cell– and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma
              </a>
            </td>
          <td>
            Xiaoke Zhang, Nian Yang, Xin Tang, Nanxi Liu, Qizhong Lu, Zongliang Zhang, Long Xu, Lu Jiang, Honglin Ge, Huaqing Lu, Yongdong Chen, Mingbin Bao, Aiping Tong, Liangxue Zhou
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Although dendritic cell (DC)- and CD8+ T cell-mediated autoimmunity is critical for destroying melanocytes in vitiligo, treatment options remain limited by the absence of therapies that cotarget both cell types. We first evaluated the association between the immunoregulatory metabolite itaconate and disease development, by determining human vitiligo serum itaconate levels and monitoring depigmentation progression in Acod1 knockout (KO) mice with endogenous itaconate deficiency. We further evaluated the therapeutic efficacy of the itaconate derivative, dimethyl itaconate (DI) in mice and assessed its effects on cutaneous infiltration and the functional properties of DCs and CD8+ T cells in vivo and ex vivo. The gene signatures and signaling pathways involved in DI-treated CD8+ T cells were also assessed. We observed an elevation of circulating itaconate in vitiligo patients, whereas itaconate deficiency accelerated depigmentation in Acod1 KO mice after vitiligo induction. The administration of DI halted vitiligo development and promoted repigmentation, with elevated circulating itaconate levels, increased melanocyte counts, and decreased cutaneous CD8+ T cell densities. Mechanistically, DI dampened CD8+ T cell activation (CD69), effector function (Interferon-γ, IFN-γ), cytotoxicity (Gzmb), proliferation, and proinflammatory gene expression (Csf1, Ifitm1, CD49a, NKG2D, and NKG2A), partly by suppressing the Janus kinase (JAK)‒STAT pathway. Moreover, DI-treated mice exhibited reduced cutaneous DC infiltration, as well as fewer DCs with mature and migratory phenotypes. Our findings identify DI as a metabolite-derived small molecule that protects against autoimmune injury by cotargeting DC and CD8+ T cell responses, thereby demonstrating a promising therapeutic strategy and providing a foundation for treating vitiligo and other cell-specific autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/156c5db64bbfe182f24ec0383004fd5ff9fc13f2" target='_blank'>
              Dimethyl itaconate suppresses dendritic cell and CD8+ T cell responses to halt vitiligo
              </a>
            </td>
          <td>
            Yinghang Wang, Yuhan Chen, Jingjing Ma, Linxuan Wu, P. Kang, Jianru Chen, P. Du, Wei Wu, Xinju Wang, Kaiqiao He, Yuqi Yang, Sen Guo, Weinan Guo, Ling Liu, Z. Jian, Tianwen Gao, Shuli Li, Chunying Li
          </td>
          <td>2025-12-01</td>
          <td>BMC Medicine</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Triple-negative breast cancer (TNBC) is a highly invasive and refractory subtype of breast cancer. Despite the promise of immune checkpoint blockade (ICB) therapy, response rates remain limited. The immune resistance driven by the tumor microenvironment has not yet been understood entirely, which hinders the personalized precision treatment of TNBC. We integrated single-cell RNA data from 12 cohorts with TNBC and performed a multi-omics analysis combining spatial transcriptomics (ST), bulk RNA sequencing, and multiplex immunofluorescence (mIF) staining to identify immune-resistant subpopulations. Cell-to-cell communication was explored based on NicheNet and CellChat, and the function of CAF was verified by gene knockdown and overexpression in human mammary fibroblasts, followed by co-culture experiments with TNBC cell lines. ST and mIF data were used to analyze and verify cellular co-localization, while deconvolution was used to examine the relationship between two-cell characteristics and immunotherapy or antibody–drug conjugates (ADC) agent benefit. We identified CA9+cancer-associated fibroblasts (CA9+CAF) as a key subset enriched in non-responders to ICB that promotes immune resistance by establishing a hypoxic and immunosuppressive microenvironment via abnormal angiogenesis and glycolysis. ST and mIF analyses revealed a strong co-localization and interaction between CA9+CAF and SPP1+tumor-associated macrophages (SPP1+TAM), forming a stroma-myeloid axis that promotes immune escape through VEGFA/NRP2 axis in co-localization core region compared to the boundary. In vitro experiments demonstrated that the over-expression of CA9 in fibroblasts enhanced the proliferation, invasion, and migration of TNBC cells, while CA9 knockdown inhibited the tumorigenic effects. The high CA9+CAF/SPP1+TAM profile indicated a poor prognosis, reduced effector T cell infiltration, and attenuated response to immunotherapy, may benefit from TROP2, MUC1, and NECTIN4-based ADC agents. The result was validated in TNBC samples treated with neoadjuvant immunotherapy from our center. This study unveils the critical immunosuppressive axis orchestrated by CA9+CAF and SPP1+TAM in TNBC, offering novel insights into the stromal regulatory mechanisms driving immune resistance. The cell-to-cell interaction signature holds promise as predictor of immunotherapy response and potential therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9990df240d9cf9afd4d976bdcb6753a231a07876" target='_blank'>
              CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer
              </a>
            </td>
          <td>
            Qin Ma, Jing Wang, Qian Jiang
          </td>
          <td>2026-01-09</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Tolerogenic dendritic cells (tolDC) are currently in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The methods for producing therapeutic tolDC vary widely, with little being known about the commonalities and differences of distinct cell products in terms of their regulatory actions on CD4+ T cells. We compared human monocyte-derived tolDC generated with vitamin D3 alone or in combination with dexamethasone. We found marked differences in the surface expression of HLA-DR and immune regulatory molecules, but also found commonalities, e.g. a strongly reduced capacity to produce interleukin-12 and a concomitant decreased ability to induce interferon-γ secretion by allogeneic CD4+ T cells. To gain a deeper understanding of how these tolDC types exert their regulatory effects, we co-cultured them with CD4+ T cells from rheumatoid arthritis patients or healthy controls and analysed the gene expression profile and function of the responding T cells. We found that tolDC generated with vitamin D3 alone, but not in combination with dexamethasone, induced potent cytotoxic activity in the responding CD4+ T cells as demonstrated by an enhanced cytotoxic gene signature, increased levels of intracellular granzyme B, and superior cytotoxic activity towards myeloid and B cells. These data identify cytotoxicity as an atypical CD4+ T helper cell effector function induced by some but not all tolDC types, with implications for their individual clinical applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e6376b65c8f61913f7a1c8c2873d5f5d98c5c617" target='_blank'>
              Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells
              </a>
            </td>
          <td>
            Gabrielle Barran, N. Naamane, Abdul Mannan Baru, Amy E Anderson, Jane Falconer, C. Hilkens
          </td>
          <td>2025-12-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Most neuroendocrine cancers lack caspase 8 protein expression. While this feature was thought to facilitate escape from extrinsic apoptosis, its cancer-regulatory function has remained unexplored. Here, we devise a mouse model of small cell lung cancer (SCLC) recapitulating the lack of expression of caspase 8 seen in humans and uncover an unexpected role for necroptosis-fueled pre-tumoral inflammation resulting in reprogramming towards a neuronal progenitor cell-like state and increased metastatic disease. Notably, transcriptional signatures of this cellular state are enriched in relapsed and metastatic human SCLC. Mechanistically, caspase 8 loss within the pre-tumoral niche promotes inflammation marked by increased recruitment of regulatory T cells (Tregs) which are responsible for the promotion of metastatic disease. Importantly, inactivation of the necroptosis executioner MLKL reverses pre-tumoral inflammation, decreases metastasis as well as neuronal-like reprogramming. Taken together, our findings suggest that pre-tumoral inflammatory cell death contributes to neuronal progenitor mimicry, immunosuppression and increased metastasis in SCLC. Caspase 8 protein expression is largely absent in small cell lung cancer (SCLC) patients. Here, the authors generate a caspase 8 deletion SCLC mouse model and show that it promotes a neuronal progenitor-like cell state and pre-tumoral immunosuppression triggered by necroptosis that promotes metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/51116aff6d9c1d775ef35df82108582297dade1e" target='_blank'>
              Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression
              </a>
            </td>
          <td>
            Ariadne Androulidaki, Fanyu Liu, Christina M. Bebber, Ilmars Kisis, V. Sakthivelu, Pascal Hunold, L. Koerner, Alina Dahlhaus, F. I. Yapici, Christina Grimm, Alicja Pacholewska, Sofya Tishina, Franka Doskotz, Lucia A Torres Fernández, J. Stroh, Ali T. Abdallah, Julia Beck, Lejla Mulalić, A. Schmitt, Holger Grüll, T. Persigehl, Alexander Quaas, M. Peifer, J. Brägelmann, H. C. Reinhardt, P. Nieper, Robert Hänsel-Hertsch, Roman K. Thomas, Julie George, M.-R. Schweiger, Manolis Pasparakis, Filippo Beleggia, S. von Karstedt
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Cancer is a leading cause of mortality worldwide, necessitating the development of novel therapeutic targets and strategies to prevent recurrence and metastasis. In this study, we aimed to evaluate whether a recombinant attenuated Salmonella vaccine (RASV) can stimulate antitumor immunity and prevent cancer progression in vivo. We established a mouse model by transplanting cancer cells subcutaneously 4 weeks after oral RASV inoculation and analyzed bone marrow (BM) cells and tumor-infiltrated immune cells by flow cytometry. Further, we established a 4 T-1-induced metastatic cancer model to evaluate the RASV-mediated prevention of tumor metastasis. Adjuvant RASV significantly reduced tumor growth by enhancing CD8+ T cell activity and inducing changes in BM progenitor cells, which contributed combinatorically to the antitumor effects of RASV by increasing the number of common lymphoid progenitor cells. The antitumor effects mediated by RASV were inhibited upon interleukin (IL)-7 receptor blockage. Moreover, interferon-γ-stimulated genes, including Irf1, were upregulated in the BM of RASV-treated mice, thus mediating IL-7 expression. Furthermore, RASV inoculation prevented lung metastasis in mice with breast cancer. RASV inoculation can promote marked alterations in the BM microenvironment, thus reshaping the anticancer immune response in vivo. This strategy holds therapeutic potential for preventing cancer recurrence and metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35644cfe7dafd62e220ed3ad70717f6970a8b294" target='_blank'>
              Recombinant attenuated Salmonella vaccine promotes CD8+ T cell-dependent antitumor immunity via IFN-γ-induced IRF-1-mediated upregulation of IL-7
              </a>
            </td>
          <td>
            Jae-Hyeon Jeong, Dae-Joon Kim, Chae-Won Kim, Youngjoo Han, Ah-Ra Jang, Jong-Hwan Park, N. Tae, Jae-Hee Ahn, Jaewon Cho, Sun Shim Choi, Mi-Na Kweon, Dae Hee Kim, Hyun-Jeong Ko
          </td>
          <td>2025-12-01</td>
          <td>Cell & Bioscience</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized tumour therapy by relieving immunosuppression and restoring effector T cell cytotoxicity. However, its clinical utility is constrained by low response rates and acquired resistance. Tumour‐associated neutrophils (TANs), key players in tumour immunoregulation, have emerged as critical mediators of ICB responsiveness and resistance, highlighting the therapeutic potential of combining TAN‐targeted strategies with immune checkpoint inhibitors (ICIs). This review systematically synthesizes current knowledge of neutrophils in ICB resistance from several dimensions: (1) clinical indicators of neutrophils, such as the neutrophil‐to‐lymphocyte ratio (NLR) and tissue TANs abundance, as predictors of ICI response and patients prognosis; (2) multifaceted TAN‐involved resistance mechanisms, including direct T cell inhibition, antigen presentation impairment, function modulation of other immune cells, promotion of tumour angiogenesis, and elevation of tumour mutation burden (TMB); (3) combination therapeutic strategies targeting TAN generation/ exhaustion, recruitment, phenotypic polarization, activation, proangiogenic functions, and neutrophil extracellular traps (NETs), along with progress in related clinical trials. Combinatorial approaches integrating TAN‐targeted therapies with ICIs hold substantial promise for overcoming resistance by reshaping the immune microenvironment. Elucidating neutrophil‐mediated resistance mechanisms and optimizing combination strategies will pave the way for precision tumour immunotherapy. Key points TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI resistance. Numerous clinical trials are evaluating combination therapies targeting neutrophils to enhance immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb8c196a123899665e6475d21ebf9639c6d4e4b" target='_blank'>
              Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren
          </td>
          <td>2026-01-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Most colorectal cancers are resistant to immune checkpoint inhibitors due to an immunosuppressive tumor microenvironment. LINC00673, previously classified as a long non-coding RNA, has been implicated in tumor progression, but its role in antitumor immunity remains poorly understood. We used single-cell RNA sequencing, flow cytometry, and functional assays in Linc00673 knockout and wild-type mouse models treated with programmed death 1 (PD-1) blockade to dissect changes in immune landscape and tumor cell behavior. Linc00673 deletion enhanced the efficacy of PD-1 therapy, reducing tumor burden and prolonging survival. KO tumors showed increased infiltration of cytotoxic CD8⁺ T cells, reduced exhaustion, and improved antigen presentation. The tumor microenvironment shifted toward a pro-inflammatory state, with elevated dendritic cell function, reduced immunosuppressive macrophages, and improved T cell–tumor interactions. Linc00673 also promoted tumor cell migration and immune evasion independently of immune cells, suggesting dual tumor-intrinsic and -extrinsic roles. LINC00673 suppresses antitumor immunity and promotes tumor aggressiveness. Its deletion synergizes with PD-1 blockade, revealing a promising therapeutic target to overcome immune resistance in colorectal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb9ef0a9a3f2685b8b34be389ae9c671f82a1666" target='_blank'>
              Single-cell RNA sequencing unveils enhanced antitumor immunity in colorectal cancer with PD-1 blockade and LINC00673 deletion
              </a>
            </td>
          <td>
            Yifei Zhu, Yanxi Yao, Yaxian Wang, Zhibing Qiu, Dingpei Zhou, Huixia Huang, Keji Chen, Qingyang Sun, Jiayu Chen, Yuxue Li, Jianqiang Tang, Dawei Li, Ping Wei
          </td>
          <td>2026-01-03</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf87d56103e47056c8390c382a196ac0a7304b81" target='_blank'>
              Rasal1 impairment unleashes anticancer immunity - a focus on T cells
              </a>
            </td>
          <td>
            Mark E. Issa, Alejandro Schcolnik-Cabrera
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Despite advancements in cancer therapies, bacterial complications remain a major challenge, delaying treatment and worsening outcomes. While immunosuppressive therapies and prolonged hospitalizations contribute, they do not fully explain the elevated infection risk in cancer patients. Here we show that tumors producing high levels of granulocyte colony-stimulating factor (G-CSF) promote the persistence of Gram-negative pathogens in head and neck squamous cell carcinoma due to neutrophil reprogramming. Mechanistically, we identify tumor-driven activation of the G-CSF / nicotinamide phosphoribosyltransferase (NAMPT) signaling axis in neutrophil progenitors, resulting in impaired antibacterial functions, such as phagocytosis and neutrophil extracellular traps formation, and development of tissue-damaging neutrophil subsets. This disrupts lung tissue integrity and facilitates bacterial persistence. Importantly, targeting the G-CSF/NAMPT pathway prevents the generation of dysfunctional neutrophils and improves bacterial clearance in vivo. Our findings reveal tumor-induced, NAMPT-dependent neutrophil reprogramming as a central driver of compromised antimicrobial defenses in cancer. Therapeutic strategies aimed at modulating G-CSF/NAMPT signaling could enhance infection control and survival for cancer patients. Cancer patients are at increased risk for severe bacterial infections due to immune dysfunction. Here, the authors show that chronic tumor-derived G-CSF drives NAMPT/NAD-dependent neutrophil dysfunction from the progenitor stage, and that targeting this pathway restores infection control.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/989ea783a50fee5cffb3981c7881623972aa98d2" target='_blank'>
              G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients
              </a>
            </td>
          <td>
            E. Pylaeva, Lea Tollrian, Jana Riedesel, Olga Shevchuk, Ilona Thiel, Irem Ozel, Nastassia Kabankova, Hannah Voss, B. Siebels, Hartmut Schlüter, Corinna Haist, Helmut Hanenberg, S. Mattheis, C. Kürten, M. Sperandio, J. Kehrmann, D. Engel, Stephan Lang, Jadwiga Jablonska
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e671ae9afcf44023adfbe654ebbd2bf2b2c59d6f" target='_blank'>
              Single-cell atlas reveals alveolar macrophage-specific Oncostatin-M drives pulmonary fibrosis via fibroblast activation in PCV2d infection
              </a>
            </td>
          <td>
            Jingmei Xu, Xinyi Fan, Panlong Chen, Yumei Yuan, Yunlong Chen, Gang Fan, Bin Yang, Fan Yang, Yan Wang, Shiqiang Zhang
          </td>
          <td>2025-12-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dfa1103b42fb7aad2cf0d81519ef11fa1c555b5" target='_blank'>
              Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
              </a>
            </td>
          <td>
            Josephine G. M. Strijker, Ronja E. van Berkum, Elisavet Kalaitsidou, Arjan Boltjes, Naima Hiddink Verberne, Mirjam A. Damen, F. van den Ham, Liselotte E. Baaij, John Anderson, Jan J. Molenaar, Wei Wu, J. Wienke
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a445e1ca795ad9ffc13ccb78dc0d267f18bdd859" target='_blank'>
              Monocyte reprogramming by nociceptors impedes T cell-mediated tumor immunity
              </a>
            </td>
          <td>
            P. Hanč, Adrian Blair, Harold R. Neely, Changwei Peng, I. Mazo, Matthias Mack, Ulrich H. von Andrian
          </td>
          <td>2026-01-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are central constituents of the tumor microenvironment (TME), recruited from circulating monocytes through chemotactic signals, and they execute complex, multifaceted functions throughout tumor progression. Functionally heterogeneous, TAMs are broadly classified into distinct subtypes that display a dynamic duality, capable of shifting between tumor-suppressive and tumor-promoting states, though the pro-tumorigenic functions tend to dominate across multiple cancer types. The polarization of TAMs is modulated by diverse cytokines and signaling networks within the TME. Key pro-tumor mechanisms include activating proliferative signaling pathways, enhancing invasive and metastatic potential, establishing an immunosuppressive TME through immune cell interactions, and conferring therapy resistance. The spatial heterogeneity of TAMs further underscores the predictive relevance. Translational research increasingly focuses on TAM-targeting strategies such as inhibiting recruitment, depleting subsets, or reprogramming function. Emerging approaches, including nanomedicine-based targeting, macrophage-mediated therapies, and novel drug formulations, highlight the importance of combining conventional treatments with immune checkpoint inhibitors (ICIs). Such combinations help overcome therapeutic resistance and improve clinical outcomes. This review systematically summarizes recent advances in TAM biology and plasticity, biomarkers from single-cell and spatial analyses for distinguishing TAM subsets, and their prognostic relevance in immunotherapy. It also discusses TAM-targeting strategies and their synergistic potential with existing therapies. Together, these insights lay the foundation for next-generation cancer treatments that precisely target TAMs to overcome therapy resistance and improve patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/364fbf1a7e99dd37bbe5b81db733d5ee958dbfae" target='_blank'>
              Tumor-associated macrophages in cancer: from mechanisms to application
              </a>
            </td>
          <td>
            Wan Tang, Xin Wang, Bing Han, Shuheng Jiang, Hongshi Cao
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Head and neck squamous cell carcinoma (HNSCC) remains a prevalent epithelial malignancy. Immune-checkpoint inhibitors have reshaped first-line therapy for recurrent/metastatic disease; yet durable benefit is confined to a subset, reflecting myeloid-centric mechanisms—SPP1+ TAM barriers, cDC1/IL-12 insufficiency, and CXCL8–CXCR1/2–driven neutrophil trafficking—distinct from, and complementary to, classical lymphoid exhaustion. In this review we summarize advances from single-cell RNA and ATAC profiling and spatial transcriptomics that resolve macrophage, dendritic-cell and neutrophil programs, and appraise translational opportunities spanning myeloid reprogramming, innate–adaptive combinations and spatial biomarkers. We also discuss enduring challenges—including HPV-status heterogeneity, limited assay standardization and a scarcity of predictive metrics—that temper implementation. By integrating myeloid-informed readouts (e.g., SPP1–TAM burden, cDC1 competency, serum IL-8) with PD-1–based regimens, EGFR-directed antibodies and myeloid checkpoints (CD47–SIRPα, PI3Kγ, CXCR1/2), emerging strategies aim to restore antigen presentation, improve lymphocyte trafficking and remodel tumor–stroma interfaces. Our synthesis provides an appraisal of the evolving landscape of myeloid-informed precision immuno-oncology in HNSCC and outlines pragmatic standards and avenues for clinical translation. We hope these insights will assist researchers and clinicians as they endeavor to implement more effective, individualized regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1e1e89f3eb622744a2cb356a1f52faae72322d69" target='_blank'>
              Myeloid-driven immunosuppression in head and neck cancer: single-cell ATAC/RNA and spatial transcriptomic perspectives
              </a>
            </td>
          <td>
            Rui Luo, Jianzheng Yang, Zimeng Cao, Bing Li
          </td>
          <td>2025-12-18</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d9d9e99d312aee7d3e8959371325610d5ce9af0" target='_blank'>
              MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapy
              </a>
            </td>
          <td>
            Ziwen Zhu, Noah C. Kanis, Anthony E. George, Michael Albdewi, Yingxiang Li, Anzar A. Mujeeb, Brandon L. McClellan, Gurveer Singh, Jialin Liu, W. Al-Holou, J. Heth, Joshua D. Welch, Justin D. Lathia, Pedro Lowenstein, Richard Bucala, Maria G. Castro
          </td>
          <td>2026-01-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) are best known for their outstanding ability to rapidly produce large amounts of type I interferons (IFN‐I), which are key antiviral mediators. However, after their initial IFN‐I burst, the pDC lineage undergoes a number of adaptations that converge on the attenuation of pDC‐derived interferons, ensuring their production remains short‐lived regardless of whether the pathogen is cleared or persists. The convergence of multiple host adaptations that result in reduced pDC numbers and/or function after infection highlights the double‐edged sword nature of pDCs: while they can be beneficial for antiviral defense, they can also drive tissue pathology. In this review, we summarize selected pDC‐lineage adaptations that arise after their initial IFN‐I peak following a viral infection, including compromised pDC development from bone marrow progenitors, fate plasticity that enables pDC conversion into conventional dendritic cells type 2 (cDC2)–like cells, and loss of the pDCs' hallmark capacity to produce IFN‐I. We also provide an overview of the underlying molecular mechanisms contributing to the aforementioned adaptations, discuss potential evolutionary advantages, and highlight future avenues to dissect the fundamental biology of pDC reprogramming with the ultimate goal of leveraging these insights to therapeutically target pDCs in infections and beyond.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb1bc29ce0ad99c199dec49375e6c4567352274b" target='_blank'>
              Plasmacytoid Dendritic Cell Lineage Adaptations During a Viral Infection
              </a>
            </td>
          <td>
            Carolina Chiale, S. Dallari, Elina I. Zúñiga
          </td>
          <td>2025-12-12</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Despite effective viral suppression, a subpopulation of people living with HIV (PLWH) receiving combination antiretroviral therapy (ART) experience a suboptimal immunological response, failing to restore CD4+ T‐cell counts to levels deemed indicative of good immune recovery. Innate immune cell dysregulation, particularly in mucosal‐associated invariant T (MAIT) and natural killer (NK) cells, is increasingly recognized as a key contributor to immune reconstitution. However, the dynamic changes, interactive crosstalk, and potential roles of these immune cells in immune reconstitution remain poorly understood. A total of 89 participants were enrolled, including 29 healthy controls and 60 HIV‐infected individuals, who were classified as immune responders (IRs, CD4 ≥ 500 cells/µL; n = 34) and suboptimal immunological responders (SIRs, CD4 < 500 cells/µL; n = 26) on the basis of immune recovery status. Longitudinal flow cytometric analysis was performed to assess the phenotypic changes in MAIT and NK cell subsets in peripheral blood mononuclear cells (PBMCs) before treatment (T0) and after 4 years of ART (T4). Correlation analysis was conducted to explore their associations with CD4+ T‐cell recovery. After 4 years of ART, both IRs and SIRs exhibited persistent depletion of total MAIT and invariant natural killer T (iNKT) cells, whereas pretreatment‐diminished CD56bright and CD56dim NK cell subsets increased significantly. MAIT cells also underwent phenotypic remodeling in both groups, with decreased CD4−CD8+ and increased CD4−CD8− subsets. Notably, these cell subset proportions and quantitative changes correlated significantly with CD4+ T‐cell counts in IRs but not SIRs. In IRs, CD4+ T‐cell recovery positively correlated with baseline CD4−CD8− MAIT and CD56bright NK cell numbers, but negatively with baseline CD4−CD8+ MAIT cell numbers. Correlation networks revealed distinct MAIT–NK interactions across ART stages. LASSO models integrating MAIT and NK subsets achieved high predictive accuracy, highlighting the dynamic role of CD4−CD8+ MAIT cells in immune reconstitution. Our study highlights the dynamic correlations between and within MAIT and NK cell subset proportions in PLWH, revealing that phenotypic remodeling rather than absolute cell counts plays a key role in immune reconstitution. CD4−CD8+ MAIT cells show time‐dependent predictive shifts, reflecting functional adaptation. These findings identify MAIT and NK subset dynamics as potential biomarkers and therapeutic targets for enhancing immune recovery of PLWH during ART.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a98d3cfcae4bc3d9e7d0f462e62d60ace1750c6" target='_blank'>
              Subset Remodeling of MAIT and NK Cells Correlates With Immune Reconstitution in People Living With HIV Following Four Years of Antiretroviral Therapy
              </a>
            </td>
          <td>
            Zhuoya Deng, Xin Zhang, Aiwei Zhu, Xiao-dong Yang, Qiuyue Zhang, Hongxia Yan, Hao Wu, Tong Zhang, Christiane Moog, Bin Su
          </td>
          <td>2025-11-29</td>
          <td>Journal of Medical Virology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, C. Du, S. Deng, Mu Hao, Yan Xu, S. Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db7963f819719f5d174aa6e308c691c9523b680d" target='_blank'>
              Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)
              </a>
            </td>
          <td>
            T. Kan, Y. Barsheshet, Tharwat Haj Khalil, B. Brant, T. Voloshin, K. Ben-Meir, Simona Zisman Rosen, M. Giladi, U. Weinberg, Y. Palti
          </td>
          <td>2025-12-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and a dismal prognosis. While immunotherapy has shown promise in treating some solid tumors, the treatment of GBM has been mostly unsuccessful because of a lack of targetable tumor antigens and high tumor heterogeneity. Here, we report RCAN1-4 as a novel tumor antigen derived from alternative splicing induced by the transcription factor C/EBPβ. Both C/EBPβ and RCAN1-4 are highly expressed in GBM and glioma stem cells as mesenchymal subtype hallmarks. We report an immunogenic HLA-A24-specific splicing junction epitope within exon 4 and exon 5 that is unique to RCAN1-4. This epitope was validated for its ability to stimulate T cell responses in HLA-A24+ donors and GBM patients, leading us to identify RCAN1-4-reactive T cell receptors (TCRs) for the construction of TCR-engineered T cells (TCR-T cells). Functional studies of TCR-Ts demonstrated the in vitro and in vivo killing of RCAN1-4pos GBM tumor cells, highlighting its potential as an immunotherapeutic target in mesenchymal GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9431f57db16fa14c7bf510b22de1e580e92e77" target='_blank'>
              C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma
              </a>
            </td>
          <td>
            Zujian Xiong, Qinglin Kong, Bhuvi Chagantipati, Amelia L Stepniak, Ambika P Jaswal, Chaim T Sneiderman, Yuanyuan Han, Sydney A Jackson, Rebecca A Raphael, Wei Zhang, Muzi Li, Yapeng Chao, Bin Qin, Zeynep Dulkadir, Lance Schwegman, Yihao Zhang, Chloe R Kuminkoski, Megan A Mahlke, Poulomi Nath, Baoli Hu, Pascal O. Zinn, M. Mantica, S. Agnihotri, Yael Nechemia-Arbely, Ian F. Pollack, L.H. Rigatti, Thomas G. Forsthuber, Xuejun Li, Itay Raphael, G. Kohanbash
          </td>
          <td>2025-12-23</td>
          <td>Cellular and Molecular Immunology</td>
          <td>1</td>
          <td>18</td>
        </tr>

        <tr id="Stem cell‐like memory T cells (TSCM) play a pivotal role at the top of the memory T cell hierarchy, understanding their involvement in immune exhaustion during HIV infection may shed light on T cell dysfunction mechanisms. We compared cellular immunity between virally suppressed people living with HIV (PLWH) under antiretroviral therapy (ART) and HIV‐negative subjects. Flow cytometry was used to assess the phenotype and function of peripheral TSCM. TSCM showed a reduction in the expression level of TCF‐1, T‐bet, as well as in multifunctional capacity, which was reflected by decreased secretion of IL‐2+TNF‐a+INF‐γ+cells in PLWH. The decreased frequencies of IL‐2+TNF‐a+INF‐γ+TSCM was positively correlated with the reduced frequency of T‐bet+ in T cells. An increased mean fluorescence intensity of TOX was observed in CD4+TSCM from PLWH. The frequency of T progenitor exhausted‐like cells (TPEX) within CD8+T cells was positively associated with the frequency of GZMK+cells in CD4+TSCM. In addition, the frequency of stem‐like T cells (TSTEM) in CD4+T cells was positively correlated with the frequency of T‐bet+cells in CD4+TSCM. TSCM from virally suppressed PLWH exihibt impaired stemness and multipotency, potentially contributing to poor immune reconstitution.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e877f2c3e88ac6b0eb7a1d60d1fb8ce388116bb5" target='_blank'>
              Residual Exhaustion of Stem Cell‐Like Memory T Cells (TSCM) in HIV Infected Patients With Viral Suppression
              </a>
            </td>
          <td>
            Jing Xiao, Fuchun Wang, Luying Zhu, Yanmin Liu, Bin Su, Xiaofan Lu, Tong Zhang
          </td>
          <td>2025-12-01</td>
          <td>Journal of Medical Virology</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Glioblastoma (GBM) is characterized by fast progression, infiltrative growth pattern, and a high relapse rate. A defining feature of GBM is the existence of spatially and functionally distinct cellular niches, where malignant cells engage in paracrine crosstalk with cell types comprising the tumor microenvironment. Here, we identify pericytes as the most active paracrine signaling hub within the tumor parenchyma. Their depletion through genetic engineering results in accelerated tumor progression and shortened survival. Mechanistic studies reveal that pericyte deficiency remodels the endothelium and impacts the immune cell landscape, exacerbating tumor cell invasion and immune suppression. Specifically, the pericyte-deprived endothelium recruits perivascular, tumor-associated macrophages polarized towards an immune-suppressive phenotype. The recruited macrophages express Hepatocyte Growth Factor, which reinforces activation of its receptor tyrosine kinase MET on GBM cells harboring a pronounced mesenchymal subtype driven by the key phenotypic regulator Fosl1. Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy. Improved understanding of the tumor ecosystem in glioblastoma is critical for developing new treatment strategies for the disease. Here, the authors identify pericytes as an active paracrine signaling hub within the tumor parenchyma that orchestrates a tumor-suppressive microenvironment, suggesting pericyte preservation as a key feature of future therapeutic regimens for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c09a05790107e087a632df06714ceec3176e20b4" target='_blank'>
              Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma
              </a>
            </td>
          <td>
            S. Braun, P. Bolivar, C. Oudenaarden, J. Sjölund, M. Bocci, K. Harbst, Mehrnaz Safaee Talkhoncheh, B. Phung, E. Cordero, R. Rosberg, E. Johansson, G. Jönsson, A. Pietras, Kristian Pietras
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) is primarily driven by leukemic stem cells (LSCs), the main cause of relapse and therapy resistance. Here, we discover that LSCs are predominantly small and mechanically soft. These mechanical properties enable their selective isolation using microfluidic chips. Single-cell RNA-sequencing of primary human AML bone marrow identifies enrichment of LSCs within the FSClow ALDH1A1+ subpopulation, which exhibits long-term stemness in functional assays. Notably, inhibiting ALDH1A1 in these cells promotes F-actin polymerization and increases cellular stiffness, reducing their stemness while enhancing their susceptibility to natural killer (NK) cell-mediated cytotoxicity. In AML patient-derived xenograft models, the combination of ALDH1A1 inhibition with NK cell therapy markedly suppresses leukemia progression. These findings suggest that targeting the mechanical properties of LSC offers a promising strategy to overcome AML treatment resistance, providing insights into stem cell mechanobiology and paving the way for combining targeted therapies with immunotherapy to improve clinical outcomes. Leukemic stem cells (LSCs) drive relapse and therapy resistance in acute myeloid leukemia (AML). Here, the authors show that increasing the stiffness of LSCs reduces their stemness and enhances their susceptibility to natural killer cell-mediated immunotherapy in AML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bd4d9af75a4b85e67dee8555546e74be5696efd1" target='_blank'>
              Targeting leukemic stem cell biomechanics suppresses stemness and enhances NK cell-mediated immunotherapy
              </a>
            </td>
          <td>
            Mingming Zhu, Haoxiang Yang, Kailong Qiu, Beibei Huang, Tingting Liang, Yan Wang, Huan Li, Mingming Wu, Xinru Liu, Na Zhao, Xian Song, Xuxu Zhao, Mengqing Gao, Yue Zhao, Xiangting He, Rui Zhao, Lili Qian, Qinhua Liu, Changcheng Zheng, Xiaoyu Zhu, Hongyuan Jiang, Fang Ni
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Introduction Sepsis leads to expansion of myeloid-derived suppressor cells (MDSC) and their subtypes. These normally transitory MDSCs suppress T cell activation and alter T cell cytokine production while simultaneously promulgating systemic low-grade inflammation. Immune metabolism can shape cell responses, regulate immune suppression, and enhance effector activity. Although MDSC metabolism has been extensively studied in cancer, the metabolic phenotype of this heterogeneous population in sepsis remains unclear. Our goal was to assess metabolic flux in blood MDSCs during and after sepsis and to stratify these patients’ clinical features and outcome with differences in metabolic flux that may guide treatment decisions. Methods Peripheral blood mononuclear cells (PBMC) from healthy subjects and sepsis patients at 4 days, 2-3 weeks, and 6 months underwent CD66b+ or CD3+ enrichment, followed by assessment of metabolic flux, flow cytometry, mRNA sequencing, and chromatin accessibility. Results Mitochondrial basal oxygen consumption rates (OCR) and maximal oxygen consumption rates (SRC, spare respiratory capacity) were decreased in MDSC from septic patients at 4 days after infection and persisted for up to 6 months after sepsis onset. Sepsis was not associated with differences in glycolysis. In contrast, oxidative metabolism in CD3+ T cells was similar between sepsis patients and healthy subjects. Reduced MDSC oxidative metabolism was linked to adverse clinical outcomes. The decline in oxygen consumption from MDSCs in septic patients was also associated with significant reductions in MDSC mitochondrial content. Transcriptomic analysis of CD66b+ cells isolated from PBMC of healthy participants and patients with sepsis at 4 days, 2-3 weeks, and 6 months revealed 19 differentially expressed genes and three long non-coding RNAs as potentially responsible for this decline in mitochondrial mass. Specifically, NR4A3, NR4A2, and TAMLIN/NR4A1 expression, all critical for mitochondrial biogenesis, were persistently decreased with reduced chromatin accessibility indicative of gene silencing. Discussion After sepsis, blood CD66b+ cells present with reduced mitochondrial mass and oxidative metabolism that continue at least 6 months after sepsis. These changes in mitochondrial function result from a reduced content of these organelles. We have also identified gene silencing, reduced gene expression of key transcription factors that regulate mitochondrial biogenesis, as well as increased long non-coding RNA as potential drivers of this unique metabolic phenotype. These results highlight the potential benefit of targeting metabolism in sepsis to promote immune homeostasis and recovery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48dac9de2c81b45da57ef12b64fdabc04b31fc63" target='_blank'>
              Prolonged Loss of Oxidative Phosphorylation and Mitochondrial Mass Characterize CD66b+ Leukocytes from Patients with Sepsis
              </a>
            </td>
          <td>
            Christine Rodhouse, Evan L. Barrios, Leilani Zeumer-Spataro, Leandro Balzano-Nogueira, Ruoxuan Wu, Xuanxuan Yu, Guimei Tian, Jason O. Brant, Marie-Pierre L. Gauthier, Jing Chen, Miguel Hernandez-Rios, Valerie E. Polcz, Whitman Wiggins, Angel M. Charles, M. Dirain, Ricardo F. Ungaro, J. Rincon, Tyler Loftus, Feifei Xiao, Guoshuai Cai, L. Moldawer, Robert Maile, Michael P. Kladde, Philip A. Efron, Clayton E. Mathews
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Background Crohn’s disease (CD) is a chronic relapsing inflammatory bowel disease characterized by persistent mucosal inflammation and immune dysregulation. While alterations in gut microbial composition are known to contribute to CD pathogenesis, the precise mechanisms linking specific microbial species to immune dysfunction remain unclear. Here, we identify Fusobacterium nucleatum (Fn), a pathobiont enriched in CD patients, as a key driver of dendritic cell (DC) activation and downstream Th17/Treg imbalance. Methods Fecal and colonic mucosal samples from CD patients and healthy controls were analyzed by 16S rRNA sequencing. A TNBS-induced colitis model with adoptive DC transfer, was used to evaluate the impact of Fn on intestinal inflammation, DC activation and Th17/Treg balance. RNA sequencing of Fn-exposed bone marrow-derived DCs (BMDCs) identified key immune mediators. CD40 signaling was verified through inhibition with TRAF-STOP, both in vivo and in vitro. Results Fn was significantly enriched in CD and positively associated with severity of inflammation. In mice, Fn aggravated colitis, resulting in heightened immune dysregulation, especially DC activation. Adoptive transfer of Fn-primed DCs aggravated TNBS-induced inflammation in recipient mice, accompanied by Th17/Treg imbalance. Transcriptomic analysis identified robust CD40 upregulation in Fn-exposed DCs, which was corroborated in inflamed colons from CD patients. CD40 blockade with TRAF-STOP suppressed DC activation, restored Th17/Treg balance, and ameliorated intestinal inflammation. Conclusions This study demonstrates that Fn exacerbates intestinal inflammation under inflammatory conditions in CD through CD40-mediated DC activation and subsequent Th17/Treg imbalance. These findings establish a novel mechanistic link between microbial dysbiosis and immune dysregulation, identifying CD40 as a promising target for microbiota-directed immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18b9dcbbc042782c28bc849cd6386b66f73de655" target='_blank'>
              Fusobacterium nucleatum drives CD40-mediated dendritic cell activation and Th17/Treg imbalance to exacerbate intestinal inflammation in Crohn’s disease
              </a>
            </td>
          <td>
            Mingyuan Wang, Junjian Sun, Jiang Yu, Jiayun Wang, Chenjing Xu, Jingjing Ma, Hongjie Zhang
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="In the ovarian cancer microenvironment, the polarization of tumor-associated macrophages (TAMs) is closely associated with immunosuppressive phenotypes. Although elevated levels of circulating interleukin-7 (IL-7) have been linked to a poor prognosis, the regulatory mechanisms underlying this association remain incompletely understood. This study demonstrated that increased IL7R expression in ovarian cancer is correlated with the polarization of CD206+ macrophages, the remodeling of the immunosuppressive microenvironment, and unfavorable patient prognosis. By employing 3D bioprinted co-culture systems and mouse models, we showed that the knockdown or knockout of IL7R inhibits tumor progression and intraperitoneal dissemination. Mechanistically, IL7R signaling promotes the polarization of macrophages toward an immunosuppressive phenotype through the NF-κB/CXCL1 axis. This is supported by the upregulated expression of Arg1 and IL-10, as well as the downregulated expression of pro-inflammatory markers. These polarized macrophages further enhance tumor cell proliferation and invasion, thereby forming a tumor-immune feedback loop. In conclusion, this study clarifies how IL7R signaling mediates crosstalk between ovarian cancer cells and macrophages to maintain the homeostasis of the immunosuppressive tumor microenvironment (TME).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7116126aaada33b14ed91a0ba7aab0478ac13e27" target='_blank'>
              IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancer
              </a>
            </td>
          <td>
            Yeqing Zheng, Cheng Qian, Shuyi Zhang, Meichen Wen, Xun Xu, Xuan Zhou, Y. Wan, Lin Zhang, Wenjun Cheng
          </td>
          <td>2025-12-08</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Interleukin-2 (IL2) has potent anticancer properties but its clinical use is limited by severe dose-dependent side effects, notably capillary leak syndrome (CLS) - a life-threatening condition marked by vascular barrier disruption and multi-organ dysfunction. Despite extensive efforts to engineer IL2 variants with improved pharmacokinetics or reduced toxicity, none of the 45 IL2-based agents currently under investigation across 139 trials have secured regulatory acceptance for cancer or autoimmune applications, largely due to unresolved safety concerns and limited efficacy, suggesting an incomplete understanding of IL2-induced CLS pathogenesis. Here, we describe the development of an immune-competent in vitro model of IL2-induced CLS comprising human primary endothelial cells co-cultured with donor-derived peripheral blood mononuclear cells (PBMCs) that recapitulates IL2 dose-dependent endothelial barrier loss. We demonstrate that neither IL2 alone nor cytokines released from IL2-stimulated PBMCs are sufficient to impair barrier integrity and show that direct cell-cell proximity is required for barrier loss and endothelial activation. Proteomic profiling identified key IL2-induced inflammatory, adhesion, and matrix remodeling pathways and pharmacological inhibition of selected targets mitigated IL2-mediated vascular dysfunction. This platform recapitulates key hallmarks of IL2-induced CLS, provides a mechanistically relevant, human-specific tool to study CLS pathogenesis and supports the development of safer IL2-based therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7242c15b7c8257703280c378aa7cb6c4b182baf0" target='_blank'>
              An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights and evaluation of mitigation strategies
              </a>
            </td>
          <td>
            Tamara Zimmermann, Edith Philipp, Sabine Marget-Muller, Gabrielle Leclercq-Cohen, S. Golling, Juliane Siebourg-Polster, A. Augustin, Remi Villenave
          </td>
          <td>2025-12-06</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. The OSM receptor was predominantly expressed on nonhematopoietic bone marrow (BM) stromal cells. OSM reprogrammed these cells via STAT3 and induced the secretion of cytokines connected to T-cell exhaustion, including IL-6 and MCP-1. Compared with control mice, OSM-overexpressing mice presented reduced T-cell numbers, increased levels of inhibitory receptors on T cells, and elevated lactic acid production by BM stromal cells. OSM induced the expansion of myeloid cells which suppressed T cells. Conversely, genetic deletion of Osm in a JAK2 p.V617F-driven polycythemia vera mouse model reduced polycythemia, BM fibrosis, inflammatory cytokine levels and the expression of inhibitory markers on T cells. Transcriptomic analyses of T cells from OSM-overexpressing mice revealed enrichment of IL6–JAK–STAT3 and inflammatory signaling pathways. Additionally, pharmacological inhibition of OSM reduced disease activity and cytokine production. These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d49eb0cd9f9aa70be266360e0a4941b4deb7497" target='_blank'>
              Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies
              </a>
            </td>
          <td>
            Michael Rassner, T. Müller, Kirstyn Anne Crossley, G. Andrieux, Sabina Schaberg, Cornelia Endres, Lena Jakob, Teresa Poggio, Natalie Köhler, J. Kolter, Gerhard Müller-Newen, Katharina Schönberger, N. Cabezas-Wallscheid, I. González-Menéndez, Leticia Quintanilla-Martinez, Melissa Zwick, Driti Ashok, T. N. Hartmann, Olaf Groß, O. Gorka, M. Follo, A. Illert, M. Boerries, R. Zeiser, J. Duyster
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="The pathogenesis of rheumatoid arthritis (RA) involves an aberrant number and/or activation of dendritic cells (DCs) within the synovial microenvironment. Targeting synovial DCs represents an attractive approach for the treatment of RA. Spleen tyrosine kinase (SYK), a pivotal molecule in immune cell receptor signaling pathways, is known to play a critical role in RA progression. However, the impact of SYK on DC biology under RA-specific pathological conditions remains incompletely understood. In this study, we employed a spontaneous RA mouse model carrying a gain-of-function SYK variant (SYKS544Y) to investigate the effects of SYK activation on DCs. Our findings demonstrate that SYK activation promotes the expansion of the DCs population (CD11C+MHCII+), particularly the CD11C+MHCII+CD11B+CD8a− subtype, in blood, spleen, and ankle. Furthermore, SYK activation enhances DC maturation and endocytosis by upregulating CD40 and CD86. Additionally, bone-marrow-derived DCs from SYKS544Y mice exhibit increased T-cell proliferative activity. Collectively, these results suggest that gain-of-function SYK may contribute to RA pathogenesis by promoting DC expansion and maturation, thereby modulating immune responses in the synovial environment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90d45bd28b2a8c3fdbadb028c0f87f36c8d6fc15" target='_blank'>
              SYK Activation Enhances Dendritic Cell Functions in Spontaneous Rheumatoid Arthritis
              </a>
            </td>
          <td>
            Zhiyang Zeng, Xiya Cao, Haozhe Guo, Yuxuan Lai, Weihua Yang, Youyuan He, Jialiang Sun, Zhenliang Sun, Dali Li, Yamin Tan
          </td>
          <td>2025-12-30</td>
          <td>Inflammation</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7eec5092ca04ca50d54f7a273e3e46cdc98efcc8" target='_blank'>
              Aging increases ovarian cancer growth, metastasis, and immunosuppression that can be alleviated by inhibiting hedgehog signaling
              </a>
            </td>
          <td>
            Asha Kumari, M. H. Elbahoty, Resha Rajkarnikar, Khushi Sureja, M. Monavarian, L. Quintero, K.C. Fuh, Daniel J. Tyrrell, L. Shevde, Camilla Margoli, Karthikeyan Mythreye
          </td>
          <td>2025-12-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/02d1f577ff573db5c6fa1e5a829b978c4c5a4e28" target='_blank'>
              Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
              </a>
            </td>
          <td>
            Yao Zhang, Yuting Lei, Yanzhao Huang, Yan Gao, Rong Liu, Kaiyun Guo, Chunlian Zhao, Ming Lei
          </td>
          <td>2025-12-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Purpose Conventional type 1 dendritic cells (cDC1s) mastermind anti-cancer immunity and play a pivotal role in determining the efficacy of cancer immunotherapies. In this study, we sought to decipher the dynamic changes in the tumor immune landscape during intrahepatic cholangiocarcinoma (iCCA) development and harness the therapeutic potential of targeting cDC1s for cancer therapy. Methods We constructed spontaneous murine iCCAs via hydrodynamic tail vein injection (HDTVi) of plasmids encoding AKT/YAP. To characterize tumor-infiltrating immune cell populations throughout iCCA carcinogenesis and progression, we performed time-of-flight mass cytometry (CyTOF). To expand and activate cDC1s, we combined Flt3L with poly I:C (FL-pIC) therapy and assessed its therapeutic efficacy in both AKT/YAP-induced iCCAs and a subcutaneous tumor injection model. Flow cytometric analyses were used to evaluate intra-tumoral infiltration levels of cDCs and CD8+ T cells. Results CyTOF analysis revealed the progressive formation of an immunosuppressive tumor microenvironment as iCCA advances. Crucially, infiltration of cDC1s dramatically decreases in advanced iCCAs compared to early-stage tumors. Combined FL-pIC therapy preferentially expanded CD103+ cDC1s, powerfully inhibiting tumorigenesis in AKT/YAP-driven murine iCCAs and sensitizing these tumors to anti-PD-1 therapy. Moreover, FL-pIC therapy markedly suppressed the growth of established mIC-23 subcutaneous tumors. Conclusions Our findings demonstrate that recruiting and activating intra-tumoral cDC1s is feasible and essential for driving anti-tumor CD8+ T cell immune responses and enhancing anti-PD-1 therapeutic effectiveness in iCCA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0302218b55971d224461dce8f8bbf85290ab2de1" target='_blank'>
              Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinoma
              </a>
            </td>
          <td>
            Dong-ni Pei, Yang Song, Yingxia Zhou, Bo Shu, Shao-wei Huang, Fa-zhao Li, Wei-dong Dai, Bao-Ye Sun
          </td>
          <td>2025-12-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Colorectal cancer (CRC) exhibits a striking dichotomy in response to immune checkpoint inhibitors (ICIs), with durable benefit largely restricted to dMMR/MSI-H disease while most pMMR/MSS tumors remain refractory. Central to this resistance is an immunosuppressive myeloid ecosystem—dominated by SPP1high tumor-associated macrophages, neutrophils/PMN-MDSCs, and LAMP3+ mregDCs—that enforces chemokine-driven exclusion, attenuates antigen presentation, and sustains metabolite-mediated T-cell suppression. Despite advances in checkpoint blockade and biomarker stratification, these microenvironmental circuits constitute a major therapeutic hurdle. Moreover, single-cell and spatial proteomic platforms (e.g., CITE-seq, CODEX, imaging mass cytometry) now resolve the composition and topology of suppressive neighborhoods and highlight their utility for patient stratification and pharmacodynamic monitoring. This mini review summarizes cellular and spatial mechanisms by which myeloid states drive ICI non-response in CRC, emphasizing stromal TGF-β–coupled SPP1+ TAM programs, granulocytic chemokine axes (CXCL1/2–CXCR2; IL-8–CXCR1/2), and mregDC-mediated co-inhibition. We outline current and emerging myeloid-reprogramming strategies—including PI3Kγ and CSF1–CSF1R targeting, TREM2 antagonism, COX-2–PGE2 blockade, and adenosine-axis inhibition—and their integration with PD-(L)1 therapy, alongside single-cell/spatial endpoints to quantify on-treatment remodeling. The purpose of this mini-review is to provide a mechanistic and technology-informed framework to reference rational trial design and clinical translation for overcoming checkpoint resistance in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9edfc8b67748eb23273fb2effc39b0c690cbbf02" target='_blank'>
              Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches
              </a>
            </td>
          <td>
            Yu Dai, Xinyu Luo, Li Zhang, Jin Yan
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/da9bce00f9152dfcb5a7060dcea63ceebf9ab41f" target='_blank'>
              NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis
              </a>
            </td>
          <td>
            Lingxing Zeng, Shuang Liu, Xinyi Peng, Chunling Xue, Daoyuan Wang, Ruihong Bai, Shaoqiu Liu, Ziming Chen, Hongzhe Zhao, Zilan Xu, Sihan Zhao, Yifan Zhou, Xiaoyu Wu, Shaojia Wu, Mei Li, Ji Liu, Jialiang Zhang, Qi Zhou, Xudong Huang, Jiachun Su
          </td>
          <td>2026-01-22</td>
          <td>Gut</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Although Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable success in treating hematopoietic malignancies, its clinical application in solid tumors is profoundly hindered by persistent T-cell exhaustion within the immunosuppressive tumor microenvironment (TME). Here, we identified SATB1—a genome organizer regulating chromatin architecture—as a key suppressor of CAR-T cell exhaustion. In Glypican-3 (GPC3)-targeted CAR-T cells, SATB1 was significantly downregulated in tumor-infiltrating exhausted populations. SATB1 overexpression not only reduced expression of multiple inhibitory receptors (PD-1, CTLA-4, TIM3, and LAG-3) but also promoted a central memory phenotype, enhancing cytokine production and cytotoxicity against hepatocellular carcinoma (HCC) cells in vitro. In vivo, SATB1-engineered CAR-T cells exhibited superior tumor control and promoted survival, accompanied by reduced exhaustion markers in tumor-infiltrating T cells. These functional improvements are consistent with the reported role of SATB1 in modulating T cell exhaustion, positioning it as a multifunctional enhancer of CAR-T cell fitness. Collectively, our study unveils SATB1 as a multifunctional modulator that simultaneously targets exhaustion and memory differentiation, offering a novel strategy to enhance CAR-T efficacy against solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d16027357945047440109d5cbaaa875926903f3" target='_blank'>
              Enhanced anti-liver tumor efficacy of chimeric antigen receptor-T cells via SATB1 modulation
              </a>
            </td>
          <td>
            Lin Zhang, Chenxi Cheng, Xinyi Bi, Jiani Cao, Xiaoyan Li, Tongbiao Zhao
          </td>
          <td>2025-12-10</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="CD169+ macrophages, a unique subset of macrophages that cannot be simply defined as M1 or M2 macrophages, have been reported to be associated with various autoimmune diseases. However, the role of CD169+ macrophages in autoimmune hepatitis (AIH) is largely unknown. Here we found that the infiltration of CD169+ macrophages increased in the liver of patients with AIH and strongly positively correlated with inflammation degree. In a mouse model, depletion of CD169+ macrophages ameliorated ConA-induced acute liver injury. Immune homeostasis was also improved when CD169+ macrophages were depleted, as the infiltration of monocytes, macrophages and T cells decreased. Bone marrow-derived Ly6ChiCD169+ macrophages were further identified as the crucial subset in AIH. Next, we found that CD169+ macrophages were IFNγ-responsive and IFNγ could induce the expression of CD169. In response to the IFNγ signal, CD169+ macrophages actively secrete chemokine (C–C motif) ligand (CCL12), thus recruiting CCR2+ monocytes and macrophages to exacerbate AIH. Finally, neutralizing CCL12 improved AIH. Our results suggest that bone marrow-derived CD169+ macrophages, the key subset of macrophages in AIH, actively secrete CCL12 in response to IFNγ to recruit CCR2+ monocytes and macrophages, thus exacerbating AIH. The CD169+ macrophages are a potential therapeutic target in AIH. Autoimmune hepatitis (AIH) is a liver disease in which the immune system attacks liver cells. Researchers wanted to understand the role of a specific type of immune cell, CD169+ macrophages. The study involved analyzing liver tissues from 40 patients with AIH and conducting experiments on mice. They found that CD169+ macrophages increased in AIH and were linked to disease severity. In mice, removing these cells reduced liver damage. The study showed that bone marrow-derived CD169+ macrophages, not those from the liver itself, were crucial in worsening AIH. These cells produce a protein called CCL12, which attracts more immune cells to the liver. The researchers concluded that targeting these specific macrophages could be a new way to treat AIH. In the future, therapies could focus on reducing the activity of these cells to help manage or prevent AIH progression. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/990bd6336a38f68350b8357b9095fec42fc85896" target='_blank'>
              Bone marrow-derived CD169+ macrophages promote autoimmune hepatitis by recruiting CCR2+ monocytes via secreting CCL12
              </a>
            </td>
          <td>
            Bingru Lin, Huayang Zhang, Pengwei Zhu, Jianing Chen, Dingwu Li, Jiaming Zhou, Tiantian Zhang, Qingxia Chen, Chenxi Tang, Xin Song, Hang Zeng, Jinghua Wang, Jie Zhang, Z. You, Xiong Ma, Chaohui Yu
          </td>
          <td>2025-12-01</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has revolutionized the treatment of hematologic malignancies, yet its efficacy in solid tumors remains limited by T cell exhaustion, restricted tumor infiltration, and an immunosuppressive tumor microenvironment (TME). Recent advances in cytokine engineering have introduced innovative strategies to overcome these barriers by modulating CAR cell survival, persistence, and cytotoxic function. This review provides a comprehensive analysis of emerging cytokine-augmented CAR platforms, highlighting mechanistic innovations such as IL-2 superkines that enhance selective CAR-T expansion, IL-15–armed CAR constructs that sustain in vivo persistence, and IL-12 and IL-18 co-expression systems that remodel the TME and recruit endogenous immune effectors. The roles of IL-7, IL-10, and IL-21 in preserving memory phenotypes, mitigating exhaustion, and improving metabolic fitness are also discussed in depth. Furthermore, the review explores synthetic and inducible cytokine circuits that enable spatial and temporal control of cytokine release, improving therapeutic precision and reducing systemic toxicity. Collectively, these innovations represent a paradigm shift toward next-generation, cytokine-engineered CAR therapies with enhanced efficacy, safety, and durability against both hematologic and solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6da7d9a1c0219aac208853d023320a8f5224de41" target='_blank'>
              Frontiers of cytokine engineering in CAR cell therapy for cancer
              </a>
            </td>
          <td>
            Yinghan Wu, Yan-Ruide Li
          </td>
          <td>2026-01-09</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Methotrexate (MTX) is one of the most prevalent drugs used in the treatment of autoimmune disorders as it has an established role in preventing T and B cell proliferation which reduces the severity of autoimmunity. However, MTX in combination with several other drugs is commonly used as chemotherapeutic regimens for the treatment of breast cancer (BC). Given the critical role of immune cells—particularly T and B cells—in recognising and eliminating tumor cells, we sought to investigate the impact of MTX on immune cell regulation in the context of breast cancer. CD4+ T follicular helper (Tfh) cells are recognised for their anti‐tumor potential during BC progression, as they support B cell differentiation and proliferation within germinal centres. In this study, we specifically aimed to observe the regulatory role of MTX during in vitro human Tfh cell differentiation under normal circumstances, and within in vivo 4T1 metastatic tumour‐bearing mice. Our findings reveal that MTX exerts a dual and context‐dependent role in modulating Tfh cell differentiation and function across the two models. Furthermore, we explored the influence of the AMPK activator AICAR in combination with MTX in both the human and mouse models. MTX when used in combination with AICAR, rescued human Tfh cell differentiation in vitro from MTX‐mediated suppression. In the 4T1 mouse model, the synergistic administration of MTX and AICAR significantly enhanced the proliferation of Tfh cells, along with increases in germinal centre B cells, memory B cells, and plasma cells in both circulation and tumor‐draining lymph nodes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1e85cb098d979a6274f2a7bf178d1a2262a231ae" target='_blank'>
              Methotrexate Exhibits a Dual Role in Regulation of CD4+ T Follicular Helper (Tfh) Cell Differentiation and Activity
              </a>
            </td>
          <td>
            Sayan Chakraborty, Poulomi Khamaru, Altamas Hossain Daptary, Saikat Mukherjee, Soubhik Ghosh, Arindam Bhattacharyya
          </td>
          <td>2025-12-01</td>
          <td>Scandinavian Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="The successes of cancer immunotherapy have inspired research aiming to increase the number of immune-responsive cancers. The first effective immunotherapeutic strategies—immune checkpoint blockade (ICB) and CAR T cells—were designed to overcome limitations in CD8+ T cell recognition and killing of tumor cells. However, most solid tumors still do not respond to these measures and new treatment approaches are needed. Tumors evolve many strategies to avoid immune control. One way to identify immunotherapy strategies is to study what distinguishes immunotherapy-responsive and -unresponsive tumors. Another way is to identify the differences in tumors that emerge after carcinogen exposure in immunocompetent versus immunodeficient hosts. Still another way is to identify changes in gene expression in emerging tumors that enable them to escape immunosurveillance (known as tumor immunoediting). Evolving tumors suppress antigen processing and presentation to avoid triggering tumor-specific T cells but also repress key innate immune genes that transmit danger signals to immune cells. In this perspective, we discuss the roles of innate immunity in anti-tumor responses and consider how innate immunity could be harnessed to make tumors more immune-responsive. This perspective focuses on the roles of innate immunity in cancer immune evasion and on related therapy strategies for enhancing tumor responsiveness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e415284a109fa627adefe7c1c902a0d731c71331" target='_blank'>
              Innate immunity in tumour immunoediting and immunosurveillance
              </a>
            </td>
          <td>
            Zhibin Zhang, Ying Zhang, Judy Lieberman
          </td>
          <td>2025-11-28</td>
          <td>The EMBO Journal</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/954805b24a989a5a800c8a228d8a6b54b8ed322d" target='_blank'>
              Cooperative Interaction Between IL-4 Signaling and FLT3 in Multipotent Progenitors Restore Lymphopoiesis in Inflammation and Aging
              </a>
            </td>
          <td>
            Jingfei Yao, Yuting Wang, Yi Zhang
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Introduction We have recently shown that the DNA hypomethylating agent decitabine (DAC) rescues lung allografts from acute rejection. This involves a mechanism that is dependent on host CD4+ FoxP3+ T cells for maximal benefit. DAC treatment also reduces host T-cell IFN-γ production. We therefore hypothesized that DAC may also reduce host macrophage activation. Our objective was to determine if an effect on macrophages contributes to the beneficial effects of DAC in transplantation. Methods In murine orthotopic lung transplant, hosts were treated on post-op day 3-8 with Clodronate (n = 5), DAC (n = 9), or DMSO (n = 11). Results Partial macrophage depletion (clodronate) improves allograft gross and histologic integrity. DAC-mediated allograft rescue was associated with reduced host macrophage recruitment into allograft airways, reduced activation of recruited macrophages, and regeneration of donor resident alveolar macrophages. Discussion These findings suggest that infiltrating host macrophages promote allograft rejection. They also suggest that donor alveolar health is indicative and/or promoting of allograft tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1c63160c7629dcafa8b9f8bf95ff593b261fc72b" target='_blank'>
              The role of macrophages in the mitigation by decitabine of acute allograft rejection
              </a>
            </td>
          <td>
            W. Daccarett-Bojanini, Manuel Sollmann, Kristine Yarnoff, Nicola M. Heller, J. Dodd-o
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Transplantation</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Liver metastasis is a primary cause of death in colorectal cancer, yet the role of immune cells called neutrophils in this process remains complex. In this study, we identify three distinct neutrophil subtypes: anti-tumor high-density neutrophils, pro-tumor mature low-density neutrophils, and immature low-density neutrophils. Here we show that tumor-derived GM-CSF converts anti-tumor neutrophils into a pro-tumor state via the AKT–NF-κB–NFAT5 signaling axis. These activated neutrophils, when further stimulated by CXCR2 ligands, release web-like structures known as neutrophil extracellular traps which promote cancer spread by enhancing cancer cell growth, suppressing immune responses, and preparing the liver for metastasis. Importantly, we demonstrate that using antibodies depleting neutrophils or drugs inhibiting their pro-tumor activity effectively reduces liver metastasis in mice. Our work defines specific neutrophil subsets as key drivers of cancer progression and highlights their therapeutic potential in preventing metastatic spread. Liver metastasis remains a leading cause of colorectal cancer mortality. This study identifies different neutrophil subtypes involved in metastasis, highlighting therapeutic potential of neutrophil subset targeting to inhibit tumor progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72f584b0e84a9c982ad9ec8521c5821285190b9d" target='_blank'>
              Agonist signaling drives neutrophil subpopulations to promote/inhibit colorectal cancer liver metastasis
              </a>
            </td>
          <td>
            Zhuoqing Xu, Haoran Feng, Wenqing Feng, Yuchen Zhang, J. Huo, Zifeng Xu, Fangqian Chen, Han Gao, Zeping Lv, Wangyi Liu, Abudumaimaitijiang Tuersun, Suyue Yu, Wenchang Li, Y. Zong, Xiaohui Shen, Xi Cheng, Jingkun Zhao, Aiguo Lu
          </td>
          <td>2025-12-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00ed13bb7acb39c5e98a4fa14592f332d5a91492" target='_blank'>
              A narrative review of therapy-induced senescence in cancer: mechanisms, immune interplay, and therapeutic opportunities
              </a>
            </td>
          <td>
            Henry Sutanto, Alfan Ahkami, D. Fetarayani, Pradana Zaky Romadhon
          </td>
          <td>2025-12-01</td>
          <td>Journal of the Egyptian National Cancer Institute</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Monocyte exhaustion is a dysfunctional state characterized by prolonged pathogenic inflammation and immune suppression, commonly observed in chronic infections and sepsis. However, the mechanisms underlying the generation and propagation of exhausted monocytes remain poorly understood. In this study, we investigate the impacts of exhausted monocytes on neighboring naïve monocytes, endothelial cells, and T cell function. Using an in vitro co-culture system, we demonstrate that exhausted monocytes induced by prolonged LPS stimulation propagate the exhaustion phenotype to neighboring naïve monocytes. Meanwhile these exhausted monocytes can promote endothelial apoptosis, upregulate adhesion molecules ICAM-1 and VCAM-1, and enhance monocyte transmigration, contributing to endothelial dysfunction. Pharmacological inhibition of CD38, a key marker of monocyte exhaustion, significantly mitigates these effects, highlighting its critical role in monocyte-driven endothelial alterations. Furthermore, we show that exhausted monocytes suppress T cell proliferation and activation, a process reversed by CD38 inhibition. We also identify mTOR signaling as a key regulator of monocyte exhaustion and its propagation, with mTOR inhibition partially restoring monocyte functionality by downregulating exhaustion markers and STAT1/STAT3/S6K signaling. Collectively, our findings highlight the CD38-mTOR axis as a central driver of monocyte exhaustion and its pathological consequences, offering potential therapeutic targets for reversing immune dysfunction in inflammatory diseases. The inhibition of CD38 can alleviate monocyte exhaustion through suppressing the sustained mTORC1-STAT1 activation. Upon LPS stimulation, TLR4 signaling is activated through the TRAM-TRIF adaptor complex, leading to the phosphorylation of Src. This activation promotes mTORC1 signaling, characterized by the recruitment of Raptor and the activation of S6K. mTORC1 activation subsequently drives STAT1/3 signaling, which further induces CD38 expression and forms a sustained positive feedback loop. Elevated CD38 levels contribute to monocyte exhaustion by depleting NAD⁺, a key metabolic cofactor. NAD⁺ depletion negatively impacts mTORC2 signaling, leading to impaired Akt phosphorylation, resulting in diminished expression of PGC1α/β, CREB and CD86, both of which are associated with exhausted monocyte immune suppression. The CD38 inhibitor 78c disrupts this exhaustion pathway, offering a potential therapeutic strategy to mitigate monocyte dysfunction during monocyte exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/339d48c34c821d9297b2f89fa7a33fe439da7b15" target='_blank'>
              Propagation of monocyte exhaustion memory and underlying mechanisms
              </a>
            </td>
          <td>
            Jing Wang, Blake A. Caldwell, Yajun Wu, Babak Razani, Liwu Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Radiofrequency ablation (RFA) has been one of the most promising local treatments for colorectal liver metastases. However, tumor progression after RFA still severely affects patient prognosis, and its molecular mechanisms remain to be further explored. Here, we show that heat-stressed residual tumor cells following insufficient RFA (iRFA) can lead to lung metastases. Specific Cd177hiPad4hi neutrophils are found as the main pro-tumor phenotype in iRFA conditions, and neutrophil extracellular traps are produced to accelerate lung metastasis via the MEK/ERK signaling pathway. Mechanistically, PPARγ-triglyceride (TG) synthesis in residual tumor cells activates the P38 signaling pathway and CXCL5 secretion, contributing to Cd177hiPad4hi neutrophil infiltration. Furthermore, the specific CD36hi-EM (epithelial-mesenchymal) - circulating tumor cells (CTCs) with activated lipid metabolism characteristics are found to assist in early identification of residual tumor cells. This study not only provides specific targets for improving the efficacy of iRFA but also realizes its early identification and intervention. A relatively high proportion of patients relapse following radiofrequency ablation. Here, authors show that neutrophils with high expression of CD177 and PAD4 promote progression of residual tumors after incomplete radiofrequency ablation via PPARγ-related lipid metabolism adaptation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce396293aed26c6525d0be11decc31973022a1b8" target='_blank'>
              Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177hiPAD4hi neutrophils
              </a>
            </td>
          <td>
            N. Huang, Yisheng Fang, Siting Zheng, Jianhua Wu, Genjie Huang, Xinyue Deng, Yijin Guan, B. Liang, Dongqiang Zeng, Beibei Xu, Yuanwen Huang, Xiaoxiang Rong, Chunlin Wang, J. Bin, Yulin Liao, Zuqiang Wu, Min Shi, Wangjun Liao
          </td>
          <td>2025-12-02</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment. This review provides a comprehensive analysis of current ACT modalities, including tumor-infiltrating lymphocytes, T cell receptor-engineered, and chimeric antigen receptor-T cell therapies, as well as emerging approaches such as bispecific T cell engager (BiTE)-secreting T cells, dual-targeting platforms, and synthetic antigen receptors. We examine their application in OC and contextualize relevant findings using insights from other solid tumors. Key barriers, including limited T cell persistence, antigen escape, and T cell exhaustion, are explored alongside strategies to enhance efficacy through cytokine armoring, checkpoint modulation, metabolic reprogramming, and gene editing. We further highlight innovations in safety engineering, including logic-gated and self-regulating synthetic circuits, to mitigate toxicity and improve precision. Additional attention is given to the evolving role of allogeneic products and in vivo engineering as scalable solutions. Finally, we emphasize the critical value of integrating high-dimensional tools such as spatial transcriptomics, single-cell profiling, and machine learning to refine ACT design, identify biomarkers of response, and support patient selection and stratification. Collectively, these advances offer a roadmap for overcoming the unique immunologic barriers to ACT in OC and accelerating the development of more potent, durable, and personalized T cell-based strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/442d1e2fb3d5094a74ddc54bd9ea24495e17f136" target='_blank'>
              Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
              </a>
            </td>
          <td>
            Gabriel Nascimento De, Souza Santos, C. DeJohn, Suzanne M. Hess, E. Zsiros, A. McGray, R. Mcgray
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background: Natural killer (NK) cells are key effectors of innate immunity with broad-spectrum anti-tumor activity. However, peripheral blood-derived NK (PBNK) cells are typically quiescent, which limits their therapeutic utility. This study aimed to develop an efficient strategy for the in vitro activation and expansion of PBNK cells and then evaluate their potential anti-tumor efficacy in vitro and vivo. Methods: NK cells were isolated from healthy blood donors’ peripheral blood and stimulated with anti-CD16 and anti-CD137 antibodies in the presence of interleukin-2 (IL-2) and interleukin-15 (IL-15) under serum-free conditions, generating super NK (SNK) cells. The expression levels of activating and inhibitory receptors on the expanded SNK cells were assessed by flow cytometry. Cytotoxicity against tumor cells was assessed at various effector-to-target (E:T) ratios in vitro. In vivo, anti-tumor efficacy was evaluated in K562-engrafted NSG mice. RNA sequencing was performed to identify differentially expressed genes (DEGs) between SNK and PBNK cells. Results: Stimulation with anti-CD16 and anti-CD137 antibodies resulted in significant expansion of donor-derived NK cells, with over 861.9 ± 48.84-fold expansion (n = 5) within 15 days of culture. SNK cells exhibited significantly elevated expression of activating receptors, including NKG2D. Functionally, SNK cells demonstrated superior cytotoxicity compared with PBNK cells across all tested E:T ratios in vitro and higher expressions of the effector molecules interferon-gamma (IFN-γ) and granzyme B (Gzm B). In vivo, adoptive SNK cell transfer resulted in significant tumor suppression and prolonged survival in a dose-dependent manner. Transcriptomic analysis revealed significant enrichment of DEGs associated with cytokine and chemokine signaling, immune activation, and cytotoxic effector function compared with the PBNK cells. Conclusions: Anti-CD16/CD137 antibody stimulation, in combination with IL-2 and IL-15, facilitates robust activation and rapid expansion of functionally enhanced NK cells from peripheral blood. The resulting SNK cells demonstrated enhanced anti-tumor efficacy both in vitro and in vivo and may be used as allogeneic NK cell-based immunotherapy in future cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f362cbccfafea48bbd34fb80c65d69a4cc57b5ee" target='_blank'>
              Antibody-Mediated In Vitro Activation and Expansion of Blood Donor-Derived Natural Killer Cells with Transient Anti-Tumor Efficacy
              </a>
            </td>
          <td>
            Shengxue Luo, Feifeng Zeng, Qitao Deng, Yalin Luo, Dawei Chen, Hui Ren, W. Xia, X. Ye, Shuxin Huang, Tingting Li, Yongshui Fu, Xia Rong, Huaqin Liang
          </td>
          <td>2025-11-29</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="B cell follicles in secondary lymphoid tissues are major sites of HIV expression in untreated people living with HIV (PLWH), but whether lymphoid B cells promote HIV expression in CD4+ T cells is unknown. Using a tonsil model and flow cytometry, germinal center B cells induced HIV expression in follicular helper CD4+ T cells (TFH) in a concentration-, contact-, and major histocompatibility complex class II (MHC-II)-dependent manner. Non-naïve tonsil B cells also induced HIV expression in nonTFH CD4+ T cells that was MHC-II restricted. In situ hybridization and immunofluorescent staining of lymph node sections from six PLWH on long-term antiretroviral therapy (ART) and six ART-naïve PLWH demonstrated most HIV RNA-expressing (vRNA+) cells were adjacent to at least one B cell. In both groups, vRNA+ cells per mm2 were elevated in B cell follicles, particularly after adjusting for CD3+CD4+ frequencies. TFH (PD-1+BCL6+) were a minority of vRNA+ cells in all PLWH. In contrast to ART-naïve PLWH, most vRNA+ cells in PLWH on ART resided outside follicles, and were preferentially adjacent to extrafollicular B cells. Thus, B cells upregulate HIV expression largely through cognate interactions in vitro and are linked to HIV expression in secondary lymphoid tissues.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3794a47de574dfccbbd2a0ad1e02e04d0a55b25c" target='_blank'>
              Lymphoid B cells upregulate HIV-1 ex vivo and are linked to its expression in vivo
              </a>
            </td>
          <td>
            M. Ollerton, J. Folkvord, Veronica Bush, David A Parry, Amie L Meditz, Martin D McCarter, Fred Yost, Cecilia M Shikuma, E. Connick
          </td>
          <td>2025-12-01</td>
          <td>PLOS Pathogens</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c872e20ed96ce9671cd91e8697d416593c662410" target='_blank'>
              Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis.
              </a>
            </td>
          <td>
            Barathan Muttiah, A. Wahab
          </td>
          <td>2025-12-24</td>
          <td>Clinical rheumatology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Circular RNAs (circRNAs) have recently emerged as critical regulators of tumor–immune interactions. Owing to their covalently closed structure, remarkable stability, and tissue-specific expression, circRNAs not only serve as molecular sponges and protein regulators but also play multifaceted roles in shaping the tumor immune microenvironment. Accumulating evidence indicates that circRNAs drive immune suppression by stabilizing PD-L1 through post-translational modifications and RNA-binding protein interactions, transmitting suppressive signals via exosomes to T cells and myeloid-derived suppressor cells, reprogramming glucose and lipid metabolism to deprive effector lymphocytes, and reinforcing cancer stemness and therapy resistance. In striking contrast, a subset of circRNAs has been shown to sensitize tumors to immunotherapy by activating innate immune pathways such as RIG-I/MAVS and STING, inducing immunogenic cell death, and overcoming resistance to endocrine therapy or ferroptosis inducers, thereby enhancing the efficacy of immune checkpoint blockade. Beyond their mechanistic functions, circRNAs also hold promise as stable and accessible biomarkers for prognosis, patient stratification, and therapeutic monitoring, particularly when enriched in circulating exosomes. Advances in antisense oligonucleotides, RNA interference, and nanomedicine provide new opportunities to therapeutically target oncogenic circRNAs or deliver engineered pro-immunogenic circRNAs. While significant challenges remain in detection accuracy, functional annotation, delivery specificity, and clinical validation, circRNAs represent a new frontier in immuno-oncology. Harnessing their dual roles may unlock innovative biomarker platforms and next-generation RNA-based therapeutics, ultimately improving the efficacy of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4d997c9720e9890b039f09060198c82b2dba63d" target='_blank'>
              From immune suppression to immunotherapy sensitization: the dual roles of circRNAs in cancer progression
              </a>
            </td>
          <td>
            Quan Dai, Xiaoli Yuan, Hang Dong, Haiyi Xue
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Many inflammatory stimuli can induce progenitor cells in the bone marrow to produce increased numbers of myeloid cells as part of the process of emergency myelopoiesis. These events are associated with trained immunity and have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many cytokines support emergency myelopoiesis, less is known about the mechanisms that temper these events. When mice that lack the cytokine IL-27 were infected with Toxoplasma gondii, there was enhanced generation of monocyte progenitors and increased numbers of inflammatory monocytes. In the bone marrow of infected mice, there was increased production of IL-27 that localized with HSPCs, and a survey of cytokine receptor expression highlighted that HSPCs were uniquely poised to respond to IL-27. Furthermore, the use of in vitro differentiation assays and mixed bone marrow chimeras revealed that HSPCs from IL-27-deficient mice are predisposed toward the monocyte lineage. Additional studies highlighted that after infection, loss of the IL-27R resulted in reduced HSPC fitness that manifested as reduced proliferative responses and a decreased ability to reconstitute the hematopoietic system. Thus, the ability of IL-27 to act on HSPC provides a regulatory brake on differentiation to limit monocyte induction and preserve HSPC stemness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4296e880a374b1ca1dccbcbdeb368a411cccee06" target='_blank'>
              IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion
              </a>
            </td>
          <td>
            D. Aldridge, Zachary Lanzar, Anthony T Phan, David A. Christian, Ryan D. Pardy, Booki Min, Ross M. Kedl, Christopher A. Hunter
          </td>
          <td>2025-12-15</td>
          <td>eLife</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6fa98043059e18d9fd50446cb2c494c87e5e2054" target='_blank'>
              Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.
              </a>
            </td>
          <td>
            Catarina M Stein, Raphael Hablesreiter, F. Christen, P. Löwe, Coral Fustero-Torre, Klara Kopp, B. Locher, Lena Nitsch, Robert Altwasser, Johanna Franziska Kerschbaum, L. Bullinger, Leif S. Ludwig, Paulina M Strzelecka, Frederik Damm
          </td>
          <td>2025-12-19</td>
          <td>Leukemia</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor‐associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM‐mediated immune responses. Furthermore, this article examines current TAM‐targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR‐Ms), as well as macrophage‐based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM‐targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7215a076e2ef0687c2a7e70ce9deca69722be237" target='_blank'>
              The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
              </a>
            </td>
          <td>
            Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng
          </td>
          <td>2025-12-19</td>
          <td>MedComm</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background Immunotherapies have revolutionized cancer care in recent decades, but approved therapies often fail and currently only target specific steps in the generation of anti-cancer immune responses. Notably, the majority of approved immunotherapies do not target antigen processing and presentation, which are key steps in the development of immune responses and harbor potential as targets to improve immunotherapy. Here, we hypothesize that tumor-mediated alterations in cytokine concentrations alter antigen presentation, which can be normalized by locoregional cytokine delivery or targeted immunological adjuvant delivery. Methods We used mouse models of breast cancer, with analysis by flow cytometry, immunofluorescence, confocal imaging, and single-cell RNA sequencing to address the impacts of tumors on locoregional antigen presentation, along with mechanisms to remedy these impacts. Results Here, we demonstrate that breast tumors induce locoregional impairments in dendritic cell antigen presentation that limits anti-cancer antigen-specific T cell responses. Antigen processing was not impaired in dendritic cells within the tumor-draining lymph node. A reduction of the cytokine IL-1β in tumor-draining lymph nodes was responsible for impairments in antigen presentation by dendritic cells. As such, we tested the ability of dendritic cells in lymph nodes at various distances from the primary tumor to be activated utilizing an antigen-agnostic immunological adjuvant delivery strategy. We observed improved antitumor T cell responses when immunological adjuvant was delivered to cancer antigen-positive lymph nodes distant from the tumor, suggesting that these lymph nodes can be targeted to improve anti-cancer immune responses. When combined with immune checkpoint blockade, delivery of immunological adjuvant to distant lymph nodes led to long-term survival and protection from recurrence. Antigen presentation by dendritic cells and T cell responses could also be recovered by exogenous delivery of IL-1β via intratumoral injection, with improved survival when combined with immune checkpoint blockade. Conclusions This study demonstrates that tumor-induced impairments in antigen presentation in tumor-draining lymph nodes can be overcome by the appropriate introduction of immunological adjuvant to tumor-distant lymph nodes or by restoring IL-1β to the tumor-draining lymph node. These strategies can induce high-quality, durable immune responses and have clinical implications for expanding the efficacy of immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/107555766613a4c07364f370f105e3c7188a7a55" target='_blank'>
              Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy
              </a>
            </td>
          <td>
            Meghan J. O’Melia, Lutz Menzel, Pin-Ji Lei, Hengbo Zhou, Xingjian Zhang, Neian Contreras-Alvarado, Johanna J. Rajotte, Lingshan Liu, M. Nikmaneshi, James W. Baish, Jessalyn M. Ubellacker, Genevieve M. Boland, Sonia Cohen, T. Padera, Lance L. Munn
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="Infected skin tumors are challenging to treat and frequently result in tumor progression, relapses, and post-surgical complications. Moreover, bacterial infections significantly contribute to tumor therapy resistance as they release tumor microenvironment (TME)-modulating molecules. Immune or cancer cells can recognize these pathogen-associated molecular patterns (PAMPs), initiating signaling and pro- or antitumoral response. Hence, understanding PAMPs in tumor therapy may improve the understanding and efficacy of cancer treatment. Cold gas plasma treatment has shown promise in treating infected, ulcerative head and neck cancers. Here, we elucidated gas plasma-induced bacterial PAMP release and their combination with direct gas plasma exposure in skin cancer cells in vitro. Evaluating metabolic activity and viability of tumor cells revealed a significantly stronger growth-inhibitory effect of the combinatory treatment, suggesting a relevant contribution of bacterial molecules to tumor toxicity. A synergistic effect was found regarding the oxidative damage marker γH2AX that was elevated in response to the combination treatment. Cancer cells subjected to gas plasma and provoked PAMPs exhibited an altered phenotype that displayed a strikingly different chemokine and cytokine profile. Mass spectrometry analysis showed improved bacterial cell lysis by gas plasma treatment, increasing intracellular protein release of all three tested bacterial strains.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/293a30a89e7025c1bd7e6b159297e4ac34cc91f2" target='_blank'>
              Gas plasma-induced bacterial PAMP release promotes skin cancer cell death
              </a>
            </td>
          <td>
            Julia Berner, Malin Sieben, Eric Freund, P. Schulan, L. Miebach, S. Bekeschus
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) harbors a dynamic tumor microenvironment (TME) in which macrophages are highly abundant and plastic. Under physiological conditions, macrophages switch between inflammatory and resolution/tissue-repair programs to maintain homeostasis; however, during hepatocarcinogenesis these programs are reprogrammed into tumor-associated macrophage (TAM) states that foster immune suppression, angiogenesis, and tumor progression. Purpose: To summarize macrophage heterogeneity and polarization mechanisms in HCC, and to highlight omics-informed therapeutic opportunities for targeting TAMs and improving precision immunotherapy. Research Design: This review summarizes physiological macrophage polarization and the mechanistic basis of macrophage reprogramming in the hepatocellular carcinoma immune microenvironment, integrating evidence from recent advances in single-cell sequencing, multi-omics, and spatial transcriptomics, with a focus on macrophage subset diversity, key regulatory pathways governing polarization and function, and emerging macrophage-targeted interventions and biomarkers. Results: Recent single-cell and spatial multi-omics studies reveal substantial TAM heterogeneity and plasticity in HCC. Macrophage-targeted strategies—including TAM depletion, phenotypic reprogramming, and exosome-mediated drug delivery—show encouraging preclinical efficacy. Macrophage-associated prognostic models and biomarkers may support individualized immunotherapeutic approaches. Conclusions: Macrophage polarization in HCC represents a dynamic continuum that is essential for homeostasis but is co-opted by tumors to drive immunosuppression and tissue remodeling. Advances in single-cell and spatial multi-omics are redefining TAM subsets and actionable pathways, enabling more rational macrophage-targeted therapies. However, challenges remain in standardizing TAM definitions, identifying robust predictive biomarkers, minimizing off-target effects, and optimizing combinations with immunotherapy. Integrating longitudinal multi-omics with AI-based modeling may help predict macrophage state transitions, guide patient-specific regimens, and advance precision medicine in HCC. Plain language summary Hepatocellular carcinoma is a highly aggressive cancer. Studies have found that immune cells within tumors—particularly macrophages—play a crucial role in cancer development and therapeutic response. Macrophages have two main “personalities”: the M1 type, which can kill cancer cells, and the M2 type, which supports cancer growth. They shift between these states in response to signals from the tumor microenvironment. Both liver-resident Kupffer cells and infiltrating macrophages are involved in this process. Various molecules, such as cytokines, enzymes, and exosomes, influence their polarization. This polarized state of macrophages, in turn, affects key tumor processes such as stemness, proliferation, metastasis, and angiogenesis. In recent years, scientists have been exploring drugs that specifically target macrophage polarization to suppress liver cancer, offering new directions for future therapy. Graphical Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b9c3d3369daa7c8bd747ff210bf91cca4945570" target='_blank'>
              Macrophage Polarization in the Tumor Microenvironment of Hepatocellular Carcinoma: From Mechanistic Insights to Translational Therapies
              </a>
            </td>
          <td>
            Xiaoqing Fu, Mingquan Pang, Zhixin Wang, Haijiu Wang
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Gastric cancer (GC) remains a major global health burden with persistently high mortality despite therapeutic advances. Accumulating evidence highlights the pivotal role of tumor-associated macrophages (TAMs) in orchestrating gastric tumor progression through immune suppression, angiogenesis, extracellular matrix remodeling, and metastasis. Within the tumor microenvironment (TME), TAMs exhibit functional plasticity, often polarizing toward an M2-like phenotype that promotes immunosuppression and tumorigenicity. These cells actively participate in immune evasion via immune checkpoint expression and cytokine-mediated T cell inhibition, while also facilitating lymphovascular invasion and chemoresistance through exosome-mediated crosstalk. The density and phenotype of TAMs have been associated with prognosis and therapeutic response in GC. Recent studies have proposed TAMs as promising targets for therapy, with strategies focusing on depleting M2 subsets, reprogramming toward M1 phenotypes, and blocking TAM-driven oncogenic signaling. Targeted interventions, including MENK, paclitaxel, and NF-κB inhibitors, have shown potential in preclinical models. This review comprehensively discusses the mechanistic roles of TAMs in GC and evaluates emerging TAM-targeted therapeutic strategies that may enhance the efficacy of immunotherapy and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/913bc3f4af4f9d7fed06d178714e6cfa582ea213" target='_blank'>
              Tumor associated macrophages in gastric cancer dual roles in immune evasion and clinical implications for targeted therapy
              </a>
            </td>
          <td>
            Chang Wang, Xu Fan, Xiaomeng Sun, Yi Xu, Yanna Sun, Jidong Liu
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is an aggressive malignancy that is often refractory to chemotherapy and immune checkpoint inhibitors. This therapeutic resistance is driven in part by the persistence of cancer stem-like cells (CSCs) and the development of an immune-cold tumor microenvironment. However, the upstream regulators that coordinate these malignant features remain poorly defined. In this study, we identified dysadherin as a novel upstream activator of YAP that promotes both CSC plasticity and immune evasion through the FAK/YAP/TEAD2 signaling axis. Using single-cell transcriptomic analysis, in vitro assays, and multiple in vivo models including a humanized immune mouse system, we showed that dysadherin enhances the expression of pluripotency genes, such as OCT4 and upregulates PD-L1. These changes support stem-like tumor behavior and contribute to T-cell exclusion, fostering an immunosuppressive niche. Notably, genetic knockdown or peptide-based pharmacologic inhibition of dysadherin effectively restored antitumor immune activation, suppressed metastasis and improved therapeutic responsiveness. Our findings reveal a mechanistic link between dysadherin-mediated cell adhesion signaling and the transcriptional regulation of both stemness and immune escape. Collectively, these findings establish the dysadherin/YAP axis as a key driver of HCC progression and resistance, and highlight it as a compelling therapeutic target that could overcome treatment failure in advanced liver cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29884335d480102826ec8b793e157ba0b7881a1e" target='_blank'>
              Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer
              </a>
            </td>
          <td>
            T. Jang, So-El Jeon, H. Yun, Choong-Jae Lee, , Sang Hoon Lee, Dajun Lee, Seungwon Lee, Jungmin Choi, Hyung-Sik Kim, Jeong-Seok Nam
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Background: Radiotherapy (RT) remodels the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are key mediators of TME, yet how RT reprograms TAMs toward a programmed death ligand- 1(PD-L1)⁺ immunosuppressive phenotype remains unclear. Materials and Methods: Esophageal squamous cell carcinoma (ESCC) subcutaneous xenografts in immunodeficient mice received localized RT or sham treatment. Tumor-infiltrating PD-L1⁺ TAMs were quantified via multiplex immunofluorescence and flow cytometry. Extracellular vesicles (EVs) derived from irradiated ESCC cells (IR-EVs) were isolated and characterized by nanoparticle tracking analysis and transmission electron microscopy. Functional assays included co-culture of IR-EVs-educated macrophages with autologous CD8⁺ T cells. RNA sequencing identified DYNLL1-AS1 as the most upregulated lncRNA in IR-EVs. Mechanistic studies employed RNA pull-down, mass spectrometry, RNA immunoprecipitation, and dual-luciferase reporter assays. Clinical validation utilized ESCC specimens for RNA in situ hybridization. Prognostic significance was assessed via Kaplan-Meier and Cox regression analyses. Results: RT triggered ESCC cells to secrete DYNLL1-AS1-enriched EVs, which reprogrammed macrophages into PD-L1⁺ immunosuppressive TAMs. IR-EVs-educated macrophages suppressed CD8⁺ T cell proliferation and IFN-γ/ Granzyme B secretion. Mechanistically, DYNLL1-AS1 bound SEC22B, enabling its interaction with FOXP1 to activate PD-L1 transcription via promoter binding. In vivo, EVs carrying DYNLL1-AS1 counteract anti-PD-L1 therapy by suppressing CD8+ T cell function and promoting tumor growth. In ESCC patients, high DYNLL1-AS1 expression correlated with PD-L1⁺ TAM density, poor immunotherapy response, and reduced survival. Multivariate analysis confirmed DYNLL1-AS1 as an independent prognostic factor. Conclusions: Radiation-induced DYNLL1-AS1 in ESCC EVs drives PD-L1⁺ TAMs immunosuppression via SEC22B/ FOXP1 signaling. Combining DYNLL1-AS1 inhibition with PD-L1 blockade may reverse RT-induced immunosuppression, offering a transformative strategy for ESCC radio-immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62c9c29a3e6d1b11c8904cf92b1d7f9e8f201bd1" target='_blank'>
              Extracellular vesicles derived from irradiated tumor cells foster immunosuppressive macrophages formation to promote esophageal squamous cell carcinoma immune evasion
              </a>
            </td>
          <td>
            Shanshan Jiang, Y. Pang, Yue Zhou, J. Ni, L. Chu, X. Chu, Jianghong Zhang, Yan Pan, Yida Li, R. Ye, Hongru Chen, Silai Yu, T. Guo, Chunlin Shao, Xi Yang, Zhengfei Zhu
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) is a multifunctional scavenger receptor expressed on tumor-associated macrophages (TAMs). In a recent study published in the Journal for ImmunoTherapy of Cancer, Yu et al reported that CLEVER-1+ TAMs accumulate in advanced gastric cancer (GC), associate with poor prognosis, and contribute to resistance to chemoimmunotherapy. CLEVER-1 blockade using bexmarilimab reprogrammed TAMs toward a pro-inflammatory phenotype by suppressing peroxisome proliferator-activated receptor gamma (PPARγ)-driven lipid metabolism and enhancing antigen presentation and inflammatory cytokine secretion. CLEVER-1 blockade also synergized with anti-programmed cell death protein 1 (PD-1) therapy in ex vivo GC models, particularly in tumors enriched with CLEVER-1+ TAM. These findings identify CLEVER-1+ TAMs as both biomarker and functional mediator of anti-PD-1 therapy resistance, providing a rationale for combining bexmarilimab with immune checkpoint blockade in GC. In this commentary, we discuss the mechanistic significance, translational potential, and clinical prospects of CLEVER-1 blockade to overcome immunotherapy resistance in GC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f7f73a277d949dbe8513657f917fab43d315e09" target='_blank'>
              CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer
              </a>
            </td>
          <td>
            Xiaonan Xiang, Fei Wang, Yanbin Shen, Sheng Dai
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>2</td>
        </tr>

        <tr id="Background Lipocalin-2 (Lcn2) is a sensitive early marker for acute kidney injury, delayed graft function and acute rejection of kidney transplants. We previously showed the renoprotective effect of recombinant Lcn2:Siderophore: Fe3+ (rLcn2) in a mouse kidney transplantation (KTx) model. Here, we investigate the molecular and cellular mechanisms underlying these effects. Methods Male C57BL/6 mice (10–12 weeks) received BALB/c kidney allografts, with or without rLcn2 treatment (250 µg, s.c.). To examine the immunomodulatory function of rLcn2, immune cells from graft, spleen, lymph nodes and blood were analyzed by flow cytometry at post-operative days (pod) 3 and 7. Syngeneic C57BL/6 grafts were used to investigate the impact of rLcn2 on alloimmune-independent tissue injury and inflammation through multiplex signaling assays, functional readouts, cytokine profiling and histopathological analyses. Results rLcn2 treatment markedly reduced frequencies of distinct T cell subsets, including effector memory T cells and their cytotoxic (Tc) and helper (Th) subsets across grafts, lymphoid tissues and blood by pod-7 following allogeneic KTx. In graft infiltrating CD8+ T cells, rLcn2 decreased degranulation capacity and diminished expression of interferon-γ and perforin. rLcn2 also lowered the proportion of NKG2D+ CD8+ T cells, an activating Tc subset, in spleen and blood. In contrast, its impact on innate immune cells was modest and selective, influencing only neutrophils, macrophages in lymph nodes and intermediate mature NK cells in spleen and blood. No significant effect of rLcn2 treatment was observed on alloimmune-independent tissue injury or inflammation in syngeneic kidney grafts. Conclusion rLcn2 selectively modulates T-cell activity after KTx without affecting alloimmune-independent injury pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed180d49cdbfb39ec89a170f0fe6750f292b2bde" target='_blank'>
              Lipocalin-2 modulates recipients alloimmune responses to the murine kidney transplants
              </a>
            </td>
          <td>
            A. M. Pfefferkorn, R. Fritsche-Guenther, Angelika Kusch, Hubert G. Schwelberger, Shiqian Liu, R. Klopfleisch, Yuhuan Li, R. Catar, Shaokun Liu, Felix Aigner, Johann Pratschke, I. M. Sauer, Muhammad-Imtiaz Ashraf
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Immunity during cancer progression involves critical responses that may be harnessed to augment anti-tumor cytotoxicity. A potent arm of immunity in cancer involves cytotoxic T cells (a key CD8+ T-lymphocyte subset): Anti-tumor responses by such cells optimally involve sensitization and acquired responses to tumor antigens by antigen presenting cells. Many tumor microenvironment (TME) biophysical and functional limitations in carcinomas limit robust achievement of this ideal cellular-immunologic pathway. This is especially challenging in lung carcinoma, on which we focus mechanistically and with an eye to therapeutic translation. Localization of tumor-sensitized and activated CD8+ T cells to tumor “nests” with efficient tumor cytolysis involves many challenging steps. Amplifying and sustaining such responses is also a unique challenge. The variety of homeostatic and immunosuppressive obstacles often becomes overwhelming. Measuring the state of this response during lung cancer progression is also challenging, making it difficult to mount (and/or predict) T-cytotoxic responses in the heterogeneous and dynamic carcinoma antigen landscape. We investigate these challenges herein, while examining strategies to boost T-cytotoxic immunity in lung cancer through novel and emerging immunotherapeutic approaches. Beyond current immune checkpoint blockade approaches that are relatively non-specific with respect to antigen recognition by the T-cell receptor, we highlight ongoing and translational vaccines, cell-therapies, antigen-presenting cell boosting approaches, T-cell therapies, and biophysical considerations with an eye to overcome key barriers of this powerful arm of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d405cc42ae9819222b3a3a0b50f4e0cc2451158" target='_blank'>
              The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma
              </a>
            </td>
          <td>
            Aditya Dash, Afsheen Banisadr, Donivian Al Dikka, Scott C. Johns, Mark M. Fuster
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Osteosarcoma (OS), the most common primary malignant bone tumor in children and adolescents, remains a major therapeutic challenge due to its high metastatic potential and limited response to conventional treatments, including immune checkpoint inhibitors (ICIs). Oncolytic viruses (OVs) have emerged as a promising strategy with dual antitumor functions: direct oncolysis and the induction of immunogenic cell death (ICD). By releasing damage-associated molecular patterns (DAMPs) and activating the cGAS–STING pathway, OVs can remodel the immunologically “cold” tumor microenvironment (TME) into an inflamed and immune-responsive phenotype, thereby enhancing CD8+ T-cell infiltration and improving antitumor immunity. Encouraging preclinical evidence has been reported: VSV-IFNβ-NIS achieved a long-term survival rate of approximately 35% in canine OS models, and synergistic combination regimens have demonstrated tumor inhibition rates exceeding 70%. Despite these advances, OV-based therapies still face critical translational challenges, including the immunosuppressive TME, intratumoral delivery barriers, and safety concerns. This review systematically summarizes the molecular mechanisms underlying OV-mediated antitumor immunity, evaluates current clinical evidence, and highlights future opportunities, such as combination immunotherapy, mesenchymal stem cell (MSC)-based delivery platforms, and AI-driven precision medicine approaches. Our goal is to provide a comprehensive theoretical framework to support the clinical translation and personalized application of OV therapy in osteosarcoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7b8f3ac180d1ad6ac4957a24ba6300ab33bd0b5" target='_blank'>
              Oncolytic virus therapy for osteosarcoma: mechanisms, opportunities, and challenges
              </a>
            </td>
          <td>
            Jia-wen Wang, Xiaolei Ge, Jia-Hui Liu, Xiaoyu Zhang
          </td>
          <td>2025-12-10</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="The mechanisms of the chronic inflammatory response in smoking-induced chronic obstructive pulmonary disease (COPD) remain unclear, with limited understanding of T cell responses to smoke exposure in lung tissue and circulation. We characterized the alterations in T cells associated with smoke exposure using single-cell RNA sequencing, TCR sequencing, and flow cytometry-based validation. Our experiments show significant recruitment of T cells within the airways, exhibiting a multifaceted immune profile, augmented TCR clonal diversity, and a prolonged CDR3 length. Notably, smoke-induced γδ T cells, particularly clonally expanded γ6δ4 T cells with high Il17a expression, accumulate in smoke-induced airway inflammation. Despite arising in inflammation, these cells function in a protective manner: γδT17 deficiency worsens smoke-induced lung injury, whereas adoptive transfer of γδT17 cells restores tissue protection in smoke-exposed lungs over time. Here, we show γδT17 cells as a potential target for addressing smoke-induced immune dysfunctions, providing alternative avenues for early prevention and treatment of COPD. T cells have been shown to have a function in chronic lung inflammation in COPD. Here the authors characterise the single cell transcriptional profile of T cells after smoke inhalation in mouse models showing changes in TCR repertoire and Il17a expression in γδ T cells, suggesting smoke-associated γδ T cells are involved in COPD inflammation and implicating γδT17 cells as a possible target for early prevention and treatment of COPD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c72bfc4278bed289c335fdcb150aff219f94dd9e" target='_blank'>
              Comprehensive profiling of smoke-induced T cells in mice implicates clonal γδT17 cells as a hallmark of COPD
              </a>
            </td>
          <td>
            Xinyue Mei, Junxiang Wang, Yuan Wang, Li Cheng, Xiaoyu Wang, Xinyuan Liu, Ge Bai, Jiaying Zhong, Mingzhu Huang, Suyin Huang, Peiyu Huang, Jieda Cui, Yu Liu, Qianmei Wen, Ruiting Sun, Erkang Yi, Fan Wu, Xiaohui Wu, Ziqing Yuan, Q. Wan, Xiaoyang Zheng, Yujie Zuo, Jingwei Zhang, Leqing Zhu, Yumin Zhou, Zhongfang Wang, Pixin Ran
          </td>
          <td>2025-12-08</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Macrophages play a key role in immunity against solid tumors. However, their development and clinical applications are limited by their difficult-to-transfect nature, low proliferative capacity, and easily changing polarization states. The combination of chimeric antigen receptor (CAR) technology with macrophages to form chimeric antigen receptor macrophages (CAR-Ms) is an emerging strategy for adoptive cell therapy. In our previous study, we confirmed that anti-CD47 CAR-Ms have potential for ovarian cancer treatment. Here, we demonstrated that the introduction of IL-21 significantly increases the tumor-suppressive effect of anti-CD47 CAR-Ms against ovarian cancer. Specifically, IL-21-modified CAR-Ms with second-generation CARs targeting CD47 showed potent tumor cell-killing activity, both in vitro and in vivo, through direct and indirect pathways (direct phagocytosis and activation of cytotoxic T lymphocytes). In addition, an IL-21 modification significantly enhanced the tumor microenvironmental regulation of immunosuppression mediated by anti-CD47 CAR-Ms in vivo, thereby improving their therapeutic efficacy in a mouse model of ovarian cancer, without any obvious adverse effects. Taken together, these results suggest that anti-CD47 CAR-Ms combined with IL-21 is a promising treatment strategy for ovarian cancer. The anti-tumor effects of a co-expression strategy of chimeric antigen receptor macrophages with IL-21 was validated in both in vitro and in vivo models of ovarian cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1287e633e565f0f44deb23e07481a37084e0b41a" target='_blank'>
              IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer
              </a>
            </td>
          <td>
            Yizhao Chen, Xiangling Zhu, Yu Chen, Zhaoyi Yang, Zhaolei Shen, Mengchen Chen, Chong Liu, Yuanyuan Zhou, Huihui Wang, Mengjuan Zhu, Jiaqi Qiu, Jinhua Huang, Xintong Han, Wei Wei, Ruilin Li, Wenming Hong, Jiajie Tu
          </td>
          <td>2025-12-23</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) abundantly infiltrate tumors and possess potent antitumor capabilities. “Don‘t eat me” signals like CD47 allow tumors to evade macrophages and proliferate unchecked. CD47 is upregulated in many tumors and interacts with the SIRPα expressed on macrophages to restrict effector function. Similarly, CD24 interacts with the Siglec-10 on TAMs to inhibit engulfment. Despite their potential, there is still a lack of effective therapeutics targeting macrophages. Recent clinical trials targeting CD47 have demonstrated limited efficacy and significant side effects in solid tumors, primarily due to the expression of CD47 on healthy cells such as red blood cells (RBCs). We therefore developed novel anti-CD47 variable domain of heavy chain of heavy-chain antibodies (vHHs) with strong ligand-blocking activity while demonstrating minimal binding to RBCs and incorporated these vHHs to generate an anti-CD47/CD24 bispecific antibody that preserves Fc-effector function and achieves improved tumor targeting while maintaining the blockade of antiphagocytic signals elicited by both CD47 and CD24. Methods Yeast display was employed to generate vHHs targeting CD47 and fully human monoclonal antibodies against CD24, respectively. The antigen binding epitopes of the vHHs to CD47 were predicted using AlphaFold3. Bispecific antibodies were designed, constructed, and characterized in vitro. Antitumor efficacy was evaluated in a human immune cell reconstitution mouse model, while safety was evaluated using a humanized syngeneic mouse model. Furthermore, the underlying mechanisms and alterations in tumor microenvironment were explored ex vivo. Results VHHs targeting CD47 and a fully human antibody against CD24 were identified, all exhibiting potent ligand-blocking activity. The bispecific antibody BiAb-103C, engineered on a human IgG1 scaffold, had strong binding to CD47+CD24+ tumor cells and could effectively inhibit the CD47-SIRPα interaction. Fc-effector activity was observed towards CD24 (but not CD47) single-positive cells to promote phagocytosis and antibody-dependent cellular cytotoxicity of CD47+CD24+ tumor cells. In mice, antibody candidates demonstrated notable antitumor activity alongside favorable safety observations. Conclusions Our study presents the discovery of an anti-CD47/CD24 bispecific antibody that offers a promising therapeutic strategy to address the challenges associated with both the efficacy and safety of CD47-targeting agents, offers insight into macrophage-driven cancer immunotherapy, and could potentially provide a therapeutic option for patients non-responsive to immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d89595c1a6134fa285ecdbf84ee39da5d2c72a21" target='_blank'>
              Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance
              </a>
            </td>
          <td>
            Lidi Nan, Liandi Chen, Weifeng Huang, Shaogang Peng, Chao Wang, Huayuan Liao, Yifei Wang, Ziyue Cui, Yanqing Lv, Xiaomu Wang, Yi-Long Luo, A. Tsun, Xiaoniu Miao, Juan Zhang
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e717b4466922c6801a12a8f82b0f2c866a33da" target='_blank'>
              PA28γ-containing tumor-derived exosomes promote T-cell dysfunction in head and neck squamous cell carcinoma
              </a>
            </td>
          <td>
            Ying Wang, Shiyu Zhang, Yang Yang, Yimei Wang, Yingxin Zhang, Ming Liu, Xin Zeng, Ning Ji, Silu Sun, Chunjie Li, Yuwei Zhao, Xikun Zhou, Qianming Chen, Jing Li
          </td>
          <td>2025-12-08</td>
          <td>Cellular & Molecular Immunology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating but poorly-understood disease. ME/CFS symptoms include immune system effects alongside incapacitating fatigue and post-exertional disease exacerbation. Symptom severity can range from mild to severe and whilst symptoms can fluctuate, few people fully recover. Immunological profiles of people living with ME/CFS were analysed by flow cytometry, focusing on cytotoxic cells, to determine whether people with mild/moderate (n = 43) or severe ME/CFS (n = 53) expressed different immunological markers. Flow cytometry data were tested for normality and the two clinical groups were compared by t-test or Mann-Whitney U-test as appropriate. People with mild/moderate ME/CFS had increased expression of cytotoxic effector molecules alongside enhanced proportions of early-immunosenescence cells, determined by the CD28-CD57- phenotype, indicative of persistent viral infection. In contrast, people with severe ME/CFS had higher proportions of activated circulating lymphocytes, determined by CD69+ and CD38+ expression, and expressed more pro-inflammatory cytokines, including interferon-γ, tumour necrosis factor and interleukin-17, following stimulation in vitro, indicative of prolonged non-specific inflammation. These changes were consistent across different cell types including CD8+ T cells, mucosal associated invariant T cells and Natural Killer cells, indicating generalised altered cytotoxic responses across the innate and adaptive immune system. These immunological differences likely reflect different disease pathogenesis mechanisms occurring in the two clinical groups, opening up opportunities for the development of prognostic markers and stratified treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e6b2fa3ad265819948a6a86e70aa620144d602" target='_blank'>
              Abnormal T-Cell activation and cytotoxic T-Cell frequency discriminate symptom severity in myalgic encephalomyelitis/chronic fatigue syndrome
              </a>
            </td>
          <td>
            Ji-Sook Lee, E. Lacerda, Caroline C. Kingdon, Ella Abken, Giada Susannini, H. Dockrell, L. Nacul, J. Cliff
          </td>
          <td>2025-12-10</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. Capping protein inhibiting regulator of actin dynamics (CRACD) that promotes actin polymerization, is frequently inactivated in SCLC. However, the role of CRACD loss in SCLC is unknown. Here we show that CRACD depletion drives neuroendocrine (NE) cell plasticity and immune evasion in SCLC. Mechanistically, CRACD inactivation disrupts actin organization, leading to suppression of Yap1-NOTCH signaling and subsequent NE gene upregulation. Simultaneously, CRACD loss drives EZH2-mediated histone methylation via nuclear actin disruption, leading to repression of MHC-I genes and depletion of CD8⁺ T cells. Consequently, CRACD-downregulated tumors exhibit increased cellular heterogeneity and escape from immune surveillance. Conversely, pharmacological inhibition of EZH2 restores MHC-I expression, reactivates antitumor immunity, and suppresses tumor growth. These findings identify CRACD as a tumor suppressor that constrains cell plasticity and immune evasion, highlighting the CRACD–EZH2–MHC-I axis as a potential therapeutic vulnerability in SCLC. Small cell lung cancer (SCLC) is aggressive with limited therapeutic options. Here, authors find that loss of CRACD induces neuroendocrine plasticity and immune evasion and suggest manipulating the CRACD-EZH2-MHC-I axis as a potential therapeutic strategy for SCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bf325651813549672f4e19a7fc99e17df10da273" target='_blank'>
              Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer
              </a>
            </td>
          <td>
            Yoojeong Seo, Shengzhe Zhang, Jinho Jang, Kyung-Pil Ko, Kee-Beom Kim, Yuanjian Huang, Dong-Wook Kim, Bongjun Kim, Gengyi Zou, Jie Zhang, Sohee Jun, Wonhong Chu, Nicole A Kirk, Ye Eun Hwang, Y. Ban, Shilpa S. Dhar, J. Chan, Min Gyu Lee, C. Rudin, Kwon-Sik Park, Jae-Ll Park
          </td>
          <td>2025-12-06</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Over the last decades, a growing number of distinct CD4+T helper cells has been identified and our understanding of CD4+T cell differentiation and function in various disease contexts has increased immensely. It has long been thought that the role of CD4+T cells in the tumor microenvironment (TME) was limited to coordinating the immune response by stimulating other immune cells and by secretion of cytokines with antitumor activity, while direct killing of tumor cells has been largely attributed to cytotoxic CD8+T cells. Notably, CD4+T cells with direct cytotoxic activity (CD4+CTLs) have been reported in the context of viral infections, autoimmune disorders, and more recently in patients with various cancer types. These cells have the ability to secrete cytotoxic molecules and kill target cells in a major histocompatibility complex (MHC) class II-dependent manner. In this review, we give an overview of phenotypical characteristics of CD4+CTLs in human cancers and the antitumor mechanisms employed by these cells. Further, we explore their role and clinical relevance in the context of cancer and describe how these cells may be used for the development of novel immunotherapeutic options to benefit patients with cancer with MHC class II-positive tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c0ef42a2ab46ef9073a88600de1a6cb52ffcf832" target='_blank'>
              Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy?
              </a>
            </td>
          <td>
            Imke V. Wandeloo, K. Bol, Carla van Herpen, J. M. D. Vries, G. Schreibelt
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Significance This research uncovers an important role for galectin-9 (gal9) in dendritic cells (DCs) during the engagement and subsequent activation of CD4+ T cells, which is indispensable to initiate adaptive immunity. Gal9 expressed by DCs aids in the establishment of durable interactions with T cells by properly displaying activating signals (MHC-II molecules) at the contact site between both cells (immune synapses, IS). Without gal9, DCs fail to efficiently stimulate CD4+ T cells, diminishing subsequent immune responses, with consequences for antitumor immunity. This study reveals an immune-regulating mechanism mediated by galectins, which can aid in understanding disbalanced immune responses, such as cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2738e2c26c92c821c7322248e0ee4235008ae63d" target='_blank'>
              Galectin-9 binding to HLA-DR in dendritic cells controls immune synapse formation and T cell proliferation
              </a>
            </td>
          <td>
            Andrea Rodgers-Furones, Thijs Brands, Guusje van Gameren, Mirane Florencio-Zabaleta, Mayukha Bathini, Sandra Delgado, Zacharias Wijfjes, Kristina Fedorova, René Classens, Lona J Kroese, M. Verdoes, Guido van Mierlo, Jesús Jiménez-Barbero, Rik G. H. Lindeboom, A. Ardá, Annemiek B. van Spriel, L. Q. Cano
          </td>
          <td>2025-12-08</td>
          <td>Proceedings of the National Academy of Sciences of the United States of America</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Natural killer (NK) cells exhibit remarkable adaptability within the tumour microenvironment (TME), where dynamic shifts in phenotype, function and metabolism govern their dual roles in antitumour immunity and tumour immune evasion. In the TME, NK cells undergo receptor remodelling, which is characterised by upregulated inhibitory signals and suppressed activating receptors, leading to the formation of dysfunctional subsets, such as exhausted TIM-3⁺ NK cells or tissue-resident CD49a⁺ populations. Immunosuppressive factors within the TME drive a transition from cytotoxic activity to regulatory or senescent-like states, impairing tumour surveillance. Metabolic reprogramming further compromises NK cell effector functions, as nutrient deprivation and metabolic byproducts disrupt energy pathways and suppress immune responses. Therapeutic strategies targeting this plasticity include engineered natural killer (NK) cells with enhanced specificity, metabolic restoration approaches and microenvironment-modulating interventions. However, challenges persist because of TME heterogeneity and persistent dysfunctional states. Understanding these adaptive mechanisms provides a framework for developing NK cell-based therapies that leverage plasticity to counteract tumour resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/910259fba0614bb5440944e1a9be14c37f13989d" target='_blank'>
              Multidimensional plasticity of natural killer cells in tumours
              </a>
            </td>
          <td>
            Xinya Yang, Zhaoyang Song, Ligang Chen, Qingge Jia, Mingyang Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Purpose Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) exert strong immunosuppressive effects and are associated with poor prognosis in breast cancer. However, the mechanism underlying their differentiation remains unclear. Here, we aimed to elucidate how transforming growth factor-β1 (TGF-β1)/SMAD4 signaling regulates PMN-MDSC differentiation and modulates the breast cancer immune microenvironment. Methods We analyzed neutrophil subpopulation heterogeneity in breast cancer tissues using single-cell RNA sequencing combined with spatial transcriptomics (GSE176078 dataset). A 4T1 mouse breast cancer metastasis model was established, and tumor progression was tracked via in vivo fluorescence imaging. Colony formation and differentiation outcomes following Tgfb1 overexpression or knockdown were assessed in spleen-derived hematopoietic stem cells using flow cytometry. Gene expression profiles and signaling pathways were characterized using RNA sequencing and Western blotting. Results Neutrophil subpopulations in breast cancer tissues exhibited significant heterogeneity, particularly the N3 subset, which showed enhanced intracellular communication and regulatory potential. Tgfb1 was significantly upregulated along the neutrophil developmental trajectory in both spleen tissue and serum of breast cancer mice. In normal mice, the number of metastatic foci significantly correlated with neutrophil proportions. Tgfb1 overexpression promoted PMN-MDSC differentiation, colony formation, and SMAD4 upregulation in normal mice but exerted opposite effects in tumor-bearing mice. Conclusion Our findings implicate TGF-β1/SMAD4 signaling in the differential regulation of PMN-MDSC differentiation in breast cancer models. The TGF-β1 pathway represents a potential therapeutic target for modulating the immune microenvironment in breast cancer, although further validation in clinical settings is required to determine therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/384d19c717f6881d268b2cff7245b623f5578409" target='_blank'>
              Differential TGF-β1/SMAD4 Signaling Regulates PMN-MDSC Differentiation and Reshapes the Immune Microenvironment in Breast Cancer
              </a>
            </td>
          <td>
            Jie Cao, Enqi Qiao, Hui Shao, Chunlei Wang, Manzhi Xia, Bo Qin
          </td>
          <td>2025-12-01</td>
          <td>Breast Cancer : Targets and Therapy</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet its unintended impact on chronic infections remains poorly understood. Here, we identify PD-L1 expression on CD14- CD16+ monocytes as a critical determinant for preventing early tuberculosis (TB) progression. By integrating real-world adverse event data, Mendelian randomization (MR), and transcriptomic analysis, we establish a causal and cell-specific link between PD-L1 downregulation and early TB progression. Analysis of the FAERS database revealed that the PD-L1 inhibitor durvalumab is significantly associated with TB-related adverse events (reporting odds ratio = 7.81; 95% CI: 4.43-13.78; P = 1.10×10-18). MR analysis confirmed that genetically elevated PD-L1 expression in CD14- CD16+ monocytes confers protection against early TB progression (OR = 0.918, P = 0.042), independent of confounding or reverse causality. Transcriptomic profiling revealed that PD-L1high CD14- CD16+ monocytes exhibit enhanced antigen surveillance, whereas PD-L1low cells display metabolic reprogramming associated with immune escape. Upstream regulatory analysis identified CDAN1, TCOF1, and LMO2 as transcriptional drivers of PD-L1, enriched in high-risk individuals. In silico drug prediction and molecular docking suggested several PD-L1-modulating compounds, including ruthenium, pomalidomide, zidovudine, and lycorine. Notably, several of these compounds (e.g., ruthenium complexes, pomalidomide, aziridine) have reported anti-mycobacterial effects, which supports the reliability of our screening results and their potential relevance to TB regulation. In vitro validation demonstrated that lycorine dose-dependently upregulates PD-L1 and inhibits Mycobacterium tuberculosis reactivation. Together, our findings define a mechanistic axis in CD14- CD16+ monocytes that underpins early TB control and is vulnerable to PD-L1 blockade. Collectively, these findings align with the established notion that assessing latent tuberculosis infection before initiating immune-modulating therapies is essential for minimizing reactivation risk, and propose tractable molecular targets for preventing TB reactivation in immunocompromised hosts.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f5006bad074eb74e5b4aa3f7c72db29845946bb" target='_blank'>
              CD14- CD16+ monocyte PD-L1 prevents early tuberculosis progression and constrains reactivation under immune checkpoint therapy
              </a>
            </td>
          <td>
            Wentao Wang, Chenyang Liu, Wenxaio Wu, Zhengjun Yi, Jie Shen
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Cellular and Infection Microbiology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Signal regulatory protein alpha (SIRPα) is an important regulator of innate and adaptive immune responses by promoting T cell and macrophage activation and macrophage adhesion (multi-nucleated giant cell formation) while preventing phagocytic cell death to sustain inflammatory responses. We determined whether SIRPα is expressed in sarcoidosis tissue and whether ELA026, a humanized SIRP-blocking Ab, suppresses sarcoidosis granuloma formation by attenuating inflammation, promoting cell death, and suppressing adhesion during granuloma formation. Based upon immunohistochemistry, SIRPα stained in greater abundance in giant cells, monocytes, macrophages and dendritic cells in sarcoidosis lung tissue than in normal lung, lung cancer, non-granulomatous lung diseases and non-sarcoidosis granulomatous diseases. All these differences were statistically significant except for non-sarcoidosis granulomatous lung diseases. We then leveraged an ex vivo human granuloma model, wherein PBMCs from sarcoidosis patients are activated to form granulomas within 7 days, to determine whether ELA026 attenuated granuloma formation, based upon MIPAR image analysis, and associated cytokine responses. A matching isotype antibody (ELA099) that does not bind SIRPs was a negative control; prednisone was a positive control. As hypothesized, pre-treatment (day 0) or post-treatment (day 4) with ELA026 or prednisone (not ELA099) caused dose-dependent suppression of sarcoidosis granuloma formation by day 7. Unexpectedly, ELA026 only modestly reduced TNFα production when used as a pre-treatment and did not suppress IL-1β release or promote cell death, as reflected by no LDH release. SIRPα is robustly expressed in monocyte/macrophage lineages within human sarcoidosis tissues, and inhibition of SIRPs (ELA026) suppresses sarcoidosis granuloma formation by preventing macrophage adhesion/aggregation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/899d8ce7f5589a64da8ac7ef8117c50a5802c943" target='_blank'>
              Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation
              </a>
            </td>
          <td>
            Marc A Judson, M. Julian, L. Foulke, S. Panicker, S. H. Arker, Paul J. Feustel, G. Parry, S. Bicer, E. Crouser
          </td>
          <td>2025-12-05</td>
          <td>Respiratory Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Chronic hepatitis B virus (HBV) infection progression is closely associated with repeated inflammatory liver injury. Myeloid-derived suppressor cells (MDSCs), known to suppress inflammatory responses during hepatitis, may play a protective role in mitigating liver damage; nevertheless, the precise functional specialization of MDSC subpopulations and the critical regulator in controlling their suppressive capacity remain incompletely understood. This study investigates the immunoregulatory role of IL-21, a pleiotropic immunomodulatory cytokine, in modulating MDSC function and its implications for HBV-associated liver inflammation prognosis. The frequencies of peripheral and intrahepatic MDSCs, along with serum IL-21 levels, in patients with chronic HBV infection were measured with freshly isolated samples. C57BL/6 mice carrying pAAV-HBV1.2 plasmids was established to explore the effect of IL-21 on aminotransferase levels and MDSC function. Patients with chronic HBV infection demonstrated significantly elevated frequencies of circulating MDSCs compared to healthy controls. Of note, the granulocytic MDSCs (gMDSCs) were markedly more abundant in hepatic tissues than in peripheral blood. Strikingly, a significant inverse correlation was observed between circulating gMDSC frequencies and serum ALT levels specifically in patients with elevated serum IL-21 concentrations, whereas this correlation was absent in the low IL-21 subgroup. In vitro functional assays demonstrated that exogenous IL-21 potentiated the immunosuppressive capacity of MDSCs, significantly attenuating IFN-γ production in co-cultured T cells. Consistent with these findings, hydrodynamic injection of IL-21 plasmid in an HBV mouse model resulted in significantly reduced serum ALT levels concomitant with enhanced arginase I expression in hepatic MDSCs. These results reveal that IL-21 enhances MDSC-mediated immunosuppression, implicating this regulatory axis in the attenuation of hepatic inflammation during chronic HBV infection. These findings provide a novel perspective on the involvement of IL-21 in the negative regulation of intrahepatic inflammation and provide a novel perspective on the role of IL-21 in developing immunotherapeutic strategies to optimize available anti-inflammatory treatments in chronic HBV infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43769e93eb8ada104943a4089afc526ef6d10aa6" target='_blank'>
              IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cells immunosuppressive function in chronic HBV infection
              </a>
            </td>
          <td>
            Xiaoyi Li, Zihan Jin, Meihan Pan, Zheyu Dong, Junling Chen, Zhipeng Liu, Hongjie Chen, Guofu Ye, S. Zhong, Weiying He, Libo Tang, GuiRong Rao, Yongyin Li
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer in Asian, Caucasian, and Hispanic populations and its aggressive form contributes to significant morbidity and mortality. Chronic ultraviolet B (UVB) exposure is a major environmental carcinogen that drives cSCC initiation, progression, and immune evasion. Regulatory T cells (Tregs) are known mediators of UVB-induced immunosuppression; however, their direct involvement in the establishment of cSCC remains elusive. Methods Flow cytometry was employed to quantify Treg populations in the skin and draining lymph nodes of UVB-exposed and untreated mice. The functional role of Tregs following UVB exposure was examined using a contact hypersensitivity assay, where Treg activity was modulated by anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4, anti-TIGIT, and anti-FR4 antibodies. The capacity of UVB to render mice susceptible to immunogenic cSCC tumor establishment was assessed under different UVB exposure regimens. Treg-modulating antibodies were administered following UVB treatment and prior to tumor implantation to explore whether UV-induced Treg manipulation can prevent cSCC tumor establishment. Results UVB irradiation for 5 consecutive days significantly increased the number of CD4+ Foxp3+ Tregs in both skin and skin-draining lymph nodes. These Tregs were shown to be suppressive in contact hypersensitivity assays. However, suppression was prevented following depletion of Tregs and/or avolition of their function using monoclonal antibodies. Consistently, chronic UVB exposure prior to tumor implantation permitted the establishment and growth of otherwise immunogenic cSCC tumors, which correlated with the expansion and recruitment of Tregs into the skin. Importantly, immunomodulation with anti-CTLA-4 or anti-FR4 after chronic UVB exposure effectively prevented cSCC establishment, indicating that the manipulation of UV-induced Tregs prevented the establishment and growth of immunogenic cSCC tumors. Conclusion Our findings show that the manipulation of UV-induced Tregs prevents early cSCC establishment. Thus, strategies aimed at modulating Treg function or abundance in the skin may represent a feasible therapeutic avenue for the prevention of cSCC tumor emergence in patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e9646d0ae217447d84ed31b1896b1daa87cf40c" target='_blank'>
              Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma
              </a>
            </td>
          <td>
            Shoaib Anwaar, Amina Ashraf, Sarah Jahfali, Joseph Yunis, Jazmina L Gonzalez Cruz, James W. Wells
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c515ee3e9e86703752ec072206a806bfdf0f76b3" target='_blank'>
              SLAMF1-peptide mediated epigenetic priming reprograms innate immune responses in sepsis
              </a>
            </td>
          <td>
            Sindre Ullmann, Birgitta Ehrnström, Jørgen Stenvik, S. Pinto, Yashwanth Subbannayya, Victor Boyartchuk, I. Mestvedt, Mahamaya Dhaware, Siddhesh S. Kamat, L. Ryan, Hilde Vagle, T. Dahl, B. Halvorsen, J. K. Damås, T. Espevik, Maria Yurchenko
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="Endometrial carcinoma (EC), particularly high-risk molecular subtypes like p53abn and NSMP, is frequently characterized by a tumor immunosuppressive tumor microenvironment (TME) that drives progression, metastasis, and resistance to therapy. This immunosuppressive milieu is orchestrated by key cellular components, including M2-polarized tumor-associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), PD-L1-expressing tumor cells, and pro-fibrotic cancer-associated fibroblasts (CAFs), which collectively inhibit effector T cell function and promote immune exclusion/desert phenotypes. Natural products offer promising multi-targeted strategies to remodel the TME. This review comprehensively summarizes the potent immunomodulatory effects of the phytosterol β-sitosterol (BSS) and the flavonoid luteolin (Lut) specifically within the EC TME. We detail how BSS and Lut synergistically reprogram TAMs towards an M1 phenotype, inhibit Treg differentiation/function and MDSC expansion, enhance CD8+ T cell recruitment, activation, and cytotoxicity (e.g., by downregulating PD-1/TIM-3), and suppress CAF-mediated immunosuppression and fibrosis. Mechanistically, these effects are achieved through targeting critical signaling pathways (STAT3, NF-κB, PI3K/AKT, Wnt/β-catenin) and modulating key chemokines/cytokines (e.g., reducing TGF-β, IL-10, CXCL12; increasing CXCL9/10, IFN-γ). Critically, BSS and Lut demonstrate significant potential to overcome resistance to immune checkpoint inhibitors (ICIs), particularly in immune-cold EC subtypes. By remodeling the immunosuppressive TME, BSS/Lut combinations can enhance ICI efficacy, as evidenced by preclinical data showing increased tumor suppression rates and T cell infiltration. While challenges remain, including EC-specific validation, bioavailability optimization, and molecular subtype stratification, BSS and Lut represent promising natural adjuvants for combinatorial immunotherapy, offering novel strategies to improve outcomes for patients with aggressive or treatment-refractory EC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7104edd872a0f11fcab8f2569253c5f8ba5f95ef" target='_blank'>
              Remodeling the tumor microenvironment: regulatory effects of β-sitosterol and luteolin on the immunosuppressive milieu in endometrial carcinoma and implications for combinatorial immunotherapy
              </a>
            </td>
          <td>
            Guojie Ji, Pengbo Wang, Zhihong Kong, Xiangxiang Cao, Xiaowei Shi, Huigen Feng, Huanhuan Hu
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Post-infectious pulmonary fibrosis remains difficult to prevent due to limited mechanistic understanding and the lack of human-relevant models. We engineered an immune-integrated lung-on-a-chip incorporating endothelial cells, fibroblasts, and macrophages to dissect early fibrotic signaling. Intravascular exposure to thymocyte selection-associated high mobility group box protein (TOX), a T cell–derived factor elevated after severe infection, impaired endothelial barrier function, upregulated intercellular adhesion molecule-1 (ICAM-1), and, through macrophages, induced fibroblast activation with increased α-smooth muscle actin (α-SMA), fibronectin, and extracellular matrix (ECM) remodeling. Pre-treatment with a receptor for advanced glycation end products (RAGE)-blocking antibody preserved barrier integrity and suppressed macrophage activation, fibroblast expansion, and collagen bundling. Similar protective effects were observed in a mouse model of TOX-induced fibrosis, where RAGE blockade improved survival and reduced collagen deposition. Analysis of profibrotic mediators revealed a conserved TOX–RAGE–macrophage signature across the chip model, mouse lungs, and patient bronchoalveolar lavage fluid (BALF) samples. These results identify TOX–RAGE signaling as a driver of post-infectious fibrotic remodeling and establish RAGE blockade as a potential preventive strategy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b85d9dbca05f18034616f4f3e47f66ed750e3a86" target='_blank'>
              Engineering an immune-integrated lung-on-a-chip to reveal TOX–RAGE axis–driven fibrosis and RAGE blockade as a therapeutic strategy
              </a>
            </td>
          <td>
            Hyelim Kim, Chai Won Park, Jisun Kim, Seong-Eun Kim, J. Ahn, J. Seong, Wonhwa Lee, Seung-Woo Cho, Hong Nam Kim
          </td>
          <td>2025-12-01</td>
          <td>Nano Convergence</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Immunotherapy has achieved remarkable progress in treating cancers that evade immune surveillance. Among the components of the tumor microenvironment, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, engulfing and promoting the adaptive immune response. It is acknowledged that blocking the CD24–Siglec-10 interaction significantly enhances the macrophage phagocytosis ability. In this study, we identified CD24 as an over-expressed molecule in ovarian and breast cancer using data from the GEO database and clinical samples. We then developed genetically programmable extracellular vesicles displaying CD24 single-chain variable fragment (CD24 scFv-EVs) and evaluated their ability to restore macrophage phagocytic activity and eliminate CD24-overexpressing cancer cells. Our findings demonstrate that CD24 scFv-EVs effectively block CD24 on ovarian cancer cells as well as breast cancer cells, thereby inhibiting the CD24–Siglec-10 pathway and enhancing macrophage-mediated clearance of cancer cells. Furthermore, CD24 scFv-EVs promote the polarization of tumor-infiltrated macrophages toward an M1-like phenotype. These results highlight CD24 blockade as a novel therapeutic strategy to target ovarian and breast cancer cells and enhance macrophage-driven tumor cell clearance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/109fa73544750677b134917b0ab8a6008286dcf5" target='_blank'>
              Genetically platform presenting CD24 ScFv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment
              </a>
            </td>
          <td>
            Guannan Zhou, Yuanyuan Gu, Menglei Zhang, Hang Zhou, Yao Li, Xiaoyan Lin, Guanming Lu, Fang Shen, Cheng Xu, Keqin Hua, Jingxin Ding
          </td>
          <td>2025-12-01</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="While the distinct roles of lymphocyte populations are well characterized in adaptive immunity, the phenotypic and functional diversity of innate immune cells is less explored. In recent years, subsets of monocytes have gained attention, as prominent shifts in population frequencies have been observed in disease states such as cancer. This narrative review summarizes current knowledge of the distribution and functional differences among the three major monocyte subsets (classical, intermediate, non-classical) in tumor settings. It includes rare populations, such as neutrophil-like, CD56+, and Tie2-expressing monocytes. Scientific evidence indicates that the phenotypical and functional heterogeneity of monocyte subsets determines their roles in either preventing cancer development or supporting the progression of disease through a remarkable diversity of mechanisms. Of note, alterations in the distribution of monocyte subsets and their functional reprogramming have been identified as drivers of cancer progression. While changes in monocyte frequencies have limited diagnostic biomarker potential for cancer detection, they may reflect the progression of disease and response to therapy. Based on subset-specific properties, distinct monocyte populations are increasingly recognized as promising targets of cancer immunotherapy. Yet novel strategies targeting monocyte populations must consider the risk of treatment reversal given the high plasticity of these cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77bbbe6076e191bbcd0831689ca9f93eac0a3b4b" target='_blank'>
              Distinct Roles of Monocyte Subsets in Cancer
              </a>
            </td>
          <td>
            Maria Amparo Sahagun Cortez, W. Eilenberg, Christoph Neumayer, Christine Brostjan
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Abstract The metabolic-immune interplay within the tumor microenvironment (TME) is a critical determinant of tumor progression and immune evasion, presenting significant therapeutic opportunities for enhancing antitumor immunity. The TME is characterized by hypoxia, acidosis, and nutrient depletion, and is also profoundly shaped by the metabolic reprogramming of cancer cells, including enhanced glycolysis, as well as amino acid and lipid metabolism. These metabolic alterations establish an immunosuppressive niche, restricting nutrient availability for effector T cells while enriching the environment with metabolites such as lactate, kynurenine, and adenosine. These metabolites impair the function of cytotoxic T lymphocytes and natural killer cells, while also promoting the survival and activity of regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. Immune cell function within this challenging milieu is dictated by metabolic adaptability: Effector T cells succumb to metabolic exhaustion, whereas regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells exhibit metabolic flexibility that sustains their survival and suppressive functions. Therapeutic strategies that target cancer cell metabolism or enhance the metabolic fitness of immune cells offer promising approaches to mitigating immunosuppression within the TME. Notably, combining metabolic modulators with existing immunotherapies holds great potential for amplifying antitumor responses. Nonetheless, critical hurdles for clinical translation remain, including target specificity, potential toxicities, and adaptive metabolic plasticity. Further investigation into metabolic reprogramming and precision immunotherapy, guided by emerging biomarkers, is critical for optimizing therapeutic efficacy and improving patient outcomes by fully leveraging the metabolic-immune axis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5305f45e5fd5b099439e1ab6af7259008e934afc" target='_blank'>
              Metabolic-immune nexus in tumor microenvironment: From mechanistic insights to therapeutic opportunities
              </a>
            </td>
          <td>
            Wenjie Zhu, Yingchen Chu, Peng Gao
          </td>
          <td>2025-12-01</td>
          <td>Chinese Medical Journal</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Cell-based immune therapies ranging from CAR-T cells to tumor infiltrating lymphocytes (TILs) and endogenous T-cell products, have produced unprecedented clinical responses in hematologic malignancies and are currently under active investigation for solid tumors. Nevertheless, several key challenges continue to limit the durability and breadth of clinical benefit. IL-7 is a pleiotropic cytokine that increases both the number and function of lymphocytes. Although not yet clinically approved, IL-7 has been used in over 620 adult and pediatric patients for a variety of reasons including, for example, to hasten bone marrow recovery after allogenic stem cell transplantation, to reverse lymphopenia due to HIV and idiopathic etiologies, to treat patients with various malignancies, and to boost vaccine responses. IL-7 is generally well-tolerated and effective in producing a durable increase in the number and function of CD4 and CD8 T cells. Recently, IL-7 has been used clinically in multiple myeloma patients receiving CAR-T cell therapy, in patients with urothelial cancer who are receiving checkpoint inhibitors, in patients undergoing endogenous lymphocyte cell therapy, and in critically-ill lymphopenic patients with COVID-19. The authors, all of whom have used IL-7 clinically, discuss how IL-7 effectively addresses all the major problems currently limiting adoptive cell therapies. Peering into the future, we believe that IL-7 will be a major advance as an adjuvant treatment in many cell therapies and hope that this commentary will expedite IL-7’s testing in multiple clinical settings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7335d5f31ce5564aecee701958f7b7c7e81963be" target='_blank'>
              IL-7: a potential next-generation adjuvant for immune cell therapies
              </a>
            </td>
          <td>
            Richard S Hotchkiss, J. Dipersio, Cassian Yee, Russell K. Pachynski, Marcel R. M. van den Brink
          </td>
          <td>2026-01-02</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>106</td>
        </tr>

        <tr id="During cancer immunoediting, cancer cells deregulate cell death executioner mechanisms to escape immunotherapy-induced antitumor immunity. Ferroptosis, a type of regulated necrosis triggered by lipid peroxidation, plays a pivotal role in the anti-tumor activity of T cell-based immunotherapies; however, mechanisms for the modulation of ferroptosis in immune-refractory tumor cells are unclear. In this study, using preclinical models of immune refractory tumors obtained following the course of immunoediting by PD-1 blockade and adoptive T cell therapy (ACT), we find that T cell-based immunotherapy drives the development of ferroptosis resistance of tumor cells. In this process, E2F1 is upregulated by immunotherapy and it in turn binds to the promoter of the HMGCR gene to upregulate HMGCR, thereby contributing to the resistance to ferroptosis. Notably, HMGCR inhibition renders immune-refractory tumor cells susceptible to ACT and PD-1 blockade. Thus, our results reveal a mechanism by which cancer cells modulate ferroptosis to acquire resistance to immunotherapy and implicate the E2F1-HMGCR axis as a central molecular target for controlling ferroptosis resistance of immune-refractory cancer. HMGCR is upregulated by E2F1, driving ferroptosis resistance by reducing oxidative damage triggered by T cell-based therapy. Notably, targeting HMGCR restores ferroptosis sensitivity in immune-refractory tumors, enhancing response to PD-1 blockade as well as adoptive T cell transfer therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9fe8f1224bafebb297cea5d3dc447af8f8d0791b" target='_blank'>
              The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells
              </a>
            </td>
          <td>
            Sung Wook Son, Hyo-Jung Lee, NaNa Kang, Seongjae Bae, Eunho Cho, Heeju Kwon, Da-Young Yoon, Chaeleen Lee, Seungho Lee, Min Kyu Son, Jisu Chae, Suyeon Kim, Se Jin Oh, Younji Sim, K. Lee, Cassian Yee, Seon Rang Woo, Yun-Jeong Jeong, Hee-Jung Choi, Jong-Young Kwak, Eun-Woo Lee, Jinuk Park, Sang Gyu Kwak, Young-Chae Chang, Tae Woo Kim, K. Song
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="A recent publication by Qin et al. in Cell reported on the ﬁ rst-in-human application of anti-BCMA chimeric antigen receptor (CAR)- T cell therapy in patients with treatment-refractory progressive multiple sclerosis (MS) with a good tolerability and ef ﬁ cacy. 1 CAR-T cells rank among the breakthrough therapeutic approaches, transforming the ﬁ eld of cancer and autoimmune conditions including neuroimmunological disorders. B-cell maturation antigen (BCMA) and CD19 antigen are B-cell target antigens frequently used in CAR constructs for autoimmune diseases. 1,2 In addition to the B-cell depletion in the peripheral blood, CAR-T cells allow deep depletion of tissue-resident B cells e.g., in lymphoid tissues and hard-to-reach compartments such as the central nervous system (CNS), an effect that has not been observed with antibody-based B-cell depletion therapies. However, little is known about direct and indirect effects of CAR-T cells on microglia, even though CNS-resident microglial cells are involved as one of the key drivers and maintainers of the compartmentalized neuroin ﬂ ammation and neurodegeneration during MS progression. This is con ﬁ rmed by emerging evidence that smoldering neurodegenerative processes are hallmarked by chronic microglia-mediated neuroin ﬂ ammation with progressive axonal injury, resulting in disability progression independent of relapse activity (PIRA) and brain atrophy. 1 To date, none of the available therapies for MS are fully effective at preventing disease progression and PIRA. The emerging study by Qin et al. showed, for the ﬁ rst time, signi ﬁ cant functional improvement during a 9-month">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aadbe175bb178ba56f15991ba7d572d20c6623b1" target='_blank'>
              Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk
              </a>
            </td>
          <td>
            F. Ismail, Hans-Peter Hartung, Nico Melzer
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="PRMT5, a type II methyltransferase catalyzing symmetric dimethylation of arginine residues, has emerged as a promising therapeutic target in various cancers. However, the precise mechanism by which PRMT5 mediated the tumor immune microenvironment, particularly CD8+ T cell recruitment in cervical cancer remains elusive. Analysis of data from The Cancer Genome Atlas (TCGA) revealed elevated PRMT5 mRNA levels in cervical cancer tissues, which correlated with reduced immune cell infiltration and poorer patient prognosis. To further investigate the role of PRMT5 in tumor development, a CD8 knockout (KO) mouse tumor model was utilized. Significant inhibition of tumor growth was observed in cervical cancer using a mouse model lacking PRMT5. Notably, this antitumor effect was attenuated in CD8 KO mice lacking functional CD8+ T cells. Mechanistically, RNA sequencing (RNA-seq) analysis was conducted to explore how PRMT5 regulates immune cell recruitment. Disruption of PRMT5 was found to increase the secretion of chemokine CXCL10 by tumor cells. CXCL10 binds to its receptor CXCR3, thereby recruiting T cells to the tumor. Furthermore, in CXCR3 KO mice, PRMT5 knockdown failed to enhance T cell infiltration into tumors. These findings indicate that PRMT5 knockdown promotes CD8+ T cell recruitment to the tumor microenvironment via CXCL10 signaling. Furthermore, the therapeutic efficacy of the selective PRMT5 inhibitor EPZ015666 was evaluated in a cervical cancer xenograft mouse model. Treatment with EPZ015666 effectively suppressed tumor growth. In summary, these findings elucidate a novel mechanism whereby PRMT5 depletion in cervical cancer cells triggers a CXCL10-mediated chemotactic response, enhancing CD8+ T cell infiltration and restricting tumor progression. Thus, our study provides compelling evidence supporting the potential targeting of PRMT5 as a viable immunotherapeutic strategy for cervical cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/501fcba059a3925513dd90f817a25dfaea616bcb" target='_blank'>
              Enhancing CD8+ T Cells Infiltration Through the Protein Arginine Methyltransferase 5 (PRMT5)/CXCL10 Axis Restricts Cervical Cancer Progression
              </a>
            </td>
          <td>
            Yongshuai Jiang, Yingying Wei, Ziyang Li, Zhenghang Huang, Junsheng Dong, Weijuan Gong, Li Qian
          </td>
          <td>2025-12-01</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Although melanoma treatment has progressed considerably in recent years, increasing patient response rates remains a significant challenge. The interferon pathway is known to promote immune recognition, but its sustained activation can contribute to adaptive immune exhaustion. In this study, we demonstrate that myeloid-specific deletion of Rictor in a mouse melanoma model enhances STAT1 signaling while reducing PD-L1 expression. Furthermore, IFN-γ–activated macrophages inhibited melanoma growth in a human skin organoid model. Notably, in vivo inhibition of AKT, in conjunction with anti–PD-L1 therapy, suppressed tumor progression. Mechanistically, we identified IFN-γ–mediated downregulation of IGF-1 as a key event during inflammation, and showed that supplementation with recombinant IGF-1 dampens STAT1 activation. Our findings reveal that targeting the Rictor-AKT axis induces a dual effect - boosting pro-inflammatory signaling while downregulating immunosuppressive factors such as PD-L1 and IGF-1. These results support the potential of AKT inhibitors to enhance the efficacy of immune checkpoint therapies in melanoma patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6008f52253955f9261442a5b18d9c18c5700cd27" target='_blank'>
              mTORC2 inhibition reduces tumor burden via STAT1 activation and enhanced response to anti–PD-L1 therapy
              </a>
            </td>
          <td>
            Anna Gschwendtner, Birgit Schütz, Madalina A. Mirea, Oliver Eckel, Mikolaj Z Kepa, S. Fritsch, Raimund Oberle, T. Weichhart, Markus Hengstschläger, M. Mikula
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Introduction Aging increases vulnerability of the elderly to influenza, but the mechanisms have not been fully understood. Although lethally infected aged mice are frequently used as models of influenza infection in the elderly, they are more suitable for studying mortality rather than the increased disease severity frequently observed in non-lethal infections. Therefore, understanding age-related differences under sublethal infection conditions is crucial. Methods Adult (8–12 months) and aged (22–24 months) mice were infected with a sublethal dose of H1N1 (PR8). Body weight loss, lung viral titers, pulmonary innate immune cell composition, and transcriptional levels of key inflammatory cytokines were assessed. Results Despite similar body weight loss, the aged mice showed significantly higher lung viral titers at day 8. Notably, key innate immune populations, including alveolar macrophages, neutrophils, and eosinophils, showed distinct age-related patterns. In the adult mice, alveolar macrophages negatively correlated with weight loss, whereas no protective immune factor was identified in the aged mice. Moreover, our data showed that persistent viral replication led to distinct innate immune cell composition in the adult and aged mice despite comparable transcription levels of inflammatory cytokines. The numbers and frequencies of both the neutrophils and eosinophils were significantly higher in the virus-persistent adult mice than those in the virus-persistent aged mice. Discussion Our findings reveal skewed acute immune responses to influenza in aged mice, which may partially account for their mild weight loss despite delayed viral clearance and highlight age-related impairments in early antiviral immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c351ed0e5d3df4fe77cb078ab0d2b65afface5c" target='_blank'>
              Skewed pulmonary innate immune cell composition underlies the delayed influenza clearance in aged mice
              </a>
            </td>
          <td>
            Xiaoyang Cheng, Fang Zhao, Jing Wu, Yanmin Wan, Zhaoqin Zhu, Jialin Jin
          </td>
          <td>2025-12-10</td>
          <td>Frontiers in Microbiology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Induced pluripotent stem cell (iPSC)-derived pancreatic islets represent a promising therapeutic approach for restoring insulin independence in type 1 diabetes (T1D). However, their clinical success remains critically dependent on overcoming rejection mediated by innate and adaptive immune responses. Current immunosuppressive therapies pose significant long-term risks and only partially control alloimmune and autoimmune reactions. Targeted immunomodulation using monoclonal antibodies is a safer, more precise alternative. Here, we explored the impacts of blocking CD276 (B7-H3) and CD155 (PVR), activating ligands involved in immune recognition and regulation, on the survival and in vivo maturation of iPSC-derived endocrine progenitors (EPs) into functional pancreatic islets. Using a humanized mouse model, we demonstrated that dual blockade of CD276 and CD155 markedly reduced NK cell-mediated graft rejection, prevented CD14+ monocyte activation, and limited overall immune infiltration. In addition, CD155 blockade increased PD-1 levels on activated CD8+ T cells and significantly enhanced regulatory T cell (Treg) expansion and function, thereby promoting graft tolerance. Combined treatment prolonged engraftment and facilitated the maturation of EPs into functional, insulin-secreting cells, as indicated by increased human C-peptide levels and glucose responsiveness 4 weeks post-transplantation. Our findings highlight CD276/CD155 blockade as a novel immunomodulatory strategy to support tolerance and the functional maturation of iPSC-derived pancreatic grafts in T1D.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/99ae440749b98ba4470d804290b5bedbd3a66a2f" target='_blank'>
              Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice
              </a>
            </td>
          <td>
            G. Siracusano, F. Deambrogio, V. Sordi, M. Malnati, L. Piemonti, R. Chimienti
          </td>
          <td>2025-12-01</td>
          <td>Transplant International</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Beyond their traditional role as short-lived antimicrobial cells, neutrophils are increasingly recognized as key regulators of adaptive immunity and tumor progression. This AI-assisted integrative review investigated the neutrophil–T-cell axis, particularly the role of Galectin-9 (Gal-9), across adult T-cell leukemia/lymphoma (ATL), Sézary syndrome (SS), coronavirus disease 2019 (COVID-19), and psoriasis. Leveraging AI tools (GPT-5 and Adobe Acrobat AI Assistant) for literature synthesis (2000–2025) and expert validation, we aimed to identify common immunological mechanisms. Across all conditions, neutrophils displayed persistent activation, elevated Gal-9 expression, and modulated T-cell interactions. In ATL and SS, neutrophilia correlated with poor survival and TCR signaling dysregulation, suggesting Gal-9-mediated immune modulation. In COVID-19 and psoriasis, neutrophil-derived Gal-9-linked innate hyperactivation to T-cell exhaustion and IL-17-driven inflammation. These findings define a recurring neutrophil–Gal-9 regulatory module connecting innate and adaptive immune responses. This study underscores the feasibility of combining AI-driven literature synthesis with expert review to identify unifying immunological mechanisms and therapeutic targets across malignancy and inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f09c2cd18cebd70f857746a605633d6065276e4" target='_blank'>
              Neutrophil–Galectin-9 Axis Linking Innate and Adaptive Immunity in ATL, Sézary Syndrome, COVID-19, and Psoriasis: An AI-Assisted Integrative Review
              </a>
            </td>
          <td>
            Toshio Hattori
          </td>
          <td>2025-12-31</td>
          <td>Reports - Clinical Practice and Surgical Cases</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple myeloma (MM) develops in the hypoxic bone marrow (BM) microenvironment, which alters tumor behavior and immune responses. While hypoxia is known to directly suppress immune function, its effect on immunotherapy-relevant antigen expression and the MM secretome remains underexplored. Here, we investigated how hypoxia affects BCMA expression and BCMA-targeted CAR T cell responses. MM cells were cultured under normoxia (21% O₂) or hypoxia (1% O₂). BCMA surface and total expression were analyzed. Anti-BCMA CAR T cells were co-cultured with normoxic or hypoxic MM cells to assess cytotoxicity and cytokine release. Conditioned media and small extracellular vesicles (sEVs) were isolated, quantified, and RNA-profiled. MM cells cultured in hypoxia showed reduced BCMA surface and total protein expression, resulting in reduced CAR-mediated signaling. Importantly, the hypoxic tumor secretome further reduced BCMA levels and significantly impaired CAR T cell killing and cytokine production, which was partially reversible by γ-secretase inhibition. To dissect the suppressive nature of the hypoxic secretome, we identified an increase in small extracellular vesicle (sEV) release under hypoxia. RNA profiling of sEVs revealed a hypoxia-induced RNA signature with potential immunomodulatory roles. This study shows that hypoxia diminishes BCMA expression and enhances secretion of immunosuppressive factors, including sEVs, thereby limiting the efficacy of BCMA CAR T cell therapy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32804a5eae759659f84b5610dc79fafee9f0e914" target='_blank'>
              Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
              </a>
            </td>
          <td>
            Chenggong Tu, A. Van der Vreken, Fien Meeus, Lauren van den Broecke, Jack Brons, K. De Veirman, K. Vanderkerken, E. De Bruyne, Karine Breckpot, E. Menu
          </td>
          <td>2026-01-08</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="CD38 is a transmembrane glycoprotein involved in NAD+ metabolism, calcium signaling, and immune cell activation. Its role in the inflammatory response has been studied extensively in innate immune cells; however, its contribution to the activation of memory T lymphocytes under inflammatory conditions is less understood. Additionally, recent studies have shown an age-related increase in the expression of the protein CD38 in various human and murine tissues. Moreover, CD8+ bystander T cells have been shown to contribute to inflammation during the aging process. Given the importance of its potential role in age-related pathologies, we examined the effect of CD38 on bystander activation of CD8+ memory T cells in aged mice following lipopolysaccharide challenge. CD38-deficient mice exhibited attenuated serum cytokine responses (IL-1β, IL-6, IFN-γ, and IL-10) and a distinct CD8+ T cell profile, characterized by a decrease in activated T cells. Wild-type mice displayed a significant expansion of CD69+TCM cells after LPS inoculation, an effect that was absent in CD38-deficient animals. LPS also promoted the expression of CD69 and CD38 in TEM/EFF subsets. Thus, our findings reveal a CD38-dependent mechanism underlying bystander activation of memory CD8+ T cells in aging. Highlighting the potential contribution of CD38 to age-related diseases, such as autoimmunity, and in the face of inflammatory conditions in aged people.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2543f635ae92595d3f140c2ea47a35fc4eab9dd" target='_blank'>
              CD38 promotes LPS-induced innate-like activation and proliferation of CD8+ T lymphocytes in aged mice
              </a>
            </td>
          <td>
            Wendolaine Santiago-Cruz, Enrique Espinosa, Jocelyn C Pérez-Lara, Héctor Romero‐Ramírez, Priyadharshini Devarajan, Fabio García-García, J. C. Rodríguez-Alba
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Aging</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Bispecific antibodies that redirect T cells or NK cells to tumors have demonstrated substantial therapeutic efficacy, but their broader application is often constrained by immune-related toxicities, limited effector cell availability, and suboptimal access to tumor sites. These challenges have prompted efforts to identify alternative effector cell types that are more abundant in circulation, readily accessible, and capable of cytotoxic activity in the tumor microenvironment. Neutrophils, which constitute the most prevalent circulating leukocyte population, represent a promising yet underutilized target for immune cell engager design. However, efforts to exploit neutrophil-mediated tumor killing through CD89 (FcαRI) have been limited by the inherent drawbacks of IgA-based formats, including poor stability, short serum half-life, and reduced developability. To address these challenges, we established an engineered bispecific antibody platform that incorporates CD89 engagement into an IgG1 scaffold. This design enables neutrophil redirection while preserving the favorable pharmacokinetic and manufacturing profiles of IgG-based therapeutics. The resulting bispecific architecture allows for programmable neutrophil engagement alongside tumor antigen recognition, offering a clinically viable strategy for innate immune activation. Among the bispecific designs evaluated, ZT-8, a humanized CD89 × HER2 bispecific antibody, demonstrated potent neutrophil-mediated cytotoxicity against tumor cells even in the absence of cytokine priming, suggesting a distinct activation mechanism that operates within the tumor microenvironment. Compared to IgA-based antibodies, ZT-8 exhibited superior immune effector engagement, enhanced tumoricidal activity, and substantially prolonged in vivo half-life through FcRn-mediated recycling. These findings define IgG-based CD89 bispecifics as a next-generation neutrophil engager platform and exemplify how antibody engineering and synthetic immunology can be leveraged to expand the effector landscape of bispecific immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bab07e40b23a7879d294b754490bbfb0a9b0b7cd" target='_blank'>
              Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy
              </a>
            </td>
          <td>
            Jisun Lee, Garam Han, Munsu Kyung, Seunghyeon Lee, Tae Woo Kim, Sang Taek Jung
          </td>
          <td>2025-12-01</td>
          <td>Journal of Biological Engineering</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Highlights What are the main findings? We find that under inflammatory conditions, B cells from streptococci-infected tonsils and blood of HLA-C*06:02-positive psoriasis patients activate a melanocyte-reactive T-cell receptor from a pathogenic psoriatic CD8+ T cell clone and also have autostimulatory properties for CD8+ T cells. We identify several self-peptides from the complex HLA-C*06:02 immunopeptidomes of B cells that may serve as autoantigens to activate the lesional psoriatic autoimmune response against melanocytes due to T-cell receptor polyspecificity. What is the implication of the main finding? The proinflammatory environment of streptococcal tonsillopharyngitis, as an important trigger for psoriasis, might break the tolerance of pathogenic psoriatic CD8+ T cells to autoantigens presented by HLA-C*06:02 on B cells that subsequently react against melanocytes, inducing psoriasis. The findings open up potential avenues for the development of therapies targeting the pathogenic B-T cell interaction in psoriasis. Abstract Psoriasis vulgaris is a T-cell-mediated skin disease that may involve an autoimmune response against melanocytes. It develops through still unexplained pathomechanisms. Streptococcal tonsillopharyngitis is a major trigger of psoriasis onset and relapses. HLA-C*06:02 is the main psoriasis risk gene. Here we find that B cells isolated from streptococci-infected tonsils or peripheral blood of HLA-C*06:02+ psoriasis patients stimulate an HLA-C*06:02-restricted melanocyte-reactive Vα3S1/Vβ13S1 T-cell receptor (TCR) from a lesional psoriatic CD8+ T cell clone in an IFN-γ-enhanced manner. Patients’ B cells furthermore induce proliferation of autologous blood CD8+ T cells. We identify several HLA-C*06:02-presented self-peptides in the immunopeptidomes we had isolated from four HLA-C*06:02 homozygous B-cell lines that stimulate the Vα3S1/Vβ13S1 TCR and differ from the melanocyte autoantigen recognized by this TCR. These data suggest that the proinflammatory environment of streptococcal tonsillopharyngitis may enable B cells to activate autoreactive CD8+ T cells that, owing to the polyspecificity of T-cell receptors, recognize several B-cell self-peptides presented by HLA-C*06:02 and subsequently cross-react against melanocytes in the skin, thereby triggering psoriasis. The capacity of B cells to stimulate a cross-reactive autoimmune response through HLA class I-presented B-cell peptides is a previously unknown mechanism in the induction of autoimmunity that could explain psoriasis onset and persistence.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5d7a0f1489f4e873304e188edfedc3bb70c48a78" target='_blank'>
              B Cells Can Trigger the T-Cell-Mediated Autoimmune Response Against Melanocytes in Psoriasis
              </a>
            </td>
          <td>
            Mengwen He, Melissa Bernhardt, Akiko Arakawa, Song-Min Kim, S. Vollmer, B. Summer, Yukiyasu Arakawa, Tatsushi Ishimoto, A. Schlosser, J. C. Prinz
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Abstract Marek’s disease virus (MDV) is an alphaherpesvirus responsible for the development of T-cell lymphoma in chickens. Despite the identification of several pro-oncogenic viral molecules encoded by MDV, the processes leading to tumourigenesis remain poorly understood. Extracellular vesicles (EVs) are important mediators of intercellular communication, carrying bioactive molecules that can elicit profound physiological changes in recipient cells. Tumour cells can release significant amounts of EVs, which influence tumour development and growth, metastatic processes and resistance to cancer therapies. These EVs favour cancer cells to evade the immune response, particularly by establishing an immunosuppressive microenvironment. Here, we investigated whether EVs produced by MDV-transformed T lymphocytes affect the proliferation of avian immune cells, a determining feature in neoplastic processes. EVs were purified from an MDV-transformed cell line cultured in vitro. Using a proteomic approach, we confirmed the presence of specific markers and identified a panel of cellular proteins enriched in these EVs. Notably, no viral proteins were detected in the purified EVs. We also demonstrated that EVs are rapidly internalized by recipient chicken cells. Moreover, these EVs can induce a decrease in primary chicken B-cell proliferation, while promoting primary chicken T-cell proliferation. Our findings suggest that EVs released by MDV-transformed cells may contribute to immunosuppression and potentially facilitate lymphoma progression by enhancing T-cell proliferation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43b084989accf17a6783519e76506e135a588a03" target='_blank'>
              Extracellular vesicles released from Marek’s disease virus-transformed T-cells impact immune cell proliferation
              </a>
            </td>
          <td>
            Laetitia Trapp-Fragnet, Julien Burgaud-Gaillard, Valérie Labas, S. Remy, Ana-Paula Texeira-Gomes, C. Denesvre
          </td>
          <td>2025-12-01</td>
          <td>The Journal of General Virology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Hypoxic tumor microenvironment (TME) is a common occurrence in the development of solid tumors, which activates hypoxia-inducible factors (HIFs) and their downstream signaling pathways in cancer cells to facilitate tumor progression and immune escape. However, among the various immune cells that constitute innate and adaptive immune systems, HIFs have a more intricate function; moreover, different isoforms of HIFs play different functions under spatial and temporal conditions. HIFs are conducive to the adaptation of various immune cells to the hypoxic TME. The stability of HIF-α can regulate metabolism and directly regulate the expression of immune genes. Additionally, the activation of HIF signaling may also inhibit the development of immune cells in some tumor environments, affecting the antigen recognition and killing processes to assist cancer cells in immune escape. Therefore, understanding the relationship between HIF signaling and immune cells more comprehensively may yield substantial benefits for the immunotherapy of various types of cancer. The present study reviewed the role of HIFs in immunity, including their role in T cells, B cells, macrophages, neutrophils, dendritic cells and natural killer cells. It also discussed the effectiveness of HIF targeted therapy in clinical application, the challenges associated with it and the development of a precise targeting drug delivery system. The present review may help researchers comprehend the tumor immune process in a hypoxic microenvironment. It aimed to offer novel strategies for cancer immunotherapy and prolonging the overall survival of patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2f2959e24720a9bfcd6ba812398c12fc625e1637" target='_blank'>
              Regulatory networks of HIFs in tumor-infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)
              </a>
            </td>
          <td>
            Chaoqun Li, Chenge Qin, Xingchen Li, Jinzhu Wang, Yang Li, Qin Sun
          </td>
          <td>2026-01-12</td>
          <td>International Journal of Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f2221a7b923d3654545a592b6523d97b8c79656c" target='_blank'>
              Acute priming using elevated fluid viscosity recovers ‘young-like’ single-cell surveillance behaviors in aged human T cells
              </a>
            </td>
          <td>
            Y. Dance, Alice Amitrano, Annaka Saffron, Chanhong Min, Ladaisha Thompson, Zhuoxu Ge, Ian M. Smith, Nico Macaluso, Charles Ezenwanne, Nicholas Milcik, Abigail Fennell, Kendall A. Pyndell, K. Stroka, Jeremy Walston, Sean X. Sun, K. Konstantopoulos, Jude M. Phillip
          </td>
          <td>2026-01-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a85afdff22ae96afa7e975dddb2b63ea9aa9cd29" target='_blank'>
              Microbiota-induced T cell plasticity enables immune-mediated tumour control.
              </a>
            </td>
          <td>
            T. Najar, Yuan Hao, Yuhan Hao, Gabriela Romero-Meza, Alexandra Dolynuk, Emma Almo, Dan R. Littman
          </td>
          <td>2026-01-14</td>
          <td>Nature</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Infections remain a key challenge during treatment of multiple myeloma (MM) patients with anti-BCMA and -GPRC5D bispecific antibodies (bsAbs). However, the underlying mechanism behind different rates and severity of infections induced by the two bsAbs remains poorly understood. Single-cell RNA-sequencing performed in bone marrow aspirates of 11 MM patients and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. By contrast, GPRC5D expression was restricted to normal and malignant plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted bone marrow (BM) mature B cells (4.9%→0%; p<0.001) and normal PCs (0.17% → <0.0002%; p<0.001) during treatment of 62 relapsed MM patients. This was observed in early and late time points of therapy. Additional flow cytometry (N=31) and single-cell RNA-sequencing studies (N=8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, which confirmed no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that while GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onwards. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and lays a foundation for individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B cell malignancies or autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3f82e6f29f4eaa2729da3c53cfa2b6609a13def" target='_blank'>
              Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.
              </a>
            </td>
          <td>
            T. Jelínek, D. Žihala, A. Zabaleta, Ioannis V. Kostopoulos, Ondřej Souček, O. Venglar, Cristina Moreno, D. Fotiou, Eva Radova, L. Tamariz-Amador, F. Theodorakakou, L. Muroňová, A. Manubens, O. Tsitsilonis, T. Popková, Carmen González, A. Anilkumar Sithara, Francesco Corrado, Nayda Bidikian, C. Guerrero, V. Kapustová, D. Bilek, Patrick Hagner, M. Larrayoz, Jose-Al Martinez-Climent, L. Broskevičová, J. Mihalyova, Maximillian Merz, T. Ševčíková, Irene M. Ghobrial, Jesús F San-Miguel, M. Dimopoulos, P. Rodríguez-Otero, J. Radocha, E. Kastritis, B. Paiva, R. Hájek
          </td>
          <td>2025-12-17</td>
          <td>Blood</td>
          <td>0</td>
          <td>76</td>
        </tr>

        <tr id="Colorectal cancer (CRC) exhibits limited responsiveness to immune checkpoint inhibitors (ICIs), largely due to its immunosuppressive tumor microenvironment (TME) and poor baseline immunogenicity. Here, we report that Pseudomonas aeruginosa (P. aeruginosa) triggers caspase-3–dependent pyroptosis in murine CRC MC38 cells, characterized by GSDME cleavage, intracellular reactive oxygen species (ROS) accumulation, and the release of damage-associated molecular patterns (DAMPs). This form of immunogenic cell death promotes robust inflammatory cytokine secretion, upregulation of PD-L1 on tumor cells, and functional maturation of bone marrow–derived dendritic cells (BMDCs) in vitro. In vivo, intratumoral injection of P. aeruginosa leads to significant reprogramming of the TME, including increased expression of proinflammatory genes, DC maturation, and enhanced infiltration of CD8+ T lymphocytes. Notably, combination therapy with P. aeruginosa and an anti-PD-L1 antibody results in synergistic tumor regression, markedly outperforming either monotherapy, without inducing detectable systemic toxicity. Together, our findings reveal that P. aeruginosa-induced pyroptosis serves as a potent immunogenic stimulus that reshapes the CRC tumor microenvironment and overcomes resistance to immune checkpoint blockade. This strategy represents a promising approach to enhance immunotherapy efficacy in poorly immunogenic solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14d2a753150ca0c9ea9da3203e435c6eae383d87" target='_blank'>
              Pseudomonas aeruginosa induces tumor pyroptosis and immune activation to enhance checkpoint blockade in colorectal cancer
              </a>
            </td>
          <td>
            Yanan Hu, Rong Li, Jiaxi Feng, Ningyi Sun, Wei Zheng, Xin Jin, Guodong Wang, Yi He, Yiwei Hao, Jun Zhang, Ke Ren, Xin Wu
          </td>
          <td>2026-01-01</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e-4). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e08f1dd96dd018add58f7a79b8066098738fcfe" target='_blank'>
              Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
              </a>
            </td>
          <td>
            Denis J Ohlstrom, William C. Pilcher, Marina E. Michaud, Chaitanya R. Acharya, Sarthak Satpathy, Edgar Gonzalez-Kozlova, R. Jayasinghe, Katherine E. Ferguson, Hope L. Mumme, Shivani Nanda, Yizhe Song, Sowmitri Mantrala, Dimitra Karagkouni, Jessica Schulman, Nick Pabustan, Junia Vieira Dos Santos, Daniel W. Sherbenou, J. Keats, Alex Gout, Steven Foltz, A. Laganà, T. Kourelis, Ravi Vij, M. Dhodapkar, D. Avigan, H. Cho, L. Baughn, Ajay K Nooka, S. Lonial, Shaji K. Kumar, Mehmet K Samur, Ioannis S Vlachos, Li Ding, Sacha Gnjatic, George Mulligan, Manoj K. Bhasin
          </td>
          <td>2025-12-09</td>
          <td>Blood cancer discovery</td>
          <td>0</td>
          <td>112</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025', '2026'],
    y: [9, 0],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>